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Patients affected by a respiratory disease or injury experience a substantially 
impaired respiratory system and as a consequence are unable to obtain a sufficient 
amount of oxygen. Hypoxia can quickly result in developing permanent tissue damage or 
death. Currently, the medical methods of treating hypoxia are mechanical ventilation or 
extracorporeal membrane oxygenation. However, these treatments are ineffective in 
certain cases and possess significant additional risks including barotrauma, infection, 
hemorrhage, and thrombosis. 
The extrapulmonary method of peritoneal oxygenation has been investigated by 
other research groups as a potential alternative to providing supplemental oxygen in 
hypoxic animals. In peritoneal oxygenation, the peritoneum, the serous membrane that 
lines the abdominal cavity and organs, functions as an interface for gas exchange. 
However, previous attempts using artificial perfluorocarbons and hemoglobin based 
oxygen carriers have demonstrated limited increase in oxygenation and substantial health 
concerns. In this work, peritoneal microbubble oxygenation (PMO) therapy has been 
investigated as a viable method for delivering supplemental oxygen to hypoxic patients 
with critical lung injury. PMO therapy is accomplished with a custom infusion device 
designed to safely deliver oxygen microbubbles (OMBs), an innovative oxygen carrier, 
into the abdomen.  
Animal models of acute lung trauma and respiratory disease were used to validate 
PMO therapy. The first model was a small animal feasibility study where fatal hypoxia 
was induced by pneumothorax. The second model was asphyxia by tracheal occlusion to 
test PMO therapy in the most severe lung injury. When animals were infused with 
OMBs, the average survival times after the incidence of injury increased significantly. 
PMO treatment increased mean survival time in fatal pneumothorax by 650% and by 
180% in asphyxia. Finally, a respiratory disease model was developed and characterized 
to replicate acute respiratory distress syndrome (ARDS) in rats. ARDS pathology was 
reproduced by aerosolizing an endotoxin, lipopolysaccharide, into the lungs to incite an 
antagonistic immune response. Additionally, delivering OMBs for prolonged PMO 
treatment to rats was facilitated by comparing the efficiencies of multiple catheters 
implanted into the peritoneal cavity. The ARDS and treatment model could then be used 
to evaluate PMO therapy and other new methods of supplemental oxygen delivery. 
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Chapter 1: Introduction 
Patients affected by a respiratory disease or injury experience a substantially 
impaired ability for oxygen intake and as consequence can develop life-threating 
hypoxemia. The condition of hypoxia can quickly result in permanent tissue damage or 
death if proper intervention is not provided. At least one third of the patients admitted to 
intensive care units (ICUs) will have conditions that require respiratory support from 
mechanical ventilation [1–5]. A major cause of patients developing hypoxia is from acute 
respiratory failure (ARF) due to coma, respiratory diseases such as pneumonia, and 
physical trauma [2,6]. ARF is the most common organ failure observed in ICUs as 35% 
of patients are admitted with or will develop it [3,6]. ARF encompasses a wide range of 
respiratory disorders and conditions including acute respiratory distress syndrome 
(ARDS). Both ARF and ARDS have reported mortality rates between 30-45% with 
severe cases having mortality rates as high as 75% [7–12]. Most deaths in patients with 
ARF or ARDS are attributed to multiple organ failure while 16% of patients with ARDS 
die from refractory hypoxemia [12,13].  
ARDS has gained significant focus in respiratory research as multiple sources 
trigger the incidence of ARDS including infections, sepsis, chemical or fluid aspiration, 
and physical trauma [3,9]. ARDS is characterized by an antagonistic immune response, 
release of inflammatory mediators such as TNF-α and interleukin cytokines, irritation of 
cells in the alveolocapillary membrane, and the alveolar space accumulates pulmonary 
edema with a high concentration of proteins [9,14,15]. Lung injury and respiratory 
dysfunction in ARDS is caused by inhibited gas diffusion from the increased thickness of 
the gas exchange membrane and the decreased surface area in alveoli from being filled 
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with edema fluid. Current medical methods are ill-suited for treating hypoxia stemming 
from ARDS and similar pathologies of respiratory disruption and injury. In these 
respiratory conditions, current oxygen delivery methods of mechanical ventilation and 
extracorporeal oxygenation are unable to supply sufficient oxygen and can contribute to 
increased risk of complications including barotrauma, pneumonia, hemorrhage, and 
thrombosis [14–19]. 
Thus, new oxygenation methods are needed to increase survivability during 
pulmonary failure by providing supplemental oxygen in cases of severe refractory 
hypoxemia. The extrapulmonary method of peritoneal oxygenation uses the large surface 
area of the peritoneum, the serous membrane that lines the abdominal cavity, as a gas 
exchanger [20,21]. The main advantages of peritoneal oxygenation are easy access for 
catheterization; relative safety of circulating oxygen through the intraperitoneal cavity 
(IPC), where the mesothelium acts as a gas permeable barrier between the perfusate and 
the blood; and avoidance of extracting and reintroducing blood. The technique is 
analogous to peritoneal dialysis, a simple, low-tech form of renal replacement therapy 
that is less expensive and complex than conventional hemodialysis [22,23]. 
1.1 Research objectives 
In this work, a new extrapulmonary method of peritoneal microbubble 
oxygenation (PMO) was explored, with future objectives for delivering supplemental 
oxygen to hypoxic patients with critical lung injury. PMO therapy involves infusing 
oxygen microbubbles (OMBs), an innovative oxygen carrier, into the abdominal cavity 
where the peritoneum functions as a membrane for gas exchange and diffusion. The 
ultimate objective of the research was to demonstrate that PMO therapy is a viable 
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treatment option for incidents of hypoxia. To progress towards the ultimate objective, the 
principles of PMO therapy were validated by refining methods of OMBs delivery into the 
peritoneal cavity, developing a disease model of hypoxia, and investigating PMO therapy 
in multiple animal models of hypoxia. 
The first goal of the research was to develop methods of infusing OMBs into the 
peritoneal cavity. An automated system was created to safely and accurately administer 
treatment to the peritoneal cavity in a bolus or continuous perfusion. Another aspect of 
infusing OMBs studied was to determine the best peritoneal catheter for performing 
prolonged PMO therapy involving repeated infusions of OMBs. The next goal of this 
dissertation was development and characterization of a respiratory disease model in rats 
to replicate chronic hypoxia. The respiratory disease selected was acute respiratory 
distress syndrome (ARDS) because of the considerable research performed on the disease 
and the current lack of an effective treatment for hypoxia attributed to ARDS. ARDS 
pathology was reproduced in rats by aerosolizing an endotoxin, lipopolysaccharide 
(LPS), into the lungs to incite an antagonistic immune response.  
Finally, PMO therapy was investigated in multiple animal models of hypoxia to 
confirm that infusion of OMBs delivered oxygen in vivo, increased survival, and 
increased systemic oxygenation. To validate these properties of PMO therapy, OMBs 
were administered as peritoneal treatment for hypoxia in three animal models. The first 
animal model in rats induced fatal hypoxia by the lung injury of a right pneumothorax. 
The second model in rabbits replicated asphyxia by tracheal occlusion. The third model 
evaluated PMO therapy in the ARDS model of hypoxemia characterized in rats. The 
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goals of these studies were to test the limits of PMO therapy in several possible 
occurrences of respiratory failure compared to the control groups treated with saline.  
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Chapter 2: Background 
Respiration of oxygen is a critical component to the survival of humans and most 
vertebrates. When respiration is disrupted or impaired, medical intervention is often 
necessary to assist in delivering oxygen. To gain an understanding of the medical 
treatments for respiratory problems, their disadvantages, and the role PMO therapy can 
fulfill, basic knowledge of the respiratory system and oxygen dynamics is presented. 
Chapter 2 overviews how oxygen is normally processed and measured in humans and 
other mammals, and then details the current medical devices employed to deliver oxygen 
and the limitations they possess.  
2.1 Physiological respiration 
Oxygen is a necessary reactant for the continued life of most vertebrates on Earth 
[24]. Energy is synthesized through cellular respiration in the mitochondria of cells only 
when there is a source of oxygen. A continuous supply of oxygen must be obtained from 
the surrounding atmosphere and distributed to every cell of the organism as most animals 
are unable to store oxygen. Animals have evolved the ability to accomplish the task of 
procuring oxygen through a specialized process. Physiological respiration is the process 
of transporting oxygen into and throughout the body while eliminating carbon dioxide 
waste [25–27]. Physiological respiration is performed by the cooperation of the 
respiratory and cardiovascular systems. The respiratory system, composed of the trachea, 
lungs, alveoli, diaphragm, and intercostal muscles, transports oxygen into the body 
(Figure 2.1). The transport of oxygen within the body is performed by the cardiovascular 
system composed of the heart, vasculature, and blood. Both the respiratory and 
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cardiovascular systems transport oxygen and carbon dioxide by the mechanisms of bulk 
flow and diffusion [26–28].  
In order to intake air from the atmosphere, the intercostal muscles and diaphragm 
contract to increase the volume of the lungs. The greater volume in the lungs decreases 
the internal pressure within the alveoli to be less than that of the atmosphere. The 
negative pressure of the lungs creates a pressure gradient that facilitates the bulk flow of 
air through the trachea and into the lower airways of the conducting zone. The 
conducting zone is the respiratory tree composed from the branching structure of the  
 
Figure 2.1: Human respiratory system. 
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bronchi and bronchioles that ends in the respiratory zone at the alveoli. In the respiratory 
zone, the oxygen concentration of the inhaled air is significantly higher than that of the 
capillary blood surrounding the alveoli. Thus, oxygen diffuses down its concentration 
gradient by crossing the alveolocapillary membrane into the blood where it binds to the 
protein hemoglobin within red blood cells [26,28,29]. In contrast, carbon dioxide diffuses 
into the alveoli because the blood has a higher concentration of CO2 than in the inspired 
air (Figure 2.2). The intercostal muscles and the diaphragm relax as the pressure gradient 
equalizes, which allows the lungs to return to their original volume and increases their 
internal pressure. The positive pressure created assists in the exhalation of gas out of the 
lungs. RBCs in the blood are circulated within the body by the heart functioning as a 
pressure pump. The pumping of the blood transports the oxygen by bulk flow through the 
vascular system (Figure 2.3). When the oxygenated blood in the arteries flows across the 
capillary beds, oxygen unbinds from hemoglobin and diffuses from red blood cells to the 
surrounding tissue due to the concentration gradient of oxygen between the tissue and 
blood. Carbon dioxide waste from cellular respiration diffuses from the high 
concentration in the tissue to the low concentration in the blood. Blood in the veins then 
returns to the lungs where the entire process will be repeated [26–28].  
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Figure 2.2: Alveolar structure and the alveolocapillary membrane (Figure modified from 
[26,28]). 
 
Figure 2.3: Main features and organs of human’s cardiovascular system (Figure derived 
and modified from [30]). 
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2.1.1 Interactions of blood and oxygen 
The dynamics of oxygen transport from the surroundings into tissue is facilitated 
by passive diffusion from pressure and concentration gradients produced by the 
respiratory system and the heart. In the environment, Earth’s atmosphere at sea level has 
an average composition of 78.08% nitrogen, 20.95% oxygen and 0.04% carbon dioxide 
by volume. Thus, the fraction of inspired oxygen, FiO2, under normal conditions is 0.21 
[27,31]. The partial pressure of oxygen, PO2, in an inhaled breath is calculated to be 
approximately 160 mmHg from a standard atmospheric pressure of 760 mmHg. The 
partial pressure of carbon dioxide, PCO2, in an inhaled breath is approximated as 0 
mmHg due to the low concentration of carbon dioxide in the atmosphere. Air that is 
inhaled is completely humidified as it passes through the trachea and bronchial tree, 
decreasing the PO2 before reaching the alveoli. The PO2 of air in the alveoli, PAO2, where 
gas exchange occurs is approximately 114 mmHg when calculated using average values 
at sea level for human oxygen consumption, VO2, and total lung volume, Vlung [32].  
 𝑃𝐴𝑂2 =  (𝑃𝑎𝑡𝑚 − 𝑃𝐻2𝑂) (𝐹𝑖𝑂2 −
𝑉𝑂2
𝑉𝑙𝑢𝑛𝑔
) [Eq. 2.1] 
The oxygen in the alveolar space diffuses across the thin alveolocapillary 
membrane and into venous blood flowing through the pulmonary capillaries. However, 
oxygen is a gas with a low solubility in liquids. Thus, for oxygen to be distributed 
throughout the body, a special cell dedicated to binding and carrying oxygen molecules 
evolved. The mammalian red blood cell (RBC) is a non-nucleated cell with 96% of its 
dry weight is hemoglobin (Hb), a metalloprotein comprised of iron [33]. A single 
hemoglobin protein is capable of binding four oxygen molecules at once. Oxygen’s 
binding affinity to Hb is a sigmoidal relationship where higher pressures of oxygen and 
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Hb with more oxygen bound to it has increased affinity for oxygen [34] (Figure 2.4). The 
factors of temperature, carbon dioxide concentration, and blood pH also affect 
hemoglobin’s affinity to oxygen. These properties shift the oxygen-Hb dissociation curve 
to the right, decreasing the affinity, or the left, increasing Hb’s affinity [26–28,34]. When 
humans and other mammals breathe atmospheric air, the diffusion of oxygen from the 
alveolar space saturates between 95-100% of the Hb in blood with oxygen [35]. The 
partial pressure of arterial blood, PaO2, as it leaves the pulmonary circulation is 
approximately 100 mmHg. The strength of the oxygen-hemoglobin bond is weakened 
due to the decreasing oxygen tension in the systemic circulation. The decreasing binding 
affinity of Hb allows oxygen to unbind from and diffuse into the adjacent tissue. When 
the blood returns to the pulmonary capillary bed, the SvO2 and PO2 of venous blood has 
decreased to ~75% and 40 mmHg from delivering oxygen [26–28,32,34]. The cycle of 
oxygenating and deoxygenating the blood in the pulmonary capillaries repeats providing 
that the respiratory and cardiovascular systems continue to operate without 
complications.  
 
Figure 2.4: Oxygen saturation of Hb in blood at normal body pH and temperature 
(Figure derived from [28]). 
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2.1.2 Impairment  
Physiological respiration is the process of transporting and utilizing oxygen for 
energy production by cellular metabolism. The process of respiration depends on the 
respiratory and cardiovascular systems effectively working in unison. Because of the 
cooperation between multiple systems, respiration can be compromised by a wide range 
of conditions. In these conditions, the exact epidemiological nature in how the body is 
affected varies considerably, involves multiple sources, or is not well understood. The 
most common impairments have been divided into four categories: airway obstruction, 
ventilation disruption, cardiovascular complications, and lung damage.  
Airway obstruction is the occlusion of the trachea or bronchi preventing the 
passage of air into and out of the lungs. Obstruction of air occurs from inflammation and 
constriction of the bronchial tubes in medical conditions such as asthma and bronchitis. 
Asthma is exemplified by “attacks” where the inflammation and constriction in the 
conducting zone, primarily of the bronchi and bronchioles, becomes exacerbated. 
Although people with asthma are known to recover from the disorder, it is not possible to 
be medically cured [36,37]. Typically, only the symptoms of asthma are treated by 
inhaling corticosteroids and bronchodilators. Acute bronchitis is a common illness mainly 
caused by viral infections. Chronic cases of bronchitis are less frequent and stem from 
extended smoking or exposure air pollution [38]. Similar to asthma, bronchitis cannot be 
cured by medical means, though patients can recover over time.  
Ventilation disruption is the inhibition of the inhalation and exhalation processes. 
Ventilation disruption can occur by damage or disturbance of the mechanisms for 
ventilation. The simplest case is swallowing or inhaling a foreign object or fluid that 
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obstructs the passage of air. Drowning is the most common case where the inhalation of 
liquid or gas prevents oxygen diffusion in the lung. To return respiratory function, the 
object or fluid is removed and in severe circumstances surgical intervention is necessary. 
In a pneumothorax, the pleural cavity or membrane is compromised, which alters the 
internal pressures of the lung causing them to collapse. Removal of the air pocket by a 
chest tube and repairing the pleural membrane is necessary to treat severe cases of 
pneumothorax [31,38]. An additional interruption of ventilation occurs when the 
contraction of the intercostal muscles and diaphragm is inhibited. The primary causes of 
respiratory muscle inhibition are muscle injury and neuromuscular shutdown from certain 
drugs and spinal cord or head injuries. Supplemental oxygen from a mechanical 
ventilator is the most common treatment for cases of ventilation disruption [39,40].  
Mechanical is also commonly employed to treat cardiovascular complications 
capable of impeding respiratory function [5,41]. Cardiovascular complications include 
heart failure, heart defects, and arrhythmias that cause disrupted or limited blood flow in 
the body limiting the efficiency of oxygen transport [24,25]. Pulmonary embolism, a 
blood clot in the pulmonary circulation, prevents blood from passing through the lungs to 
be oxygenated and remove carbon dioxide [42]. Another type of cardiovascular 
complication that impairs respiratory function is anemia, a reduced quantity of RBCs in 
the blood. Severe anemia and other the cardiovascular complications can lead to 
significant hypoxia due to the decreased oxygen carrying capacity and circulatory flow of 
the blood.  
The final category of respiratory impairment that causes hypoxia is damage and 
injury to the lungs. Damage to the lung tissue can instigate multiple methods of inhibited 
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oxygen diffusion. Alveoli and lung tissue damage reduces the surface area available for 
the airflow to experience gas exchange in the respiratory zone. Lung damage can also 
trigger excessive immune and inflammatory responses from the cells. These excessive 
responses lead to swelling of the alveolocapillary membrane and developing pulmonary 
edema, the accumulation of fluid in the alveoli. Pulmonary edema significantly inhibits 
the capabilities of the lungs by limiting the surface area that air can exchange gas with the 
alveolocapillary membrane and forcing oxygen to dissolve in the fluid to diffuse into the 
blood [14]. Bacterial and viral infections are predominant sources of lung damage and 
include pneumonia, tuberculosis, SARS, and MERS. Other leading causes of lung 
damage include lung cancer, emphysema, smoke, and chemical inhalation [36,43,44]. 
Similarly, pulmonary fibrosis and interstitial lung disease lead to scarring and thickening 
of the alveoli and lung tissue which decreases the elasticity of the lung [31,37,38,42]. If 
damage from lung injury or disease becomes significant, a patient can develop acute 
respiratory distress syndrome (ARDS), a severe medical complication with no known 
treatment and a high mortality [11]. In these cases where the respiratory system is 
impaired by a respiratory illness or injury, the condition of oxygenation in the patients is 
critical to their treatment and survival. 
2.2 Measuring oxygen saturation in the body 
The amount of oxygen in the body is an important metric that medical 
professionals depend on to care and treat their patients. The primary focus for patient care 
is determining the oxygen saturation of hemoglobin in arterial blood (SaO2). Determining 
oxygen saturation of the patient is used to verify the degree of hypoxia, the deficiency of 
oxygen in the tissue, (Table 2.1). The SaO2 is commonly measured or estimated with 
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pulse oximetry, blood gas analysis, and hemoximetry. These methods of determining 
oxygen saturation are used by physicians to determine the efficiency of the respiratory 
system, status of the patient, and interventions that should be applied.  
Table 2.1: Degrees of hypoxia and corresponding oxygen measurements 
[24,34,45–48]. 
Degree of hypoxia SpO2 (%) PaO2 (mmHg) FO2Hb (%) 
Mild 85-92 60-79 90-95 
Moderate 75-84 40-59 75-89 
Severe <75 <40 <75 
2.2.1 Pulse oximetry  
The most commonly utilized method of determining the oxygenation status of a 
patient is pulse oximetry [46]. Pulse oximetry is a noninvasive method to quickly and 
continuously approximate the oxygen levels of the body. Pulse oximetry results in an 
indirect measure of oxygen saturation referred to as peripheral oxygen saturation (SpO2), 
as it is primary measured on thin external body parts such as the fingertip or earlobes. 
The pulse oximeter is a device employed in most medical settings including intensive 
care, surgery, emergency rooms, and ambulances due to being simple to use and accurate 
in many scenarios.  
2.2.1a Operating principles 
Pulse oximetry operates on the principles of the unique light absorption properties 
of hemoglobin and spectrometry. Pulse oximetry is capable of measuring only the oxygen 
saturation of arterial blood by taking advantage of two physiological properties. A 
property of unbound or reduced hemoglobin is that hemoglobin possesses a distinct 
absorbance spectrum that is considerably altered when it binds to oxygen 
(oxyhemoglobin) and changes the protein’s structure. Hb and oxyhemoglobin (O2Hb) 
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have the greatest difference in absorbance spectrums at the wavelengths of red, 660 nm, 
and near-infrared (NIR), 940 nm [49]. Red light is absorbed more effectively by Hb, 
while NIR light is absorbed better by O2Hb. These wavelengths are optimal as they 
transmit through tissue more efficiently than blue, green, yellow, and infrared light [49]. 
Thus, the quantity of O2Hb and Hb is determined by transmitting the red and NIR 
wavelengths of light through a thin layer of tissue and measuring the transmitted intensity 
of red and NIR with a photodiode (Figure 2.5). The physiological property of the tissue 
the light is transmitted through is then exploited to estimate the oxygen saturation of only 
arterial blood.  
The exploited physiological property is that the volume of arterial blood in the 
tissue being measured fluctuates as it is pumped by the heart, while the volume of venous 
blood remains constant [45]. The measured values of total absorbance can be considered 
a linear combination of pulsatile arterial and static venous blood. As only the absorbance 
of arterial blood varies over time, any change in the total absorbance is attributed to the 
change in arterial blood [45]. The change in blood volume is measured as a pulse 
waveform which classifies pulse oximeters to also be photoplethysmographs. Thus, a 
pulse oximeter requires a steady pulse to generate an oscillating arterial absorbance and 
multiple bursts of light at two different wavelengths to measure the change in absorbance 
over time (Figure 2.5).  
The two properties are used to approximate the SaO2 of an individual. The 
red/NIR modulation ratio, R, is a ratio of the different measured combinations of 
absorbance, A, and is calculated by the equation [45]:  
 𝑅 =  
𝐴𝑟𝑒𝑑,𝑝𝑢𝑙𝑠𝑎𝑡𝑖𝑙𝑒
𝐴𝑟𝑒𝑑,𝑠𝑡𝑎𝑡𝑖𝑐
×
𝐴𝑁𝐼𝑅,𝑠𝑡𝑎𝑡𝑖𝑐
𝐴𝑁𝐼𝑅,𝑝𝑢𝑙𝑠𝑎𝑡𝑖𝑙𝑒
 [Eq. 2.2] 
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Healthy volunteers whose SaO2 levels are altered from 75-100% then have their red/NIR 
modulation ratios measured and compared. The red/NIR modulation ratios are calibrated 
to a curve for matching to SaO2 and result in a pulse oximetry approximation of oxygen 
saturation, SpO2 [45,49]. The normal range for oxygen saturation in the body measured 
by pulse oximetry ranges from a SpO2 between 95-100%, 93-95% for smokers, while a 
SpO2 value below 90% is to be indicative of hypoxia [46]. The two properties from which 
pulse oximetry is developed from give it many advantages such as a rapid reading of 
oxygen saturation and compact components to allow the oximeter to be portable.  
 
Figure 2.5: Functionality of a pulse oximeter. 
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2.2.1b Limitations 
The method of pulse oximetry possesses several advantages resulting from the 
properties of hemoglobin and arterial blood. However, these properties result in 
limitations in the performance of pulse oximeters. The first acknowledged limitation of 
pulse oximeters relates to how the calibration curves between the red/NIR modulation 
ratios and SaO2s were developed. The validity of the calibrations has been questioned 
when applied to the elderly or individuals with certain medical conditions such as sickle 
cell anemia [46,49]. The pulse oximeter calibrations were performed in healthy 
volunteers from a relatively small population sample. The volunteers had their SaO2 
levels artificially changed from 75-100% while a pulse oximeter measured the 
modulations ratios. These modulation ratios were related to the SaO2s of the volunteers to 
generate calibration curves for the pulse oximeter that ranged from SpO2 between 70-
100%. Thus, pulse oximeter measurements below SpO2 of 70% are not considered as 
accurate or reliable because these values are extrapolated from the calibration curves 
generated [45,46,49]. Also, only healthy volunteers were included in the calibration trials 
because of the health and safety concerns of artificially inducing hypoxia during the 
trials. As a consequence, the readings of pulse oximeters in cases with abnormal pulses 
and tissue perfusions have been mostly untested and contribute to poor transmittance of 
signals and incorrect readings hindering the performance of pulse oximeters. Pulse and 
perfusion disruptions that lead to failure of the pulse oximeter are caused by conditions 
including hypothermia, hypotension, low cardiac output, septic shock, vasoconstriction, 
and tremors [46,49]. The more recognized and examined limitation of pulse oximeters 
relates to the light absorbance spectra for the varieties of hemoglobin. 
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As pulse oximeters use light to measure O2Hb, results are obtained noninvasively, 
quickly, and continuously from a patient. Light and absorbance properties also are the 
source of several of the limitations inherent to pulse oximeters. The absorption spectrum 
of hemoglobin deviates depending on the structure of the protein as it binds oxygen. 
However, hemoglobin will bind to several other ligands if present such as carbon 
monoxide, which has approximately a 240 times greater binding affinity to hemoglobin 
than oxygen [50]. Carbon monoxide bound to hemoglobin forms carboxyhemoglobin 
(COHb), which absorbs red light to an equivalent extent as O2Hb [50]. Pulse oximeters 
then mistakenly measure COHb as O2Hb because the absorbance of red light is increased. 
Because it cannot distinguish between the absorbance of red light from COHb and O2Hb, 
a pulse oximeter overestimates SpO2 when high concentrations of carbon monoxide is 
inhaled [51]. Pulse oximeters measure the absorption of light incorrectly from another 
form of hemoglobin, methemoglobin (MetHb). MetHb differs from Hb in that the iron 
ion has a charge of +3 instead of +2, which prevents it from binding oxygen. MetHb 
normally composes less than 1% of hemoglobin and absorbs NIR light to a much more 
effectively than both O2Hb and Hb [50,52]. Thus, high levels of MetHb in the blood 
results in the SpO2 to be measured between 80-85% as the MetHb absorbs both red and 
NIR light the pulse oximeter transmits [45,52]. Because pulse oximeters are limited in 
several medical conditions and in interpreting differences between the hemoglobin types, 
other methods of measuring oxygen are used to confirm the oxygenation of a patient.  
2.2.2 Blood gas analysis 
When pulse oximetry readings are suspect or if the oxygenation status of a patient 
needs confirmation, blood gas analysis is commonly used in clinical practice. Blood gas 
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analysis is an invasive method to approximate the oxygen levels in the body from a blood 
sample. Blood analyzers are trusted in most medical settings including intensive care, 
surgery, and emergency rooms. Analysis of blood gases results in an indirect measure of 
oxygen saturation referred to as partial pressure of oxygen (PO2) or oxygen tension, as it 
is measures the pressure of free gaseous oxygen that is dissolved in the blood.  
2.2.2a Operating principles 
The processes for measuring oxygen in blood are similar to that of measuring the 
acid/base balance of the blood. Blood gas analysis measures the chemical interactions of 
the blood with several types of electrodes. Using multiple electrodes, blood analyzers 
measure the qualities of acid/base, oxygen, and carbon dioxide concentrations in a 
patient’s blood. Blood gas analysis consists of three parameters: pH, PO2, and PCO2 
(Table 2.2). Only the balance of acid and base in the blood can be accurately determined 
from a venous blood sample. To determine the oxygenation status of the patient, blood 
gas analysis is performed on arterial blood sampled from the radial artery [48,53].  
Table 2.2: Parameters measured by blood analysis. 
Variable Abbreviation Units 
Acceptable range 
Human 
[27,28,48,54] 
Rat 
[55–57] 
pH pH -- 7.3-7.5 7.34-7.46 
Partial pressure of carbon 
dioxide in arterial blood 
PaCO2 mmHg 30-50 34.6-53.9 
Partial pressure of oxygen 
in arterial blood 
PaO2 mmHg 80-100 80-100 
Bicarbonate HCO3
-
 mmol/L 22-26 17.7-26.8 
Base excess BE mmol/L -2 to 2 -2 to 2 
Total CO2 tCO2 mmol/L 23-30 18-27 
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Once the blood is collected from the patient, the analyzer pumps the blood across 
the series of electrodes. All the electrodes in the blood analyzers are maintained at 37°C 
because the chemical reactions of the electrodes depend on a fixed temperature to 
calibrate values based on the normal body temperature. A glass electrode is used to 
measure pH of the blood [58,59]. The concentration of H
+
 ions in the blood interacts 
withthe measuring electrode, while a reference electrode contacts a solution with a 
known and stable pH. The voltage generated between the two electrodes is then 
calculated based on the calibrated relationship between the outputted voltage and pH. 
Similarly to measuring pH, the partial pressure of carbon dioxide is measured in blood 
analyzers with a modified glass electrode, the Severinghaus electrode [47]. With a 
Severinghaus electrode, carbon dioxide in the blood sample diffuses through a gas 
permeable membrane into a bicarbonate solution in the measuring electrode. The 
diffusing CO2 disrupts the chemical balance of the bicarbonate solution. The bicarbonate 
solution then releases H
+
 ions to return to equilibrium. The pH adjustment from the H
+
 
ions generates a voltage with a standard glass electrode. The voltage from the glass 
electrode is compared to the reference electrode for calculating the PCO2 from calibrated 
samples [47,58,60]. Because the measurement of pH and PCO2 is closely connected, they 
are often measured in parallel. However, measuring oxygen requires a completely 
different electrode.  
 𝐶𝑂2 +  𝐻2𝑂 ⇋ 𝐻2𝐶𝑂3 ⇌ 𝐻
+ + 𝐻𝐶𝑂3
− [Eq. 2.3] 
The measurement of PaO2 is performed with a Clark electrode [47,59]. The Clark 
electrode is a silver anode and a platinum cathode suspended in a potassium chloride or 
potassium bromide electrolyte solution. In the electrolyte solution, the reference and 
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measurement electrodes are applied with a known voltage [47,60,61]. The voltage 
between the electrodes is increased when free oxygen dissolved in the blood plasma 
diffuses through a semipermeable membrane into the electrolyte solution. The current is 
generated from the oxygen being reduced at the cathode and silver being oxidized at the 
anode. Thus, the more the current increases, the higher the oxygen tension is within the 
blood. However, at a PO2 greater than 150 mmHg, the relationship between the oxygen 
reaction and increase in current becomes increasingly nonlinear and results in error in the 
analysis [59]. Additionally, deterioration of the electrolyte solutions and electrodes from 
the oxygen reactions causes the signal from the Clark electrode to continually drift from 
its initial values. The drifting of the Clark electrode’s signal requires the electrode of the 
blood analyzer to be periodically recalibrated and the solutions replaced [47,58–61]. The 
drifting of the Clark electrode’s signal is the only limitation inherent from the principle 
used to measure the oxygen tension in the blood. However, other limitations are 
attributed to the method of measuring oxygen saturation with blood gas analysis. 
2.2.2b Limitations 
Blood gas analysis is notably more reliable than pulse oximetry with fewer 
inaccuracies resulting from the technique of using electrodes to measure oxygen. The 
major limitation in measuring oxygen saturation with blood gas analysis is the Clark 
electrode is not a direct measurement of the patient’s oxygenation. The Clark electrode 
measures the oxygen that is dissolved in the blood and not the oxygen in the tissue or 
bound to hemoglobin. Thus, the oxygen saturation is estimated by the hemoglobin 
saturation curve (Figure 2.4) [53,54]. The Hb saturation curve shifts depending on 
multiple factors including temperature, content of CO2, blood pH, carbon monoxide, and 
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MetHb. The shifts in the Hb saturation curve are not always accounted for resulting in the 
calculations relating PaO2 to oxygen saturation to be slightly inaccurate [48,59,62].  
Other limitations of blood gas analysis are related to sampling and handling of the 
blood. If venous or mixed venous blood is mistakenly collected instead of arterial blood, 
the patient’s respiratory status is poorly assessed from the venous blood sample. The 
blood is also analyzed incorrectly if the blood sample is diluted by adding excessive 
amounts of heparin to the collection syringes. The blood sample is also contaminated 
when bubbles of air are in the syringe, potentially increasing the oxygen in the blood 
sample and resulting in an artificially high measurement of PO2. The PO2 of the blood 
sample significantly decreases when leukocytes and platelets in the blood continue to 
metabolize O2 and CO2. Therefore, the blood gases in the sample are altered if the sample 
is not refrigerated or analyzed quickly after it is collected [48,59]. In most clinical 
settings, blood gas analysis is not immediately performed as the analyzer is located in the 
lab and not by the patient [48,54]. The final limitation of blood analyzers is the expenses 
and calibration protocols associated with the analyzer. The blood analyzer requires 
comprehensive operation and maintenance procedures to ensure that quality of analysis is 
preserved [47,48,53,58,59]. The pulse oximetry and blood gas analysis are both indirect 
methods of measuring oxygen saturation, but oxygen saturation is directly measured 
when principles from each method are combined in hemoximetry.  
2.2.3 Hemoximetry 
Hemoximetry or CO-oximetry is a method to directly measure the oxygen 
saturation of peripheral tissue or the blood. The peripheral tissue or blood sample is 
measured for the fraction of oxyhemoglobin, carboxyhemoglobin, methemoglobin, and 
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deoxyhemoglobin with hemoximetry (Table 2.3). Hemoximetry can be analyzed with two 
methods based upon pulse oximetry and blood gas analysis. 
The noninvasive variation of pulse hemoximetry is comparable to pulse oximetry 
as the principles of spectrometry are applied to the unique light absorption properties of 
hemoglobin. However, hemoximetry measures the light absorption spectra of 
oxyhemoglobin, carboxyhemoglobin, methemoglobin, and deoxyhemoglobin. A light 
emitting diode transmits burst of red and NIR light at several wavelengths and measures 
the transmitted light with a photodiode [67]. From the measured modulation ratios, the 
pulse hemoximeter then calculates the fractions of O2Hb, COHb, MetHb, and Hb based 
upon the absorption spectra of the Hb types and calibrated values obtained from hypoxic 
and healthy volunteers. Measuring the spectra from the multiple Hb variants eliminates 
the errors that pulse oximetry generates in measurement of Hb and O2Hb absorption 
spectra when the structure of hemoglobin is altered. Though it does not have the 
limitation from other forms of Hb confounding the spectra, disruptions of the pulse and 
tissue perfusion contributes to poor transmittance of signals and incorrect pulse oximeter 
readings [66,68]. 
The invasive variation of hemoximetry is related to blood gas analysis as they 
both require collection of an arterial blood sample. The arterial blood is pumped through 
an opaque fluid channel while the transmitted light spectra from multiple wavelengths is 
Table 2.3: Parameters measured by hemoximetry [63–66]. 
Variable Abbreviation Acceptable range in arterial blood 
Fraction of oxyhemoglobin FO2Hb 95-98% 
Fraction of carboxyhemoglobin FCOHb 0-3% 
Fraction of methemoglobin FMetHb 0-3.8% 
Fraction of deoxyhemoglobin FHHb 0-2% 
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measured [65]. Measuring the spectra after light transmits through arterial blood, the 
oxygen saturation of hemoglobin in the sample is directly determined without the 
inconsistencies from pulse or tissue perfusion as in pulse oximetry. Unlike blood gas 
analysis, blood hemoximetry does not utilize a Clark electrode that requires regular 
calibration. Blood hemoximetry also does not approximate oxygen saturation by relating 
oxygen tension to the oxygen-hemoglobin saturation curve. However, because a blood 
sample is used similar in blood gas analysis, procedures in handling and analyzing the 
sample are followed to minimize errors occurring from air contamination and living cells 
consuming the oxygen. The methods of pulse oximetry, blood gas analysis, and 
hemoximetry are employed by physicians to determine the status of the patient. If the 
patient is found to be experiencing hypoxia, oxygen is delivered to the patient with one of 
two approaches. 
2.3 Current O2 delivery methods 
Currently there are only two medically accepted methods for delivering oxygen to 
a patient suffering from respiratory dyfunction or hypoxia. These approved interventions 
are mechanical ventilation and extracorporeal membrane oxygenation, and both 
implement different principles for oxygen delivery. Mechanical ventilation and 
extracorporeal oxygenation possess several advantages and drawbacks. In specific cases 
of respiratory failure, neither of these methods has proven to be an optimum treatment as 
the mortality rate of patients with respiratory failure remains high. 
2.3.1 Mechanical ventilation 
Mechanical ventilation (MV) is the oldest and currently the most common 
treatment method for oxygen delivery to a patient. The origins of MV begin in the fifth 
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century B.C. when Hippocrates conceptualized that sticking a reed into the trachea allows 
for air to be forced into the lungs [69]. Further reported development of MV is 
nonexistent for centuries until the 16
th
 century when Andreas Vesalius records the use of 
a MV device. The MV device consisted of a tube inserted into the trachea of an animal 
attached to bellows that inflated and deflated the lungs when compressed [70]. In the 
1700s, bellows were then used as a positive pressure ventilator to resuscitate drowning 
victims. Derivatives of the bellows design continued to be developed and still exist today 
in the form of bag valve masks typically used in ambulatory care and anesthesia. 
However, due to common disuse and over-inflation with these devices, victims can suffer 
pneumothorax or severe pulmonary barotrauma. The poor outcome of these early devices 
led them to be temporarily abandoned for most cases of medical practice when newly 
developed negative pressure ventilators became popularized [69,70].  
The first negative pressure ventilator, the body-tank ventilator, was developed by 
John Dalziez in 1838. The body-tank ventilator used a hand pump to change the pressure 
in an air-tight box the patient would sit in. The body-tank ventilator circulated and altered 
by several others, but no design ever established widespread use. The body-tank 
ventilator proved unwieldy to operate and caused patients to suffer from “tank shock” or 
accumulation of blood in the lower extremities [39,70]. Body-tank ventilators were 
eventually operated automatically and more efficiently with the accessibility of electricity 
in the 1900s. The most notable body-tank ventilator, the iron lung, was created by a 
Harvard collaboration of engineer Philip Drinker, physiologist Louis Shaw, and physician 
Charles McKhann. The iron lung passed animal trials in the late 1920s and later became a 
valuable device in treating patients with respiratory distress during the poliomyelitis 
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epidemics of the 1950s [39,69,70]. However, iron lungs still induced “tank shock”, were 
expensive to manufacture, and not widely available. Because of the problems with the 
iron lung, negative pressure ventilators experienced a rapid decline in use despite the 
success of the iron lung in the poliomyelitis epidemics. 
The resurgence of positive pressure ventilators occurred after a 1952 outbreak of 
poliomyelitis in Copenhagen, Denmark. At their only hospital, Copenhagen had a 
mortality rate of 87% in polio patients treated with a small number of negative pressure 
ventilators. The doctors quickly decided to switch to a different treatment strategy due the 
high mortality and lack of iron lung ventilators for the large number of polio patients 
admitted. Doctors instead performed a tracheostomy and positive pressure ventilation 
with a manual bag valve mask. This procedure using bag masks reduced the mortality 
rate to 40% in the 200 polio patients for whom this was implemented [70,71]. Due to the 
polio epidemic, the principles of MVs underwent considerable refinement to improve 
their efficiency at treating respiratory complications in ICUs and hospitals.  
2.3.1a Operating principles 
The central principle of MV is to deliver oxygen to the patient by assisting with 
the transport of gases into the lungs. Oxygen can be delivered noninvasively with a face 
mask, but leaks around the mask seal and face inhibit airflow control and limit the 
effectiveness of oxygen supply [72]. The most effective methods for oxygen delivery to 
the lungs are tracheal intubation with an endotracheal tube (ETT) or surgical placement 
of a tracheotomy tube. Modern MVs increase oxygen delivery to the body with two 
methods. The first method is increasing the concentration of oxygen inhaled, FiO2. The 
FiO2 is increased by mixing air with oxygen from an external source before being 
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supplied to the patient. The higher FiO2 increases the oxygen gradient within the alveoli 
and facilitates greater diffusion into the blood. However, if the patient is having severe 
difficulty breathing on their own, MV assists the patient through the second method. MV 
assists the patient with labored breathing or MV completely performs the ventilation 
process for the patient. MV facilitates the movement of gas for the patient by 
manipulating pressure differentials by two methods: negative or positive pressure.  
Negative-pressure ventilators function with the same principle as the respiratory 
system of mammals to facilitate the transport of oxygen into the lungs. In negative 
pressure ventilators, a chamber encloses the chest or body and is sealed from the 
surrounding atmosphere (Figure 2.6). Air is pumped out of the chamber to decrease the 
pressure in the chamber to be lower than the pressure in the lungs. The altered pressure 
causes the lungs to expand and draw in air from the surrounding atmosphere to facilitate 
inspiration. In order to facilitate expiration, air is pumped into the chamber to increase the 
 
Figure 2.6: Schematic of negative pressure ventilation. 
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pressure until it is greater than that in the lungs [73]. In contrast, positive-pressure 
ventilators operate by a simpler principle. Positive-pressure ventilators force an air-
oxygen mixture through a tracheal tube to directly inflate and deliver oxygen to the lungs. 
Depending on the condition of the patient, the positive-pressure ventilator allows the 
patient to breathe on their own or imposes ventilation by pumping gas into and out of the 
lungs [74]. Though positive-pressure ventilators operate with a simpler principle, the 
design of these ventilators is more complex (Figure 2.7). Regulating the breathing of a 
patient with MV operates with two different cycles to provide measured airflow within 
the lungs. In the cycle of volume control, a fixed volume of air, determined from the 
patient’s tidal volume, is delivered to the patient for each breath. For the cycle of pressure 
control, the lungs are inflated with the air-oxygen mixture until a selected positive 
pressure is reached in the circuit. These cycles of MV possess numerous variations in 
settings and strategies for treating different respiratory conditions [74,75]. One of the 
more successful strategies of MV is low tidal volume ventilation which reduces the risk 
of barotrauma and ventilator induced injury. Low tidal volume ventilation is the preferred 
treatment for several conditions, including ARDS. However, with the strategy of low 
tidal volume ventilation, there is increased risk of insufficient oxygen supply and 
hypercapnia, excessive carbon dioxide in the blood [76,77].  
2.3.1b Clinical utility 
MV is used in many scenarios where oxygen needs to be provided to patients. MV is 
utilized in cases including ARF, COPD, ARDS, pneumonia, neuromuscular disorders, 
and non-pulmonary sepsis [41,78]. When used to treat these conditions, the overall 
mortality rate ranges widely from 10-52% and highly depends on the condition affecting 
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the patient [79–81]. The mortality rate is lower in patients with conditions where the 
lungs were not impaired, such as in neuromuscular disorders. In cases of ARDS, where it 
is known that the functionality of the lungs is significantly decreased, the mortality was 
greater at 41-52% [80,81]. The high mortality demonstrates that MVs are capable of 
forcing air into the lungs and delivering sufficient oxygen to a patient for survival if there 
is something wrong with the musculature or nervous system which controls normal 
respiratory function. However, in an injured lung, gas exchange through the 
alveolocapillary membrane is compromised and MV is unable to adequately provide the 
necessary amount of oxygen to the patient for respiration. 
 
Figure 2.7: Schematic of modern positive-pressure mechanical ventilators. 
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Not only is MV ill-suited for supplying oxygen to damaged lungs, but several 
prominent risks are associated when used to treat these cases. When MV is done by an 
ETT or tracheotomy, a direct pathway is made to the lungs. Direct access to the lungs 
greatly increases the possibility of the patient contracting bacterial infections, such as 
pneumonia [82,83]. MV treatment with a tracheotomy is also uncomfortable for patients 
and limits their ability to communicate. Another recognized risk of MV is ventilator 
induced lung injury or pulmonary barotrauma [84,85]. These conditions are when the 
forced air creates excessive stress on the lungs causing tears in the capillary endothelium, 
epithelium, and basement membrane. The damage from excessive stress can lead to fluid 
leakage into the lungs and atelectasis which further inhibits the ability to breathe and 
transfer oxygen into the body. An additional risk of MV is significant atrophy of the 
diaphragm and respiratory muscles when used for at least 18 hours [86].  
2.3.2 Extracorporeal membrane oxygenation 
Extracorporeal membrane oxygenation (ECMO) is a relatively new medical 
treatment procedure. ECMO is currently the only form of extrapulmonary respiration 
treatment that has been shown to facilitate survival for prolonged treatment periods where 
the lungs are nonfunctional. The clinical benefit of ECMO has taken many years to attain 
sufficient support and was plagued by moral issues, highly criticized trials, and continual 
advancement of the technology. Beginning in the 1950s, the advancement of medical 
technologies and surgical techniques cumulated in the development and success of the 
heart-lung machine in human patients [87]. The heart-lung machine is used to keep a 
patient alive by circulating and oxygenating the blood while surgery is performed on the 
heart and lungs. However, first generations of the heart-lung machine were only able to 
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be used for a maximum of four hours. The four hour limitation was because the device 
oxygenated the blood being in direct contact with oxygen gas. The direct contact 
extracorporeal oxygenators caused severe hemolysis, clotting, protein denaturation of the 
blood, and air embolism during prolonged procedures [88]. 
To limit the blood trauma of direct contact extracorporeal oxygenators, research 
was directed towards developing membrane oxygenators that could exchange oxygen and 
carbon dioxide through a gas permeable membrane, while preventing blood from 
interacting with air surfaces. Progress stalled due to a lack of biomaterials with 
acceptable mechanical properties and that were permeable to oxygen and carbon dioxide 
gases. After years of development, the first successful human trial of prolonged ECMO 
support was accomplished for 75 hours in an adult patient with respiratory failure 
experienced from trauma of being hit by a car [89]. In 1974, the first success of ECMO 
treatment in neonate care was accomplished for a case of meconium aspiration causing 
severe pneumonia [90]. 
These encouraging results spurred the medical community into research to 
confirm the clinical benefit of ECMO treatment for respiratory failure. However, a 
randomized trial of adult ARDS patients treated with mechanical ventilation or VA 
ECMO had mortality rates of 90% in both groups [91] which led to ECMO treatment in 
adults with respiratory failure being recognized as impractical. In contrast, randomized 
clinical trials in neonates revealed a dramatic increase in survival when ECMO was 
utilized [92–94]. In the 1980s, previous work in using ECMO to treat adults was 
questioned by the supporters of ECMO under the basis that the equipment used was 
primitive, the staff was not highly trained in its use, and ECMO was used in conjunction 
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with mechanical ventilation which confounded the results. Due to the evident success of 
ECMO in neonates, improvement in technology, and the controversy over previous 
studies, interest in adult ECMO treatment was renewed. Results of more recent ECMO 
clinical trials detail promising outcomes from treatment. ECMO was found to reduce the 
rate of disability 6 months after treatment compared to conventional MV [95]. 
Additionally, ECMO has been successfully utilized in treating patients with ARDS 
contracted from H1N1 influenza [96]. Finally, the overall survival rate of ECMO patients 
has been increased to 56% [97]. With the amount of progress made in the field of 
medicine and biomaterials, ECMOs have become more efficient in oxygen exchange and 
have been utilized more often in patient care.  
2.3.2a Operating principles 
ECMO is an example of an extrapulmonary respiration treatment method and 
currently the only clinically accepted method for prolonged use. The basis of ECMO is to 
circumvent the necessity of the lungs by removing venous blood from the body, adding 
oxygen, and returning the re-oxygenated blood to the body [98]. ECMO’s procedure 
requires several specialized components to operate efficiently. These components include 
a heat exchanger to warm the blood to body temperature before reinfusion into the 
patient, a gas trap to prevent air embolism, and access ports for introduction of 
anticoagulants and drugs or analysis of blood oxygen saturation levels (Figure 2.9). 
 In order to access the patient’s blood to remove, oxygenate and return it to the 
body, large catheters are inserted into major veins. There are two types of cannulation 
techniques used for ECMO: veno-venous (VV) and veno-arterial (VA). The most 
common technique is VV ECMO, which only provides respiratory assistance to the  
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Figure 2.8: Schematic of ECMO circuit. 
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circulation is required to further increase oxygenation, then drainage cannula will be 
placed in both the inferior and superior vena cavae [99,100]. With new cannula designs, 
it is possible to do VV ECMO with only one dual lumen catheter inserted into the right 
atrium [88,100]. The VV ECMO setup decreases recirculation of blood in the ECMO 
circuit, bleeding issues from cannulation, and increases the mobility of the patient [101]. 
VA ECMO is able to provide both cardiac and respiratory assistance. VA ECMO is 
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the ascending aorta or the femoral artery. The method of VA ECMO has a higher chance 
of serious arterial injury, air embolism, and thrombosis [99].  
A pump is required to control the flow of blood from the patient into the ECMO 
machine. Current ECMO machines typically use peristaltic, also called roller, pumps, but 
advances with centrifugal pumps have increased their use. Both types of pumps are 
known to cause hemolysis and platelet breakdown, which increases the chance of 
thrombosis and decreases the oxygen carrying capacity of the blood. Peristaltic pumps do 
not need to be primed with fluid to begin pumping and the blood does not interact 
directly with the pumping mechanism. The disadvantage of peristaltic pumps is that 
excessive wear on the tubing from the rollers can cause ruptures in the line and the 
drainage of blood is assisted by gravity and a reservoir, so clotting is more likely to occur 
[102]. Centrifugal pumps allow for a shorter circuit length and smaller surface area for 
blood-prosthetic surface interaction, which decreases the activation of inflammatory 
factors. However, centrifugal pumps have been documented to increase the amount of 
hemolysis and risk of acute renal failure [103]. 
The next critical component is the membrane oxygenator, which has always been 
the major limiting factor of ECMO. Initial oxygenators were direct-contact oxygenators 
such as the Mayo-Gibbon pump-oxygenator, Kay-Cross disc oxygenator and the DeWall 
bubble oxygenator. These designs were revolutionary at the time, but they could not be 
used longer than four hours without serious risks. Complications of damage of the red 
blood cells and platelets, thrombosis, and protein denaturation stemmed from the direct 
contact of blood with air. To reduce damage to the RBCs, a membrane composed of a 
biomaterial was incorporated into the oxygenator to act as an interface between the air 
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and blood. The membrane interface has to be gas permeable for transfer of oxygen and 
carbon dioxide, rigid, and prevent the adhesion of blood to its surface [104]. Current 
membranes are composed of silicone, microporous hollow polypropylene fibers, or 
polymethyl pentene (PMP). Silicone membranes are very durable, have a high resistance 
to flow, and the lowest gas exchange efficiency of modern membranes. Microporous 
hollow-fiber oxygenators are used in cardiopulmonary bypass machines due to their 
efficient gas exchange properties. However, plasma leakage from the micropores occurs 
within a few hours of use and therefore they must be replaced frequently. PMP 
oxygenators are the newest type of membrane with gas exchange efficiency similar to 
microporous hollow-fiber and the longevity of silicone membranes. They also slowly 
develop leaking of plasma and have increased resistance of blood flow from deposition of 
fibrous networks [105].  
2.3.2b Clinical utility 
ECMO was originally developed as a long term solution for cardiopulmonary 
bypass in surgeries on the heart or the lungs, as the current bypass machine could only be 
used for short periods of time. With the development of the membrane oxygenator, long 
term ECMO treatment was possible. ECMO is utilized as a bridge to lung transplantation, 
cardiac failure, hypoxia, and respiratory failure caused by lung trauma, pneumonia, 
influenza, sepsis, COPD, or ARDS [17,102]. According to the registry of the 
Extracorporeal Life Support Organization (ELSO), the mortality rate for pneumonia 
patients treated with ECMO in 2013 was 38.5%, while mortality in patients with ARDS 
or ARF was 47% [97]. These mortality rates for clinical trials of ECMO treatment remain 
within the 34-53% range that has been reported for the past 20 years [88,95,100,106–
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108]. Despite the lack of improvement seen, cases have shown that ECMO treatment can 
possibly improve the outcome of respiratory failure and ARDS. Patients diagnosed with 
severe ARDS have an expected mortality greater than 80%, yet mortality for those treated 
with ECMO is 48% [106]. Another influential study in respiratory failure showed that the 
mortality rate for ECMO patients was 37% compared to 45% for patients treated with 
conventional MV [95]. However, ECMO involves a significant chance for complications 
to occur regardless of current advancements in clinical procedures and components. 
There are many recognized risks associated with ECMO which affect the outcome 
of the patient. The most prevalent risks are bleeding related complications including 
cannulation site bleeding, cardiac arrest, thrombosis, hemorrhaging, and hemolysis 
[99,100,106]. Bleeding complications are not only the most common risks of ECMO, but 
thrombosis and hemorrhaging have the greatest capacity to negatively impact survival 
[97,107,109]. Bleeding risks have also been indicated as more likely in VA ECMO 
compared to VV ECMO [99,109]. The risk of bleeding complications also increases 
when high doses of anticoagulants, such as heparin, are given to the patient. To reduce 
the amount of anticoagulants needed to prevent clotting in the circuit, ECMO 
components have been developed with heparin coatings [98,101,102]. However, ECMO 
treatment can still result in hemolysis and thrombosis despite utilization of heparin 
coatings, more stable flow from pumps, and biocompatible membranes. Another 
prevalent complication is infection from either contamination of the blood while in the 
circuit or from the catheter placement site [99,109]. Other major complications include 
renal failure, pneumothorax, seizures, and mechanical failures [99,100,106,107,109]. 
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Seizures and intracranial hemorrhaging though rare in adult patients, are more common 
in pediatric and neonatal patients [97].  
ECMO retains considerable stigma as a clinical treatment of “last resort” despite 
confirmed clinical benefit in certain cases of respiratory failure. The stigma remains 
because ECMO still exhibits a wide range of risks, requires continuous oversight by 
experienced perfusionists, and remains unable to be used in ambulatory cases due to its 
large size. Thus, considerable research and development occurs to realize an alternative 
method for delivering oxygen to a patient suffering from respiratory failure and hypoxia.  
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Chapter 3: Peritoneal oxygenation 
Peritoneal oxygenation is a proposed alternative to MV and ECMO treatments for 
patients with hypoxia or respiratory failure in ambulatory, emergency, and long-term 
care. Peritoneal oxygenation is a method of extrapulmonary oxygenation without the 
limitations or associated risks of MV and ECMO. Peritoneal oxygenation is 
accomplished by utilizing the peritoneum as a location for gas exchange in place of or in 
addition to the lungs. The peritoneum is the serous membrane that lines the abdominal 
cavity and the peritoneal organs (Figure 3.1) [22,110]. The peritoneum qualifies as a 
location for the supportive delivery of oxygen because it possesses a large surface area 
for diffusion [111,112], close proximity to multiple organs [26], extensive vascular 
structure [22,110], and considerable circulation of blood (Figure 3.2) [113–115]. The 
main advantages of peritoneal oxygenation are easy access for catheterization, relative 
safety of cycling oxygen gas through the intraperitoneal cavity (IPC) as the mesothelium  
 
Figure 3.1: Anatomy of peritoneum and intraperitoneal organs. 
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acts as a gas permeable barrier between the perfusate and the blood, undiminished gas 
exchange properties during respiratory failure, and avoidance of the external circulation 
of blood. Peritoneal oxygenation is analogous to peritoneal dialysis, which is used in 
cases of renal failure. Peritoneal dialysis is a simple, low-tech form of renal replacement 
therapy that is less expensive and complex than conventional in-center hemodialysis 
[22,110]. When the IPC is filled with dialysis solution, waste compounds such as urea 
and creatinine diffuse out of the bloodstream and into the dialysis solution. After a period 
of dwell, the fluid is drained and the IPC refilled with fresh dialysis solution [116]. 
Similarly, in peritoneal oxygenation, an oxygen carrying perfusate is infused into the IPC 
where the oxygen will diffuse into the blood and be transported throughout the body 
(Figure 3.3). However, as with MV and ECMO using peritoneal oxygenation as an 
alternative method of supportive oxygen delivery possesses several inherent limitations.  
 
Figure 3.2: Splanchnic circulation and average blood flow rates of human at rest (Figure 
derived and modified from [117]). 
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Figure 3.3: Pathway of oxygen diffusion for peritoneal oxygenation. 
3.1 Limitations 
There are five acknowledged limitations when utilizing the peritoneal cavity for 
extracorporeal oxygenation (Table 3.1). Though the surface area of the peritoneum is 
large compared to other structures in the body, it is relatively small when compared to 
lungs [118–120]. The smaller surface area of the peritoneum indicates that the potential 
for gas exchange is also less than the lungs. Further limiting the delivery of oxygen to the 
body, only 20-30% of total blood flow passes through the splanchnic circuit at any time 
[113,115,121]. The thickness of the peritoneum membrane is greater than that of the 
alveolocapillary membrane, which slows down diffusion of oxygen into the capillary bed 
of the splanchnic circulation [22,110,122]. Also, the intra-abdominal pressure (IAP) must 
be carefully regulated to not surpass 10 mmHg. IAP increased above 10 mmHg is 
documented to reduce splanchnic blood flow, cardiac output, and peripheral tissue 
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oxygen saturation [21,123–126]. Inciting hemodynamic changes negatively impacts the 
potential effectiveness of oxygen delivery through the IPC. The final limitation of 
peritoneal oxygenation is a complication that also occurs in MV and ECMO. The long 
term cannulation into the peritoneal cavity increases chances for infection of the 
peritoneum, peritonitis [22,116]. However, in contrast to ECMO, peritoneal oxygenation 
possesses no direct pathways to the bloodstream or risks of bleeding unless a 
complication occurs during implanting the abdominal catheter. 
Despite these limitations, peritoneal oxygenation continues to demonstrate 
potential to be utilized as a method of supplemental extrapulmonary oxygenation. In a 
study to validate the effectiveness of peritoneal oxygenation, normoxic dogs had their 
peritoneal cavity implanted with an inflow and outflow catheter [21]. The catheters were 
attached to a centrifugal pump and a membrane oxygenator. The peritoneal cavity of the 
dogs was then circulated for 2 hours with unoxygenated saline, oxygenated saline, or 
oxygenated human RBCs while arterial blood gases were periodically measured. While 
dogs that were circulated with unoxygenated saline maintained a constant PaO2, 
oxygenated saline and human RBCs increased the PaO2 by 15 and 30 mmHg, respectively 
[21]. The experiment of peritoneal oxygenation in dogs confirmed that though the 
method of peritoneal oxygenation may not be as efficient as ECMO or MV due to several  
Table 3.1: Limitations of peritoneal cavity when compared to the lungs.  
Gas Exchange 
Locations 
Surface 
Area 
(m
2
) 
Volume 
(L) 
Blood 
flow 
(L/min) 
% of total 
blood flow, ie 
cardiac output 
Membrane 
thickness 
(μm) 
Lung 
[43,44,119,120] 
24-75 4-6 
4.4-8.4 
[127,128] 
100 
[127,128] 
0.1-2.2 
Peritoneum 
[22,110,116,118] 
1-2 2-3 
1.4-2 
[113,114] 
17-30 
[113,115,121] 
24 -500 
[22,122] 
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inherent limitations, peritoneal oxygenation is capable of delivering a clinically relevant 
increase to oxygen saturation with an effective oxygen carrier. However, an optimal and 
safe oxygen carrier has not yet been developed for peritoneal oxygenation to be feasible 
as a method of supplemental oxygenation. 
3.2 Previous peritoneal oxygenation methods 
Peritoneal oxygenation is developed as an extrapulmonary method of supplying 
oxygen to the body. However, previous techniques of peritoneal oxygenation attempted 
in animals were unable to demonstrate a consistent clinical improvement in models of 
hypoxia (Table 3.2). The previous techniques of peritoneal oxygenation attempted 
ventilating the peritoneal cavity or infusing different artificial oxygen carriers to deliver 
supplemental oxygen through the peritoneum in animal models of hypoxia.  
3.2.1 Beginning of peritoneal oxygenation 
The first method of peritoneal oxygenation reported was by the infusion of 
hydrogen peroxide (H2O2) in 1968 [129]. The theory was that when hydrogen peroxide 
was infused into the IPC, H2O2 would decay into water and oxygen, which would 
increase systemic oxygenation during hypoxia. In animal trials, a momentary increase in 
arterial oxygen saturation was observed. The increase in oxygen saturation was minor 
and indicated no clinical benefit as an outcome. Based on the results of several studies, 
hydrogen peroxide infusion for peritoneal oxygenation was determined to be ineffective 
and hazardous due to high risk of gas emboli formation [129,136]. However, the idea of 
peritoneal oxygenation remained and researchers continued attempts at validating 
peritoneal oxygenation with different techniques.  
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Table 3.2: Summary of peritoneal oxygenation studies.  
Animal 
model 
Hypoxia 
method 
Duration of 
experiment 
(minutes) 
Perfusate 
Outcomes in 
survival/oxygenation 
Rabbit 
[129] 
FiO2 reduced 
to 10% 
30 H2O2 
SaO2 increased 2-9% for 2 
min; decreased after 10 and 
30 min 
Rabbit 
[130] 
Pulmonary 
lavage with 
saline 
120 O2 gas (PV) 
1.7 fold increase in PaO2 and 
80% survival; controls had 
0% survival 
Rabbit 
[131] 
Pulmonary 
lavage with 
saline 
120 O2 gas (PV) 
100% survival, 2.2 and 4.8 
fold increase in PaO2 without 
and with cisapride 
Swine 
[132] 
FiO2 reduced 
to 15% 
180 O2 gas (PV) No increase in SvO2 
Rabbit 
[133] 
Clamped 
trachea 
10 O2 gas (PV) No relevant increase in PaO2 
Rat 
[134] 
FiO2 reduced 
until PaO2  
55 mmHg 
60 
PFC (FC43) 
PaO2 and SaO2 increased ~20 
mmHg and ~6% 
PFC 
(Haemaccel) 
PaO2 and SaO2 increased ~10 
mmHg and ~4% 
None 
PaO2 increased ~10 mmHg 
and SaO2 decreased 2% 
Canine 
[122] 
FiO2 reduced 
variably 
270 
PFC 
(decalin) 
PaO2 increased 5-25 mmHg 
during mild hypoxia, but 
decreased in severe hypoxia 
Swine 
[20] 
FiO2 reduced 
to 10% 
300 
PFC 
(decalin) 
PaO2 increased an average of 
12.8 mmHg 
Rat 
[135] 
Pneumothorax 45 
Synthetic Hb 
(TRM-645) 
Survival time increased 
360% and PaO2 increased 
740% compared to saline 
controls 
3.2.2 Peritoneal ventilation 
Another attempted method was application of mechanically ventilating the 
peritoneal cavity. In peritoneal ventilation (PV), the peritoneal cavity is inflated and 
deflated with pure oxygen from a positive pressure ventilator similar to traditional MV of 
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the lungs. The first reported study of peritoneal ventilation was in 1994 when rabbits 
were submitted to a pulmonary lavage of saline to induce severe ARDS symptoms [130]. 
The animals were divided into the control group, which was treated with conventional 
MV, or the experimental group, which was treated with conventional MV in parallel with 
PV. All six animals in the control group rapidly developed severe hypoxia and died 
within 75 minutes after the lavage, while four of the five rabbits in the peritoneal 
ventilated group lived with an average PaO2 of 81 mmHg until the two hour endpoint 
[130]. 
In 1996, the same research group reported on a modified peritoneal ventilation 
therapy, which significantly increased the oxygenation in rabbits with ARDS induced by 
pulmonary lavage [131]. The modified PV therapy used a dose of cisapride, an agent that 
increases gastric emptying, to improve the blood flow through the splanchnic circuit. The 
study showed that healthy rabbits dosed with cisapride had splanchnic blood circulation 
increase by 188%, but did not exhibit changes in PaO2 while on conventional MV. 
Rabbits with ARDS were injected with a dose of cisapride or saline and treated with 
conventional MV. The MV groups treated with only cisapride or saline did not show any 
increase in PaO2 and all died 45 minutes after the lavage. In contrast, all rabbits with 
ARDS treated with PV in addition to MV survived until the two hour endpoint. 
Additionally, the peritoneal ventilated rabbits injected with cisapride developed 
significantly higher levels of PaO2 after 30 minutes than those injected the saline vehicle 
[131]. 
With the results from studies in rabbits, peritoneal ventilation with oxygen 
demonstrated potential in improving the outcome in cases of respiratory failure and 
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hypoxia. However, a subsequent large animal study published in 1998 challenged the 
clinical potential of peritoneal ventilation [132]. Six pigs were mechanically ventilated 
with a normal FiO2 of 0.2 then a hypoxic FiO2 of 0.15. Pigs underwent peritoneal 
ventilation after being stabilized for 30 minutes at each FiO2. All pigs had their SvO2 
measured and peritoneal oxygen uptake determined with a spirometer. No increase was 
found in oxygen uptake or SvO2 of pigs with PV compared to when the peritoneal cavity 
was not ventilated [132]. The study with pigs revealed that PV with oxygen yielded little 
potential for clinical applications. The potential of PV was tested once more in the most 
recent study of asphyxiated rabbits. 
The most recent study of peritoneal ventilation was published in 2010 and 
detailed an experiment where 24 rabbits experienced asphyxia by tracheal clamp [133]. 
Rabbits were randomly assigned treatment of no PV, PV with air, or PV with pure 
oxygen. Groups with peritoneal ventilation were found to have a marginal increase in the 
PaO2 measured compared to the control group without PV. The control group survived an 
average of 5.0 minutes after the tracheal clamp and was not significantly different from 
the air ventilation group average of 5.3 minutes. The oxygen ventilated group had an 
average survival time of 6.5 minutes and was significantly different than the other two 
groups [133]. The increase in survival time and PaO2, however, was not substantial 
enough to be of any clinical benefit and supported the claim that peritoneal ventilation 
has a low clinical utility. Despite the failure of peritoneal ventilation, other techniques 
using artificial oxygen carriers have demonstrated a greater clinical relevance regarding 
the treatment of hypoxia with peritoneal oxygenation.  
 46 
3.2.3 Artificial oxygen carriers 
The technique of peritoneal oxygenation that is investigated in addition to 
peritoneal ventilation is infusing the peritoneal cavity with artificial oxygen carriers. 
Artificial oxygen carriers were originally developed for liquid ventilation or as blood 
substitutes. The blood substitutes of perfluorocarbons and hemoglobin-based oxygen 
carriers have demonstrated carrying capacities for oxygen that are greater than blood. The 
potential of these blood substitutes as oxygen carriers gained interest for their use in 
peritoneal oxygenation.  
3.2.3a Perfluorocarbons 
The most studied method of peritoneal oxygenation involves infusion of 
perfluorocarbon (PFCs) variants into the intraperitoneal space. PFCs are fluorinated 
carbon chains similar to hydrocarbons and are extremely hydrophobic. Aqueous PFCs are 
inert colorless liquids twice as dense as water with a high solubility for oxygen and 
carbon dioxide gases [137,138]. Because the solubility of oxygen in PFCs is a linear 
relationship to the partial pressure of oxygen, PFCs are poor oxygen carriers compared to 
RBCs and hemoglobin at physiological pressures of oxygen. However, PFCs are very 
efficient at delivering oxygen as the oxygen is never bound [137,138]. The delivering 
efficiency of oxygen sparked interest in the use of PFCs as an alternative method of 
oxygenating tissue. PFCs were researched thoroughly in the area of liquid ventilation due 
to a sensationalist experiment in 1966 where mice and cats were submerged in a 
container filled with PFCs and survived while “breathing” the fluid [139]. When removed 
from the container, the animals returned to breathing air. However, the PFC formulation 
was not ideal because animals undergoing liquid ventilation treatment only lived for 
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several weeks afterwards as the inhalation of PFCs caused significant pulmonary damage. 
Despite the long term effects, the demonstrations of liquid ventilation showcased the 
biocompatibility and medical applications of PFCs. Since then, alternative oxygen 
delivery methods with PFCs have been investigated including peritoneal oxygenation. 
The first study of peritoneal oxygenation with oxygenated PFCs was performed in 
1986 with slightly hypoxic rats (PaO2 ≈ 55 mmHg and SaO2 ≈ 87%) caused by reduced 
FiO2 [134]. In the experiment, only one of the two PFC variants (FC43) provided a 
significant increase in PaO2 and SaO2 from the induced hypoxic baseline compared to the 
untreated controls [134]. In a subsequent study in dogs, oxygenated PFCs were infused 
into the IPC during normoxic, mild hypoxic (SaO2 > 80%), or severe hypoxic (SaO2 < 
80%) conditions [122]. The PaO2 of dogs was increased 5-25 mmHg above the baseline 
during mild hypoxia, while the PaO2 continually decreased in dogs with severe hypoxia 
despite infusion of oxygenated PFCs. The studies with PFCs in small animal displayed 
moderate potential to be utilized as an oxygen carrier for peritoneal oxygenation. The 
benefit of peritoneal oxygenation with PFCs was then attempted in pigs to determine if 
there was potential for clinical use. 
The most recent study in peritoneal oxygenation with PFCs was in 2006 with 
hypoxic pigs [20]. The animals were intubated and mechanically ventilated. The 
experiment consisted of a dwell period and a circulation period with either oxygenated 
saline or PFC. The dwell period consisted of infusing a volume of perfusate based upon 
body weight into the peritoneal cavity and then decreasing the FiO2 from 18% to 10% by 
2% intervals every 30 minutes. After the dwell period, the perfusate was circulated 
through an oxygenation circuit into the peritoneal cavity while FiO2 was elevated from 
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10% to 18% by 2% intervals every 30 minutes. The administration of PFC showed an 
overall effective increase of 12.8 mmHg in PaO2 when compared to the saline treatment. 
The greatest increase in PaO2 with PFC treatment observed was 15.9 mmHg which 
occurred when FiO2 was set at 14% [20]. The large animal study in pigs demonstrated 
promising results for peritoneal oxygenation with PFCs being utilized as an alternative 
method of extrapulmonary support. However, the use of PFCs as an oxygen carrier 
encounters several severe disadvantages.  
Though the results of peritoneal oxygenation with PFC are significantly more 
promising than those of peritoneal ventilation with oxygen, there are factors that prevent 
PFCs from being the ideal oxygen carriers for supportive oxygenation. PFCs for 
biomedical and oxygen carrying purposes are required to be emulsified because of the 
PFCs highly hydrophobic and lipophobic properties. The hydrophobic and lipophobic 
properties of PFCs also causes the manufacture and emulsion process to prepare PFCs for 
biomedical applications to be complicated and difficult [137,140]. Gaseous PFCs are also 
extremely stable compounds with lifespans of thousands of years and entrap heat in the 
atmosphere 10
3
-10
4
 times greater than CO2 [141]. Thus, gaseous PFCs are recognized as 
an environmental hazard and under strict emission standards according to the Kyoto 
Protocol because gaseous PFCs possess exceptional potency as greenhouse gases with 
significant impact for increasing global warming [142]. Also, despite extensive research, 
an optimal PFC for peritoneal oxygenation has not been developed and many PFCs 
previously approved by the FDA have been removed from the market [143,144]. During 
multiple preclinical and clinical trials, PFCs were tested as a blood substitutes in cases of 
hemorrhagic shock and ischemia. In the trials, PFC treatment caused a significant 
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increase in flulike symptoms, stroke, and thrombocytopenia [133,144,145]. In addition to 
these health concerns, early evidence suggested that PFC emulsions would be 
metabolized and removed from the body by the reticuloendothelial system of the liver, 
spleen, and bone marrow [137]. However, in the trials of PFC treatments, the PFCs were 
observed to cycle through and suppress the reticuloendothelial system. The suppression 
of the reticuloendothelial system lead to PFC particles being retained for long durations 
in the body, particularly in the liver, spleen and lungs [144,145]. The retention of PFCs in 
the lungs was recognized to cause chemical pneumonitis and death by accumulation of 
gas emboli [145,146]. Retention of PFCs was attributed to the PFC compounds being so 
biologically inert and unable to diffuse through cell membranes. Due to the multiple 
health risks from PFC treatments in preclinical and clinical trials, the FDA has suspended 
clinical trials where PFCs were used as blood substitutes or oxygen carriers. Due to the 
health concerns PFCs have encountered as blood substitutes, the biocompatibility of 
PFCs is now suspect and its future as an oxygen carrier for peritoneal oxygenation is 
uncertain. 
3.2.3b Hemoglobin based oxygen carriers (HBOCs) 
The second type of artificial oxygen carrier currently being developed are 
hemoglobin based oxygen carriers (HBOCs). HBOCs are originally designed for use as 
an allogenic substitute for blood while alleviating the substantial shortage in donations. 
The optimal HBOC would be able to replace the need for blood transfusions in surgeries 
or cases of hemorrhage shock and anemia without being concerned about compatibility 
[144,147]. Because of their oxygen carrying properties, HBOCs are also being 
investigated for use as oxygen carriers to treat local tissue ischemia and tumor hypoxia 
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and for preserving donated organs [143,144]. The hemoglobin used for creating HBOCs 
is obtained from the lysis of human or bovine red blood cells or by altering the genome of 
Escherichia coli to produce human hemoglobin proteins. Because of the inadequate and 
limited sources for hemoglobin protein, the cost of HBOCs is three times that of donated 
human blood [148,149]. Most HBOCs developed are categorized as acellular HBOCs 
where the hemoglobin proteins remain unbound by a membrane [143,150,151]. The 
hemoglobin is heavily modified by crosslinking, polymerizing, or conjugating to increase 
its intravascular and room temperature stability while maintaining its oxygen affinity 
[138,151]. Recently, nanoparticle HBOCs have been developed where the hemoglobin 
proteins are encapsulated in a lipid or polymer membrane [143,147,152].  
HBOCs have seldom been used as an oxygen carrier for peritoneal oxygenation. 
However, the most successful application of peritoneal oxygenation in previous literature 
was using a nanoparticle HBOC [135]. The HBOC, TRM-645, is produced from donated 
human blood that is not acceptable for transfusion because it is too aged. The expired 
blood is lysed and the hemoglobin is encapsulated in liposomes synthesized from 
phosphatidylcholine, cholesterol, and stearic acid with the surface modified by the 
addition of PEG [152]. Hypoxia from a fatal right pneumothorax was created by stabbing 
the ribcage with a scalpel blade and piercing through the pleural membrane. After 
inducing the pneumothorax, rats were treated with a peritoneal injection of the same 
volume of saline, oxygenated human blood, or oxygenated TRM-645. Saline treated rats 
rapidly developed respiratory acidosis and hypoxia leading to cardiac arrest. Rats treated 
with TRM-645 showed a significant increase of PaO2 compared to rats treated with saline 
and human blood. Another factor indicating the effectiveness of peritoneal oxygenation 
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with TRM-645 was that the survival time after pneumothorax was significantly increased 
to 32.9 minutes from 9.2 and 22 minutes with saline and human blood, respectively 
[135]. 
HBOCs require further development in order to accomplish their purpose as an 
ideal blood substitute and artificial oxygen carrier. The progress in acellular HBOCs has 
mostly been discontinued because multiple clinical trials reported health complications 
and negligible benefits and were suspended by the FDA [143,149–151]. Treatment with 
acellular HBOCs is responsible for causing vasoconstriction from excessive nitric oxide 
scavenging, neurotoxicity when the blood brain barrier was compromised, severe 
gastrointestinal distress, producing oxygen free radicals, and degrading into 
methemoglobin. There is also concern that treatments with acellular HBOC may lead to 
an increased risk of myocardial lesions and infarctions [153,154]. To remedy the issues 
with acellular HBOCs, nanoparticle HBOCs were developed to mimic how RBCs safely 
transport hemoglobin. Nanoparticle HBOCs have demonstrated lower methemoglobin 
formation, limited scavenging of nitric oxide, and similar behavior to RBCs in binding 
and releasing ligands [155–157]. Currently, nanoparticle HBOCs are limited by their 
lower oxygen affinity, short in vivo half-life, membrane stability, obtaining a stable 
inexpensive source of hemoglobin, and hepatosplenomegaly at large dosages [143,147–
149,152]. Overall, results in research and development of nanoparticle HBOCs is 
encouraging, but they could possibly produce the negative symptoms recognized by 
acellular HBOCs if the encapsulated hemoglobin were to be released when the membrane 
degrades or fails. Currently, the limitations and safety concerns of using HBOCs and 
PFCs as oxygen carriers prevents peritoneal oxygenation from being considered as a 
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feasible method of supplemental oxygenation. To fulfill the role of a safe and effective 
artificial oxygen carrier, an alternative method of delivering oxygen is needed for 
peritoneal oxygenation.  
3.3 Peritoneal microbubble oxygenation with oxygen microbubbles 
Advances in developing peritoneal oxygenation as a treatment method for 
delivering supplemental oxygen in cases of acute hypoxia is evidenced to be difficult. 
Current methods of peritoneal oxygenation attempted in hypoxic animal models provided 
marginal clinical benefit in improving oxygenation. The lack of progress is mainly from 
the disadvantages of current oxygen carriers, PFCs and HBOCs, which include limited 
oxygen carrying capacities, manufacturing obstacles, and health concerns [144,148]. Due 
to these significant limitations current artificial oxygen carriers are ineffective for 
delivering short or long term supplemental oxygen through the peritoneum.  
Oxygen microbubbles (OMBs) have been proposed as an alternative to fulfill the 
role as an efficient and safe oxygen carrier. OMBs are derived from gas microbubbles 
originally used as contrast agents for ultrasound, vehicles for drug and gene delivery, and 
potential blood substitutes [158–161]. Gas microbubbles are formed by a thin membrane 
which encloses a gas core. The membrane of the microbubbles is typically composed of 
amphiphilic proteins, polymers, or most commonly lipids and phospholipids. Using 
amphiphilic molecules like phospholipids for the membrane material of the gas 
microbubbles allows for greater control of the surface structure and for self-assembly into 
a monolayer that can surround gas [162,163]. Microbubbles used as contrast agents 
generally encapsulate biologically inert gases such as perfluorobutane, while 
microbubbles for gene delivery contain DNA suspended perfluorocarbons [158,160,163]. 
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Because of the long history and widespread use of microbubbles in the medical field, 
phospholipid microbubbles have been extensively characterized, optimized, and 
investigated [164–170]. 
3.3.1 Microbubbles as a blood substitute 
Lipidic oxygen-containing microparticles (LOMs) are a variant of oxygen 
microbubbles composed of a DSPC lipid monolayer with polyoxyethylene stearyl ether 
(BRIJ 100) linked to the surface. LOMs were tested as a blood substitute for short-term 
oxygen delivery by intravenous injection [171]. The LOMs were tested in rabbits 
experiencing one of two scenarios, hypoxic ventilation with a FiO2 of 11% or asphyxia 
by clamping of the endotracheal tube (ETT) for 15 minutes. Rabbits under hypoxic 
ventilation had no hemodynamic instability and oxyhemoglobin saturations between 65-
75%. When the rabbits were administered 80 mL of 50% per volume LOMs for two 
minutes (40 mL LOM50/min), their oxyhemoglobin saturations were increased to normal 
levels of ~90%. Once the LOM injection was completed, the oxyhemoglobin saturation 
of the rabbits returned to hypoxic levels [171]. Asphyxia rabbits were intravenously 
administered 70% LOMs at 4.5 mL/kg or a control solution at 1.3 mL/kg per minute for 
15 minutes after the clamp was placed. All the control rabbits suffered cardiac arrest 
within 10 minutes and only 75% were able to be resuscitated by continuous chest 
compressions for the remaining five minutes. Their oxyhemoglobin saturation decreased 
below 20% three minutes after the clamp was placed and never increased until removed. 
However, the rabbits injected with LOMs maintained oxyhemoglobin saturations above 
40% during the entire 15 minutes, never had to be resuscitated by chest compressions, 
and had a survival of 85% by the end of the period of asphyxia [171].  
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The study with intravenous LOMs demonstrates that phospholipid oxygen 
microbubbles have significant potential as an oxygen carrier for clinical cases of hypoxia. 
However, intravenous injection of LOMs is limited to cases of short term hypoxia as 
several factors prohibit the use of intravenous injection of microbubbles. The first 
problem is that injecting a large volume of fluid into the bloodstream for long periods 
will result in hypervolemia, pulmonary edema, hemodynamic instabilities, and decreased 
hematocrit [24,28,36]. Another problem is that injecting large quantities of lipid into the 
blood could result in clotting and thrombosis within the vasculature. When the oxygen 
diffuses out of the bubbles, the membrane collapses and the lipids more readily coalesce 
[168,169]. The coalesced lipids could then obstruct the blood vessels before they can be 
removed. The multiple problems associated with using microbubbles as a blood substitute 
can be circumvented by employing oxygen microbubbles as an efficient and safe oxygen 
carrier for peritoneal oxygenation.  
3.3.2 Properties of oxygen microbubbles 
The OMBs used in my investigation of peritoneal microbubble oxygenation 
therapy are phospholipid microbubbles, which encapsulate pure O2 gas and are suspended 
in sterile saline (Figure 3.4). The outer surface of the lipid monolayer is modified by PEG 
covalently linked to the hydrophilic head. The PEG molecules form a “brush” that 
stabilizes the lipid monolayer and prevents coalescence of the microbubbles. The 
phospholipid and PEG monolayer only comprises ~1% of the OMBs volume. The 
oxygen gas core and saline constitute the remaining volume of the OMB solution. The 
volume of saline can be decreased for a suspension with a higher density of microbubbles 
or increased for a suspension with a lower density of microbubbles. Increasing the 
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density of the microbubbles increases both the oxygen carrying capacity and the viscosity 
of the OMB solution. Thus, to more greatly mimic the fluid properties of blood, OMBs 
are often diluted to ~70% per volume mixture with the remaining 30% being saline. Even 
with the OMB fraction only comprising 70% of the solution, the selected OMB solution 
has the greatest capacity for carrying oxygen compared to all other existing artificial 
carriers (Table 3.3). 
Oxygen microbubbles were designed to comprise a phospholipid coating 
stabilizing a microscopic bubble of oxygen gas (Figure 3.5a). This design was chosen to 
mimic the naturally occurring surfactant that lines the lung alveolus, which is primarily 
composed of diacyl phosphatidyl-choline (DPC) [175]. Saturated DPC lipids self-
assemble at the gas/water interface to form a 3-nm thick monomolecular layer that can be 
compressed to achieve very low interfacial tensions [176], which is necessary to avoid 
premature microbubble dissolution [177]. Distearoyl phosphatidyl-choline (DSPC) was  
 
Figure 3.4: Structure of oxygen microbubbles used for PMO therapy. 
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Table 3.3: Comparison of artificial and biological oxygen carriers.  
Carrier 
O2 carrying capacity, 
BO2 (mgO2/mL) 
Volume O2/volume 
carrier (%) 
Size/diameter 
(μm) 
Saline, water, 
blood plasma 
[28,32,34,38] 
0.038 0.03  
RBC 
[28,32,34,38] 
0.31 17-20 6-8 
PFC 
[20,143,172] 
0.57 5-7.2 0.01-0.35 
HBOC 
[135,143,173] 
0.62 5-15 0.05–0.3 
OMB 0.88 70 5-7 
OMB90 1.13 90 5-7 
chosen as the main lipid component because it provides an optimal tradeoff between in-
plane rigidity to stabilize microbubbles for long durations in storage [166] and relatively 
low gas permeation resistance [164]. The lipid monolayer is permeable to oxygen and 
other gases, so the bubble is in continuous diffusive exchange with surrounding dissolved 
gases [167]. While highly permeable, the lipid shell modulates gas exchange by resisting 
monolayer expansion and compression beyond the close-packed lipid configuration at the 
microbubble resting radius [168]. A polyethylene glycol (PEG) conjugated lipopolymer 
with a matching stearate lipid anchor was also chosen as an emulsifying agent to improve 
yield by promoting lipid adsorption onto newly formed oxygen microbubbles and 
inhibiting microbubble coalescence. Self-consistent field theory calculations indicate that 
under these conditions the PEG chains form a ~10-nm thick hydrated brush layer [165], 
which can lead to very high repulsive pressures between closely approaching 
microbubbles [178]. The DSPC/PEG shell comprises only ~1% of the total microbubble 
volume, but is essential for stabilizing the microbubbles against coalescence and 
dissolution. 
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Figure 3.5: Lipid-coated oxygen microbubbles [179]. (a) Oxygen gas comprises 99% of 
the microbubble volume. The oxygen core is stabilized by a thin (~3 nm) phospholipid 
monolayer membrane, which reduces surface tension and provides in-plane rigidity. A 
hydrated PEG brush (~10 nm height) grafted to the lipid surface provides steric repulsion 
to prevent microbubble coalescence. (b) A scaled-up OMB manufacturing process is used 
to generate up to 2 L of OMBs (~70 vol%) per day. (c) Bright field microscopy of diluted 
OMBs showed discrete, spherical microbubbles. (d) OMBs have a milky white 
appearance and can be stored and transported in 500-mL serum bottles. (e) Shown are the 
volume and number weighted size distributions for freshly generated OMBs. The dashed 
lines are the number (blue) and volume (red) mean diameters. The shaded area covers the 
size range for 90% of the total OMB gas volume. 
Oxygen microbubbles were prepared by adapting the process design developed by 
Swanson et al. [174] for synthesizing large volumes of concentrated (~70 vol%) 
microfoam (Figure 3.5b-c). OMBs were synthesized and stored in sealed 500-mL serum 
bottles for storage and transport (Figure 3.5d). The microbubbles were stable to several 
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days of storage and transport for animal studies. The OMBs were polydisperse in size 
(Figure 3.5e), with a number-weighted mean diameter of 3.4 ± 1.9 μm (mean ± SD) and a 
volume-weighted mean diameter of 7.7 ± 4.2 μm. 90% of the total gas volume was 
contained in microbubbles with diameters less than 14 μm. 
3.3.3 Quantity of OMBs required for PMO therapy 
Supplemental oxygen with PMO therapy was administered to animals suffering 
hypoxia by infusing predetermined quantities of OMBs. The quantity of OMBs infused 
for PMO therapy was derived from the total resting oxygen consumption of the animals, 
not the level of hypoxia or depression of lung function. The amount of OMBs delivered 
corresponded to the animals’ total oxygen consumption because a greater quantity of 
OMBs would be required to provide sufficient oxygenation with the limitations inherent 
to peritoneal oxygenation. When a bolus of OMBs was used for PMO treatment, the 
OMBs were infused until the intra-abdominal pressure reached the accepted limit of 8 
mmHg to prevent collapse of the microvasculature [21,123–125,183]. Continuous PMO 
therapy required circulating OMBs at a flow rate, QOMB, based on the reported total 
oxygen consumption of the animal while at rest, VO2, calculated by the equation: 
 𝑄𝑂𝑀𝐵 =  
𝑚∙𝑉𝑂2∙𝜌𝑂2
𝐵𝑂2
𝑂𝑀𝐵  [Eq. 3.1] 
Where density of oxygen, ρO2, and carrying capacity of OMBs, BO2
OMB
, were known and 
the animals’ mass, m, was measured at the start of the experiments. To keep the 
administration of PMO therapy consistent between trials, a peritoneal infusion device was 
created for accurate and autonomous delivery of OMBs.  
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Table 3.4: Dosage of OMBs used for PMO treatments. 
Animal VO2 (
𝐦𝐋 𝐎𝟐
𝐤𝐠∙𝐦𝐢𝐧
) 
𝐐𝐎𝐌𝐁
𝐦
 (
𝐦𝐋 𝐎𝐌𝐁
𝐤𝐠 ∙ 𝐦𝐢𝐧
) 
Rat [184,185] 12 17.7 
Rabbit [186,187] 9.2 13.7 
Pig [188–190] 7 10.3 
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Chapter 4: Development of a peritoneal infusion device 
Validating PMO therapy required the accurate and repeated administration of 
OMBs into the peritoneal cavity. To perform the function of administrating PMO therapy 
and limit human error, an infusion device was developed to deliver OMBs or saline 
treatments into the peritoneal cavity for the acute hypoxia experiments in animals. The 
infusion device was designed to perform peritoneal infusion and fulfill several criteria for 
delivery, safety, and effectiveness. The first criterion was that the infusate must not be 
exposed to outside contaminants or the atmosphere. If the OMBs are not isolated from 
their surroundings, the encapsulated oxygen rapidly diffuses out of the bubbles and into 
the air before it can reach the peritoneal cavity. In addition, isolating the infusate prevents 
potential contaminants from entering the body directly reducing the risk of infection. The 
second criterion was that the system must continuously infuse fluid to the animal while 
maintaining pressures within the peritoneal cavity below 8 mmHg. If the intra-abdominal 
pressure (IAP) is greater than 8 mmHg, there is risk of damaging the organs within the 
abdomen, but collapsing the capillary beds in the splanchnic circuit [123–126]. 
Collapsing the capillary bed of the splanchnic circuit alters the normal cardiac function 
and limits the amount of blood flow in the region, thus decreasing the effectiveness of 
PMO therapy. Thus, the balance between continuously supplying OMBs and limiting the 
intra-abdominal pressure is essential and must be precisely controlled. The third criterion 
was the device must be programmed to infuse treatment into the peritoneal cavity 
autonomously with minimal supervision. The program of the device also must be 
implemented with a simple user interface to monitor the sensor outputs and manually 
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control the device when necessary. The final criterion was that the device must be 
durable and portable to be transported between facilities. 
The infusion device developed was designated as the peristaltic peritoneal 
perfuser and infuser (Peri3). The Peri3 is a pressure controlled dosing pump designed to 
deliver infusate into the IPC of animal subjects during the administration and evaluation 
of PMO therapy (Figure 4.1). The function and the criteria of the Peri3 are fulfilled by 
implementing several subsystems. The Peri3 delivers infusate with a peristaltic pump to 
prevent contamination of the fluid, as well as isolate OMBs from the surrounding 
atmosphere. The Peri3 continually monitors the IAP with pressure transducers attached to 
secondary catheters implanted into the abdomen. By continually measuring the IAP of 
the animals, the volume in the abdomen can be controlled to increase oxygenation, 
promote circulation of OMBs, and prevent over-pressurizing the cavity. The Peri3 is 
controlled by a LabVIEW program with an interface to set several key parameters for the 
experiment including animal mass, species, and the IAP range.  
 
Figure 4.1: Peri3 system hooked up to in vitro replica abdomen without fluid warmer. 
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4.1 Fluid infusion 
The first critical component of the Peri3 is the fluid infusion subsystem required 
to deliver the infusate solution the peritoneal cavity. A peristaltic pump was chosen as it 
does not expose the infusing fluid to the pump, will not damage the OMBs, and is 
capable of pumping viscous fluids. For the Peri3, the FH100M peristaltic pump from 
Thermo Fisher Scientific was utilized. The FH100M peristaltic pump was selected 
because of its main features and versatility. The FH100M is capable of a flow rate range 
of 0.013-760 mL/min and a maximum output of 200 rpm. The wide range of flow rates 
allows the pump to be used for infusion of small animals such as rats and rabbits and 
large animals such as pigs. The FH100M pump also includes an extended rotor head for 
multiple tubing lines which facilitates infusing multiple animals or fluids. The FH100M 
pump features adjustable cartridges to accommodate a range of tubing diameters for 
infusing. At greater flow velocities, small diameter tubing yields higher pressures that 
could potentially damage the OMBs. Thus, the option of using tubing with larger 
diameters is desirable for the higher flow rates required in treating larger animals. For 
experiments in acute hypoxia of animal, the infusion line tubing selected was 3.2 mm 
inner diameter (ID) Tygon tubing (5155T16, McMaster-Carr, Elmhurst, IL). 
Additionally, the FH100M possesses a DB-25 input/output for controlling the pump 
remotely through a 0-10 V input.  
The second component of the fluid infusion subsystem is a fluid warmer. OMBs 
are required to be heated before infusion into the peritoneal cavity because they are 
cooled between 4-8°C during storage. To prevent the risk of hypothermia, the infused 
fluids are warmed to body temperature before entering the abdomen. The infusion line 
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was heated by positioning the tubing in an external IV heater (iWarm, Midmark, Dayton, 
OH) set at 40.4°C. The infusion system is completed by attaching the tubing of the Peri3 
to a catheter implanted in the peritoneal cavity. Once the infusions system of the Peri3 is 
connected to the peritoneal cavity, the pump is then controlled by a voltage input for 
infusing fluid treatment. 
4.2 Data acquisition and controller  
The Peri3 utilizes two myDAQs (781326-01, National Instruments, Austin, TX) 
to send the voltage signals of the pump. A DB-25 break-out board (BRKSD25M-C, 
Winford Engineering, Auburn, MI) with screw terminal blocks and a six-foot extension 
cable (02665, Cables to Go, Moraine, Ohio) connects the FH100M pump to the myDAQ 
for simple replacement and disassembly. The myDAQ is a multipurpose data acquisition 
and control device that operates with LabVIEW. The myDAQ can generate supply 
voltages of ±15 V and +5 V while it acquires and generates analog ±10 V signals. The 
myDAQ is able to acquire millivolt signals without requiring an external amplifier. The 
myDAQs of the Peri3 also acquire and measure the output signals from temperature and 
pressure sensors. 
4.3 Electronic sensors 
Multiple sensors are included into the Peri3 for monitoring and regulating the 
infusion of fluid treatment to the abdomen. For measuring the pressure within the 
peritoneal cavity, pressure transducers are attached to a catheter. The sensor is then 
outside the body and is not required to be water resistant or biocompatible. Two 0-5 psi 
pressure transducers (MS4426, Measurement Specialties, Hampton, VA) are used to 
measure the IAP with reliability. The pressure transducers have a linear relationship 
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between voltage outputs and pressure that was calibrated to a digital pressure sensor to 
confirm the measurement precision of the transducers.  
The final sensor in the Peri3 system is a thermocouple (a14053000ux0250, REED 
Instruments, Wilmington, NC) placed in the infusion line after the fluid warmer exit to 
measure the temperature of the infusate. The thermocouple output is amplified with a 
cold junction compensator (CJC) chip (AD595-AQ, Burr-Brown, Tucson, AZ) The 
electronic sensors are placed onto a custom printed circuit board (PCB) designed with 
Altium Designer (Figure 4.2). The PCB was then fabricated by the UNL Engineering 
Electronics Shop with a ProtoMat S103 (LPKF Laser & Electronics AG, Garbsen, 
Germany).  
 
Figure 4.2: (a) Wiring and (b) routing diagram for PCB of Peri3 designed in Altium. 
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The complete electronics of the Peri3 is presented in Figure 4.3 and the wiring 
diagram for each electrical component is presented in Figure 4.4. All electronic 
components except for the solenoid, peristaltic pump, and fluid warmer are powered by 
the myDAQs. The myDAQs connect to any laptop through a USB port for data 
communication and power supply. The electronic components and sensors are protected 
by enclosing them in a modified acrylic case. The acrylic case was modified with holes 
on the bottom to secure the electrical components into the case (Appendix A). The 
secured electronic sensors are connected to the myDAQs for measuring and recording the 
data with a LabVIEW program. The LabVIEW program uses the output of the sensors to 
control various functions of the Peri3 including the regulation of fluid flow through the 
peritoneal cavity. 
 
Figure 4.3: The electrical components and sensors used in the Peri3. 
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Figure 4.4: Wiring diagram for all data acquisition, sensing, and control components of 
the Peri3. 
4.4 Control of intraperitoneal volume and LabVIEW 
To control the fluid volume contained in the IPC, the flow into and out of the 
abdomen is regulated with the Peri3. As a fixed rate of OMBs is delivered into the 
abdomen to provide PMO therapy, the inflow is not a factor considered for controlling 
the IPC volume. Thus, the fluid flow out of the IPC is controlled to limit the cavity’s 
pressure while oxygenating the animal. A 36 V solenoid (ROB-10391, Sparkfun, 
Boulder, CO) clamps the tubing of the drainage line to prevent the fluid flow from exiting 
the cavity (Figure 4.5, Appendix A). A length of drainage tubing is fixed to a custom 
mount for the solenoid to clamp the drainage line as the solenoid actuates. The tubing  
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Figure 4.5: Solenoid assembly for restricting outflow from peritoneal cavity. 
mount consists of two metal plates bolted to the top and bottom of the solenoid. The 
tubing is secured to the solenoid mount with a fixture designed in SolidWorks and then 
3D printed (Objet30 Pro, Stratasys, Eden Prairie, MN). When the solenoid actuates, the 
secured section of the drainage tubing is clamped, prevents fluid from exiting the IPC, 
and increases the IAP. When the peritoneal pressure reaches the set value of 5 mmHg, the 
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solenoid is switched off releasing the drainage tubing for fluid to flow out of the cavity. 
The solenoid actuates with a supply voltage as low as 12 V, but the current required (0.8 
A) is too high for the myDAQ because the myDAQ only supplies a current of 32 mA. A 
120 V AC to 24 V DC power adapter (US24DC-100, Electro-Harmonix, New York City, 
NY) is used as an external power supply for the solenoid. A low current solid state relay 
(RSDC-DC-108-000, Continental Industries, Tulsa, OK) is used as an intermediary 
between the solenoid, myDAQ, and power adapter in order to control the solenoid via 
LabVIEW.  
LabVIEW is a unique system design platform that uses graphical programming 
called dataflow programming instead of typical line coding. Graphical programming 
permits the programmer to visualize how different code fragments interact. However, 
drawback of graphical programming is that complicated systems and programs can 
quickly become disorganized. Disorganized programs are avoided by nesting virtual 
instruments (VI, basically graphical subroutines) just like nesting functions in Matlab or 
other programming software. The general control scheme of nested VIs used for the Peri3 
is presented in Figure 4.6. The LabVIEW program for operating the Peri3 is divided into 
4 main functions: temperature measurement (red), pressure measurement (blue), pump 
control (yellow), and solenoid control (green). 
The LabVIEW program of the Peri3 also incorporated a user interface to set the 
animal’s mass, species, and IAP range for the experiment (Figure 4.7). The animal 
species is selected from a drop-down menu including: rat, rabbit, and pig. From the mass 
and species inputted, the LabVIEW program calculates the necessary flow rate of OMBs 
to provide supplemental oxygenation with PMO therapy. When the program is initiated, 
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Figure 4.6: General control scheme utilized for the Peri3 LabVIEW program. 
the start time, flow rate of OMBs for the animal, and the number of required infusion 
lines is displayed. While the Peri3 is activated, the program provides feedback to the user 
from the two pressure transducers and the thermocouple through 4 graphs. The LabVIEW 
interface also includes manual controls as a safety precaution. The manual controls 
override the solenoid to open and close the drainage line on the user’s demand. The 
manual controls also selects which pressure transducer is used as a reference to control 
the solenoid without stopping the procedure in the event where one of the pressure 
transducers fails. An additional safety precaution of the Peri3 is the peristaltic pump is 
not fully controlled with the LabVIEW program. Though the pump is remotely activated 
and controlled with LabVIEW through the DB-25 pins, the peristaltic pump can still be 
manually deactivated if the laptop or LabVIEW program becomes unresponsive. After 
the assembly of the subsystems, the function of Peri3 was tested to confirm that all the 
design criteria are accomplished.  
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Figure 4.7: LabVIEW Peri3 interface and sensor feedback.  
4.5 Testing of the Peri3 system 
Section 4.5 details the materials and methods used to test that the Peri3 system 
operates appropriately and accomplishes the design criteria. The results of the tests 
performed with the Peri3 are then presented and evaluated. 
4.5.1 Materials and methods 
The performance of the Peri3 was evaluated in a series of four benchtop tests. The 
first test was to confirm the manual override features operated correctly. The Peri3 was 
activated and saline was pumped into a beaker. At random times, the pump was stopped 
and the flow rate increased or decreased with the manual LabVIEW controls. The second 
test was to confirm that the Peri3 was infusing fluid at the correct flow rates designated 
by the input parameters. The Peri3 system was activated with a random number between 
1-3 kg inputted as the animal’s mass. The system pumped saline into a glass beaker for 
30 minutes. Every five minutes, the saline in the beaker was measured and compared to 
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the volume that was expected from the calculated flow rate of the random mass. The third 
test confirmed if the pump and solenoid were triggered by the feedback from the pressure 
sensors. The Peri3 was set to deactivate the pump and solenoid when the pressure was 5 
mmHg. The Peri3 was activated and infused saline into a closed container where the 
pressure sensors measured the increased internal pressure as the container filled. The 
pump and solenoid of the Peri3 were then confirmed if they deactivated when pressure 
was at or above 5 mmHg.  
The final test was performed to replicate infusion into a peritoneal cavity of a 
rabbit. The test confirmed that the Peri3 would maintain continuous infusion of fluid for 
15 minutes with the pressure below 6 mmHg. The Peri3 was activated and pumped fluid 
into the replica abdomen. The solenoid was initially engaged to clamp the drainage line 
from the replica abdomen and set to disengage for fluid drainage when the pressure in the 
replica abdomen reached 5 mmHg. The replica rabbit abdomen was a 1.5 L rubber water 
bag (B00BNVHS6Y, Amazon, Seattle, WA) modified with inlets of 16G plastic catheters 
and an outlet of 7.9 mm ID tubing. The replica abdomen was inserted with three balloons 
filled with 250 mL of water, 25 and 60 mm square sections from rubber gloves, and 2.5 x 
20 cm strips of synthetic intestine (T-INT-S-0005, SynDaver, Tampa, FL) and mesentery 
tissue (T-MES-A-0005, SynDaver, Tampa, FL) to mimic the contents of a real abdomen 
(Figure 4.8). The replica abdomen was confirmed to be capable of internal pressures of at 
least 35 mmHg without developing leaks. The fluids used in the final tests were saline 
and inert gas microbubbles (IMBs). IMBs are equivalent to OMBs in manufacturing 
process, PEG surface structure, and composition of the lipid monolayer. The only 
difference is that the IMBs are more stable because they encapsulate sulfur hexafluoride 
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(SF6) gas, a biologically inert gas with greater molecular weight and less permeability 
through the lipid monolayer [163,167].  
 
Figure 4.8: Replica rabbit abdomen used for testing of Peri3 system.  
4.5.2 Results  
The performance of the Peri3 was evaluated in four benchtop tests. The Peri3 was 
activated and at random times the pump was operated via the manual LabVIEW controls. 
Trials of the first test confirmed the manual override features functioned correctly and the 
pump speed could be increased, decreased, and stopped with minimal lag in operation. 
The second test confirmed that the Peri3 was capable of infusing fluid at the correct flow 
rates for randomly designated masses. The Peri3 system was activated for 30 minutes 
with the pumped saline having an accuracy of ±1 mL from the calculated volume after 
every 5 minutes. The third test confirmed that the pump and solenoid were triggered by 
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feedback from the pressure sensors. The pump and solenoid of the Peri3 system was 
deactivated whenever the pressure in the closed contained reached 5 mmHg. 
The final test was performed to confirm that the Peri3 maintained continuous 
infusion for 15 minutes without having the internal pressure increase above 6 mmHg. The 
Peri3 system infused saline and IMBs into a replicated abdomen of a rabbit (Figure 4.9). 
When the system was activated, the peristatic pump filled the replica abdomen as the 
solenoid was engaged to clamp the drainage line. The solenoid was disengaged and fluid 
flowed out of the replica into the waste container when the pressure within the replica 
abdomen reached 5 mmHg (Figure 4.10). When IMBs were infused, the pressure in the 
replica abdomen required more time to initially reach 5 mmHg and disengage the clamp 
on the drainage line for the initial cycle. Removal of fluid from the replica rabbit was 
never inhibited by the fake tissue and debris within the abdomen.  
 
Figure 4.9: Setup of the Peri3 benchtop tests. 
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Figure 4.10: Measured pressure in the replica abdomen from representative trials. 
4.6 Subsequent iteration of the Peri3  
Due to the success of the original iteration, the Peri3 was modified and developed 
further for use as a peritoneal infusion device to administer long term PMO therapy. I 
provided assistance in coding, design, building, and testing of subsequent iteration of the 
Peri3 developed as a peritoneal infusion device for OMB and saline treatment of 
conscious rats [191]. The subsequent iteration included four solid state relays and four 
solenoid valves to control the flow of fluid into and out of the rat and to flush the tubing 
with saline after every infusion. The second iteration contained two thermocouples to 
measure the temperatures of the fluid infused into the animal and the OMB supply. A 
new PCB was created to position the two thermocouples and the output from a different 
pressure sensor (S7d, Gaeltec Devices Ltd., Isle of Skye, UK). Finally, the LabVIEW 
program was updated to control the additional solenoids and record the measurements 
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from the sensors. The second version of the peritoneal infusion system has undergone 
successful preliminary testing in delivering OMBS to rats inflicted with ARDS [191] 
4.7 Conclusion 
The Peri3 system was confirmed to accomplish all the designated criteria and 
functions for the required peritoneal infusion device through its successful performance 
in four benchtop tests. The Peri3 system accomplished the required functions of 
administering PMO therapy to animals with accuracy, consistency, and safety. Thus, the 
Peri3 was implemented in all acute hypoxia experiments administered saline and OMB 
treatments to the peritoneal cavities of both rats and rabbits. The Peri3 was successful in 
delivering bolus treatments to the peritoneal cavities of rats and rabbits. However, the 
Peri3 was only effective in administering continuous PMO therapy to rabbits in hypoxia 
experiments. The inability of the Peri3 to provide continuous PMO therapy in rats was 
attributed to catheters that were obstructed by the rat’s omental tissue. To provide 
continuous and prolonged PMO therapy, the failure of the catheters to infuse and drain 
perfusate was investigated by evaluating a catheter for use within the peritoneal cavity of 
rats. 
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Chapter 5: Evaluation of catheters for intraperitoneal infusing and 
draining fluid 
PMO therapy has been investigated in rat and rabbit models of acute hypoxia 
[179,192,193]. The peritoneal infusion, removal, and circulation of OMBs and saline 
experienced minimal complications in rabbits when using the Peri3 system. Conversely, 
treatments in rats were restricted to a single bolus due to omental and intestinal tissue 
obstructing the needles and catheters implanted in rats during preliminary trials with the 
Peri3. To administer continual and prolonged PMO therapy, multiple catheters were 
investigated for extracting OMBs after the OMBs briefly dwelled in the peritoneal cavity 
of rats [191]. The Jackson-Pratt catheter (JP-7, MILA International Inc., Florence, KY) 
facilitated the highest removal efficiency of OMBs at ~50% with no instances of tissue 
obstruction. Thus, the Jackson-Pratt (JP) catheter was chosen to be implanted in rats for 
delivering periodic OMB boluses during long-term studies validating PMO therapy.  
However, when JP catheters were implanted in rats to validate PMO therapy in 
long-term trials of ARDS, the JP catheters failed to remove saline and OMBs from the 
abdominal cavity after a designated surgical recovery period of seven days. The failure of 
the JP catheters imposed a premature end to the ARDS trials as the extraction of saline 
and OMBs was unsuccessful and ultimately impossible. Being unable to remove the 
previous treatment bolus prevented administration of subsequent treatments as the 
accumulated volume and pressure posed a risk to the animal [21,123–126]. After the rats 
in the PMO trials were euthanized, the implanted JP catheters were inspected. The pores 
of the JP catheters were completely obstructed with omental, fat, and fascial tissue while 
the JP catheters were implanted in the animal’s body. The porous structure of the 
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Jackson-Pratt catheter was hypothesized to function as a scaffold for cell and tissue 
growth [194–196]. Thus, an investigation was performed to identify a catheter more 
effective than the JP catheter at periodically infusing and draining fluid from the 
peritoneal cavity for prolonged periods of time. An optimal catheter was considered to 
either prevent or overcome the obstructing tissue growth while the catheter dwells within 
the peritoneal cavity. The most effective peritoneal catheter determined in the 
investigation would be selected for future PMO therapy trials in rats inflicted with 
ARDS. 
5.1 Measuring catheter efficiency 
The maximum bolus volumes that will be administered for future long-term 
peritoneal OMB treatments in a ~500 gram conscious rat were determined to be 50 mL. 
A 50 mL bolus volume was determined from experiments establishing that the maximum 
volume, in mL, for intraperitoneal fluid injection in a sedated animal was 1/5 the body 
weight in grams [21,135,179]. The maximum volume for a sedated rat was divided in 
half to provide a safety factor of 2 for conscious rats that would be administered 
treatment for ARDS. The OMBs used in evaluation of PMO therapy are composed of 
30% saline, thus each OMB bolus of 50 mL contains 15 mL saline [179,191,192,197]. 
Therefore, 15 mL saline was infused into the peritoneal cavity to quantify the efficiency 
of the catheters implanted because, after pure oxygen gas, saline is the primary 
constitutive component of OMBs [170,179,192]. Saline is also the main constituent of the 
OMBs that will dwell within the peritoneal cavity as the O2 gas will more rapidly diffuse 
into the vasculature than saline and the phospholipid membrane comprises only ~1% of 
the OMB volume. Thus, the residual saline volume must be removed from the cavity 
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after the dwell period of the bolus to allow the following bolus to be administered. Some 
of the saline will diffuse into the tissue surrounding the peritoneal membrane because the 
peritoneum is highly permeable to fluid transport and adsorption from the cavity. The 
permeability of the peritoneum enables peritoneal dialysis to be a viable treatment for 
renal replacement [198–200]. The fluid adsorption rate from the peritoneum of rats is 
approximately 20 μL/min after the injection of a large volume of fluid, but the adsorption 
rate decreases over time [201,202]. Typically, 10-18% of the fluid volume injected is 
absorbed after 4 hours with the remaining fluid requiring considerably more time to be 
absorbed as the adsorption rate from the peritoneum decreases [201,203]. Therefore, an 
average of 3 mL of saline is estimated to be absorbed from the 15 mL infused through the 
rat’s peritoneum after 4 hours, which prohibits the ability to remove the total infused 
volume of 15 mL saline after a dwell period of 12 hours. To offset the absorbed volume 
and prevent significant negative pressures and the aspiration of tissue into the catheter, 
the maximum extraction volume after each dwell period was considered to be 12 mL. 
The maximum extraction volume after a period of dwell was considered an important 
criterion for determining the efficiency of the catheters evaluated. 
The effectiveness of each implanted catheter was scored by three weighted 
criteria: extraction volume of fluid after a dwell period, ease of function for fluid 
drainage from the catheter, and time the catheter remained patent. The extraction volume 
of a saline bolus was measured for the entire duration of the study twice daily after a 15 
mL bolus of saline was infused and dwelled in the cavity for 12 hours. The dwell 
extraction with the evaluated catheters was not performed 12 hours after the surgery to 
implant the catheter. During each measurement of extraction volume, 12 mL of saline 
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was the maximum volume drained with the catheters after the dwell period and 
contributed to the efficiency score of the catheter (1 point per mL). The extraction 
performance of the catheter was then determined from a maximum score of 276 points 
(11.5 days × 2 measurements daily × 12 mL per extraction). The second scoring criterion 
was the ease of function for extracting the fluid bolus with the catheter and was measured 
as the relative force to draw the plunger of the syringe. The relative force of drawing the 
plunger to extract saline from the peritoneal catheter was scored on a 1-4 point scale. The 
score correlated to the force to draw the plunger of the syringe and how well the fluid 
flowed from the catheter: 1) drawing the plunger was difficult with minimal to no fluid 
flow; 2) drawing the plunger was moderately hard with slight fluid flow; 3) the plunger 
was drawn moderately simple with a steady and slow flow of fluid; 4) the plunger draw 
was effortless with quick and consistent fluid flow. The ease of function score of the 
catheters’ efficiency was from a maximum 96 points (12 days × 2 measurements daily × 
4 points per extraction). The final criterion of scoring efficiency was the time the catheter 
remained patent. Every day the catheter functioned contributed one point to the efficiency 
score with a maximum of 12 points if the catheter was patent for the entire study. The 
catheter was considered not patent when the catheter failed to remove saline during three 
consecutive measurements (36 hours). The ease of function and patency scoring criteria 
were weighted to contribute equally to the final efficiency score (288 points) with the 
sum of the dwell extraction volumes being slightly less (276 points). The following 
equation was used to normalize the efficiency scores: 
 
Catheter 
Efficiency
=
(Σ𝑉𝑜𝑙𝑢𝑚𝑒𝐸𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑 )+(3×Σ𝐸𝑎𝑠𝑒 𝑆𝑐𝑜𝑟𝑒𝑠)+(24×𝑇𝑖𝑚𝑒 𝑃𝑎𝑡𝑒𝑛𝑡)
852
× 100 [Eq. 5.1] 
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5.2 Materials and methods 
All animal studies were performed in accordance with the University of 
Nebraska-Lincoln, Institutional Animal Care and Use Committee. Male Wistar rats  
(n = 12, m = 551.9 ± 0.2 g) were housed individually with free access to food and water. 
The animals were randomly assigned housing by the animal facility staff and allowed to 
acclimate 4 days before the study. Omental ingrowth into the JP catheter was previously 
observed to prevent drainage of intraperitoneal fluid. A sample size of three rats per 
catheter type was decided to distinguish catheter effectiveness. Rats were randomly 
implanted with one of four catheter types. The catheter was surgically implanted and 
routed subcutaneously to the back of the rat. The catheter types included: a Jackson-Pratt 
(JP) catheter which had failed in previous PMO trials (JP-7, MILA International Inc., 
Florence, KY) [191], a 15 French round fluted drain catheter (072188, Bard Medical, 
Covington, GA), a 7 mm flat ¾ fluted flat drain catheter (072210, Bard Medical, 
Covington, GA), and an originally designed catheter (Figure 5.1, Appendix B). All 
catheters were trimmed, so 10 cm of tubing was within the peritoneal cavity.  
5.2.1 Surgical and implantation procedure of catheters 
Rats were anesthetized in an induction chamber with 5% isoflurane and 
maintained on 2% isoflurane during the surgery. Each animal was weighed and placed in 
the supine position on a warming pad (Gaymar T/pump Classic, Stryker Corporation, 
Kalamazoo, MI) set at 38°C. After the animal was fully sedated and unresponsive to paw 
pinches, the back and left lateral abdomen was shaved and sterilized. A small incision 
was made on the left lateral abdomen to expose the peritoneal cavity where a randomly 
selected catheter was then inserted into the cavity (Figure 5.2a). The fascia was stitched 
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Figure 5.1: Catheter types evaluated in the study (a) Jackson-Pratt, (b) round fluted 
drain, and (c) flat fluted drain and their respective cross-sections (d-f). 
around the catheter with a purse-string suture to prevent the catheter from sliding out 
during the study [204–206]. The rat was then turned onto its right side, and a small 
incision was made into the skin at the upper back. The catheter was subcutaneously 
tunneled to the back incision and the extra length was trimmed so the end of the catheter 
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was even with the back incision (Figure 5.2b). An access port for the catheter was 
attached to the back by connecting the catheter end with a luer elbow fitting (EW-45502-
84, Cole-Parmer, Vernon Hills, IL). The fitting was sutured in place under the skin to the 
back and closed off with a male luer lock cap (51525K38, McMaster-Carr, Elmhurst, IL). 
Because both the luer elbow fitting and lock cap were not sterile, they were submersed in 
glutaraldehyde plus for 20 minutes and rinsed with sterile saline before being placed in 
the rat. The incisions on the abdomen and back were closed after pain medication was 
administered into the abdominal incision (1.2 mg/kg, Buprenorphine SR, Zoopharm, 
Windsor, CO). The rat was then allowed to recover from anesthesia and returned to its 
home cage. 
 
Figure 5.2: Experimental setup for implanting the catheter into the peritoneal cavity of 
the rat. (a) The catheter was secured in the cavity with purse-string suture. (b) The back 
access port of the rat with the elbow adapter inserted into catheter exit and closed with a 
luer lock cap. 
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5.2.2 Evaluation of the catheters 
Every 12 hours for 12 days, the efficacy of the catheters was determined by an 
infusion and drainage procedure to analyze the three efficiency criteria: ease of function, 
the volume of saline extracted, and duration the catheter remained patent. The procedure 
started with the drainage of the previously injected saline bolus after the bolus dwelled in 
the peritoneal cavity for 12 hours. The drained volume of saline was measured to 
determine the extraction efficiency after a dwell period. Next, 15 mL of fresh sterile 
saline was infused into the catheter and immediately drained from the peritoneal cavity. 
The extracted volume of fresh saline was measured and reinfused into the peritoneal 
cavity to dwell 12 hours for the next measurement.  
The extracted volumes of fresh saline were recorded but not used in determining 
the efficiency of the catheters. The fresh saline extractions provided an indication for if 
the catheters were functional and patent. If the catheter was unable to extract fresh saline 
for three consecutive measurements (0 mL in 36 hours), the catheter was determined to 
not be functional and the study for the catheter was then concluded.  
5.2.3 End points and necropsy 
End points for the observation of each animal were 12 days after the peritoneal 
catheter was implanted or fresh saline was unable to be drained from the cavity with the 
catheter after three consecutive measurements. The study also concluded when the 
catheter was dislodged from the back incision either from movement or the incision re-
opening. The open wound from the back incision causes pain and risk of infection 
requiring the animal to be withdrawn from the study and evaluation of the catheter to be 
concluded. At the end of the study, the rats were euthanized by carbon dioxide inhalation 
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following Institutional Animal Care and Use Committee (IACUC) procedure guidelines. 
After death, the abdomen was opened by an incision along the medial plane. The 
implanted catheter was removed from the peritoneal cavity without detaching any tissue 
adhered to or obstructing the catheters. After the catheters were removed from the cavity, 
images were taken to compare the amount of tissue adherence and obstruction of the 
catheters.  
5.2.4 Statistics  
Analysis of variance (ANOVA) with separate means followed by the Tukey 
multiple comparison test was performed on efficiency scores to test for any differences 
between groups. All tests used the same level of significance (α = 0.05). 
5.3 Results 
Twelve catheters were implanted into the peritoneal cavity of rats to determine the 
most efficient catheter type for infusion and drainage of saline boluses over 12 days. The 
peritoneal catheter with the longest duration of patency was the flat fluted drain, which 
remained patent for the entire12 days (Figure 5.3). The round fluted catheters remained 
patent for 11.5±0.6 days with two catheters patent for 12 days. The third round fluted 
catheter concluded early on day 11 because 15 mL of fresh saline was not able to be 
infused. The saline leaked from the back incision where the round fluted catheter was 
fixed instead of being infused into the peritoneal cavity. The JP and custom catheters 
were patent for the shortest durations at 6.8±0.3 and 5.8±1.5 days, respectively. All three 
JP catheters were removed from the study early (days 6.5 and 7) because fresh saline was 
not drained for three consecutive measurements. All three of the custom design catheters 
were removed from the study early (days 4, 6, and 7). Two of the custom catheters ended 
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because they leaked from the back incision during infusion of fresh saline with one of 
custom catheters unable to infuse the saline bolus. The third custom catheter was dropped 
because three consecutive extractions of fresh saline failed to drain any volume. 
The flat fluted catheter had the highest score for ease of function with an average 
of 2.8±0.6 during study (Figure 5.4). The remaining catheters’ score for relative force 
were similar with the round fluted catheters average score of 2.5±0.7, JP catheters 
averaged a score of 2.0±0.8, and the custom catheters scored an average of 2.0±0.5. 
During the 12 day study, all catheters except for the flat fluted catheters experienced a 
decrease in the ease of function score. 
The flat fluted catheter achieved the highest average volume of fresh saline 
drained at 8.3±2.0 mL (Figure 5.5). The round fluted catheter was the second most 
efficient at draining fresh saline with an average of 7.1±2.7 mL per measurement. The JP 
 
Figure 5.3: Time the catheter remained patent within the peritoneal cavity.  
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Figure 5.4: Ease of drawing the syringe plunger to extract saline from the peritoneal 
cavity. 
 
Figure 5.5: Volume of fresh saline drained from the peritoneal cavity after infusion.  
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catheter drained an average of 6.1±4.5 mL of fresh saline while patent and the custom 
catheter drained an average of 4.4±2.1 mL per measurement. The flat fluted catheter 
drained an increased volume of fresh saline as the study progressed while all other 
catheters drained less fresh saline. After 7 days, the JP and custom catheters removed 
zero milliliters of fresh saline. 
The catheter with the highest average volume of fluid extracted after a 12 hour 
dwell period was the flat fluted drain catheter with 2.4±1.9 mL (Figure 5.6). The round 
fluted catheter extracted the second highest amount of saline after the dwell period with 
1.2±1.2 mL. The custom catheter extracted an average of 0.3±0.3 mL per measurement 
while the JP catheter extracted the smallest average volume of saline at 0.1±0.2 mL per 
measurement after the dwell period. While the JP and custom catheters did not extract an 
average volume of saline greater than 1 mL per measurement four days after the catheters 
were implanted, the round fluted drain would experience an increased extraction volume 
of saline from day 4 to day 8. In contrast, the implanted flat fluted catheters exhibited an 
increased average extraction volume of saline after the dwell period until the end of the 
study.  
The flat fluted catheter experienced the highest overall average efficiency from 
the weighted scoring at 63.8±13.2% (Figure 5.7). The catheter with the second highest 
weighted efficiency was the round fluted catheter with 56.3±4.0%. The third highest 
score was the JP catheter with an average efficiency of 29.4±4.4%, while the least 
efficient was the custom catheter with an average of 24.2±8.85%. The efficiency of the 
flat and round fluted catheters was significantly greater than the JP and the custom 
catheters (p < 0.05). 
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Figure 5.6: Volume of saline extracted from the peritoneal cavity after the dwell period.  
 
Figure 5.7: The efficiencies of the peritoneal catheter tested and calculated from their 
weight scores. *Significantly different from Jackson-Pratt and the custom catheters (p < 
0.05) 
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Each implanted catheter was excised and photographed after the rat was 
euthanized to examine the degree of tissue growth and obstruction. The pores of the JP 
catheters were completely obstructed by ingrowth of omental, fat, fascia, and organ tissue 
(Figure 5.8a). The ingrown tissue was found to be strongly attached to the surface and 
pores of the JP catheters. In contrast, the flat and round fluted catheters were partially or 
completely surrounded by a fibrotic capsule (Figure 5.8b, c). The fibrotic capsule around 
the fluted catheters was highly vascularized and integrated to nearby organs such as the 
liver, intestine, or colon. However, the flutes of the flat and round catheters were never 
fully occluded by tissue. The fluted catheters were easily removed from the fibrotic 
capsule with little to no tissue actually adhered to the surface (Figure 5.9). When the 
custom catheters were removed from the peritoneal cavity, the tubing segments were 
revealed to be unraveled (Figure 5.8d). Omental and fibrotic tissue was observed to grow 
between the tubing segments separating the braid of the custom catheter. In addition, 
tissue growth was focused predominately around the heat shrink bands which bound the 
tubing segments of the custom catheters.  
 
Figure 5.8: Representative images of excised (a) Jackson-Pratt, (b) round fluted drain, 
(c) flat fluted drain, and (d) custom catheters after being implanted in the peritoneal 
cavity. 
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Figure 5.9: Images of the (a-b) round and (c-d) flat fluted catheters (a, c) in and (b, d) 
removed from the fibrotic capsule.  
5.4 Discussion 
The purpose of this study was to evaluate catheters for providing reliable infusion 
and drainage of liquid boluses from the peritoneal cavity for prolonged periods in rats. In 
the previous investigation, the JP catheter was highly efficient at removing OMBs from 
the peritoneal cavity after dwelling within the cavity less than 30 minutes [191]. The JP 
catheters were used in experiments of treating rats suffering from ARDS with PMO 
therapy of repeated OMB boluses. However, when the JP catheters were implanted into 
the peritoneal cavity of rats, the JP catheters failed after recovering for seven days from 
the implantation surgery. The omental tissue of the rat as grew around and into the pores 
of the JP catheters preventing the flow of fluids into or out of the peritoneal cavity. Thus, 
a different type of catheter was required to administer and drain repeated treatment 
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boluses to the peritoneal cavity, while overcoming the growth of tissue into the catheter. 
The flat fluted catheter and the round fluted catheter were selected for evaluation because 
other variants of fluted catheters were successfully utilized for peritoneal dialysis of dogs 
and humans [207,208]. Additionally, a custom catheter was attempted to combine the 
best principled from designs of fluted catheters into a catheter able to be made 
inexpensively. 
The custom catheter was the lowest scoring catheter with an average efficiency of 
29.6±14.5%. The duration of patency was 5.7±1.5 days with a low volume of dwell 
extractions (0.27±0.25 mL) and ease of function (1.8±0.5). The low efficiency of the 
custom catheter was attributed to omental tissue growing between the tubing segments 
and compromising the braided structure and fluid transport in the channels. The custom 
catheter functioned to a limited degree, but subsequent iterations require several 
alterations to increase the catheters effectiveness. The braided segments of tubing 
exhibited minimal tissue adherence and was not considered the cause of the custom 
catheters failure. However, the peritoneal tissue was observed to grow and attach 
specifically to the heat shrink tubing indicating the heat shrink material possessed surface 
properties conducive to cell growth and adherence (Figure 5.8d). The heat shrink tubing 
of the catheter needs to be replaced with a permanent method of binding the tubing 
segments to construct future catheters. A permanently binding the tubing segments would 
avoid tissue adherence and maintain the structure of the catheter’s fluid channels. 
The flat and round fluted catheters were chosen because the flutes or channels on 
the exterior face of the catheters were similar to peritoneal dialysis catheters that were 
previously demonstrated to be successful (Figure 5.1b, c, e, f). The principle of the fluted 
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catheters was to prevent tissue from blocking the fluid inlets and pathways by creating a 
large surface area for fluid to flow [208,209]. The design principle of the fluted catheters 
was highly successful in the rat peritoneal cavity as the two fluted catheters resulted in 
significantly higher scores of the measured criteria and overall efficiencies (Figure 5.7). 
Another property of the fluted catheters that contributed to their effectiveness was the 
minimal tissue adhesion and obstruction on the surface of the catheters (Figure 5.9). The 
surface of the fluted catheters was sufficiently hydrophobic that water, saline, and blood 
would bead off the fluted catheters even after they were implanted in the peritoneal cavity 
for 12 days [210]. The shape and profile of the flat fluted catheter was similar to the JP 
catheter. However, the fluid flow of the JP catheter was facilitated by surface pores 
instead of external channels. 
The principle of the Jackson-Pratt catheter is supplying a large quantity of inlets 
and outlets for fluid transport with pores on the catheter’s surface. The large number of 
pores reduces the potential risk that the flow of fluid would be completely obstructed. 
However, within the peritoneal cavity, the principle failed as the pores instead functioned 
as a scaffold that facilitated cell and tissue ingrowth into the interior of the catheter [194–
196]. The drainage of fresh saline was very effective shortly after the JP catheter was 
implanted, but the volume of fresh saline drained quickly decreased over time as the 
pores of the catheter were obstructed by tissue (Figure 5.8a).  
Another possible hindrance to the performance of the peritoneal catheters was the 
formation of a fibrotic capsule that surrounded the fluted catheters (Figure 5.9). The 
encapsulation of the fluted catheters indicated a strong foreign body response. The 
foreign body response was triggered by the implanted catheters and activating the 
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omentum that increased the expression of vascularization, growth, and healing factors 
[211–213]. If omental tissue completely surrounded the fluted catheter in a fibrotic 
capsule, the saline was infused into the fibrotic capsule and not into the peritoneal cavity. 
Fresh saline being infused into the fibrotic capsule is a possible explanation to the high 
volumes that were drained with the fluted catheters. After infusing the fresh saline, the 
capsule possibly prevented infused saline from circulating throughout the cavity, but 
remained localized in the capsule allowing the saline to be readily drained. The 
entrapment of saline in the fibrotic capsule could also have affected the stability of the 
catheter in the surgical incisions. Once the fibrotic capsule was full, infusion of additional 
saline would result in saline to leak through the back incision the catheter was secured in 
preventing the skin from properly healing around the catheter. Saline leakage from the 
back incision was observed in several occasions during catheter evaluation and may have 
contributing to the catheter being able to slide out of the back incision. Additionally, the 
fibrotic capsule could have hindered the performance of the catheters while extracting 
saline after the dwell period from tissue being aspirated against the catheter and 
preventing fluid flow. Another possibility that may have hindered the efficiency of the 
catheters evaluated was the small volume of saline extracted after the dwell period. The 
fluted catheters were highly effective at draining fresh saline, but no catheter type was 
effective at extracting saline after the dwell period. The low extraction of saline after 
dwelling in the cavity for 12 hours was that significantly more saline was absorbed 
through the peritoneum than the estimated 3 mL [201–203]. A greater absorbed volume 
of saline would result in the maximum volume of 12 mL never being able to be extracted, 
artificially decreasing the weighted score and the catheter efficiency. 
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A limitation of the study was that the efficiency of the catheters was not 
accurately assessed due to complications the peritoneal catheters experienced after being 
implanted. One round fluted and two custom catheters were removed from the study early 
due to the incision on the back reopening. When the back incision reopened, the catheter 
was released from the suture securing it to the back allowing the catheter to extend and 
retract when the rat moved. The open wound and movement of the catheter caused 
noticeable discomfort in the animal. The movement of the catheter may have dislodged 
the catheter from the peritoneal cavity and contributed to the saline leaking from the back 
incision when infused into the catheter. The dislodgment and leakage of the catheters 
decreased the weighted score and efficiency measured because the trials were concluded 
early. In future implants of the catheters, the back incision will be closed more securely 
and the elbow of the catheter access port will be fixed to the subcutaneous tissue below 
the incision. The catheter will also not be stretched from the peritoneal to the back 
incision as tightly when implanted to decrease tension on the suture, skin, and fascia from 
the movement of the rat. 
5.5 Conclusion 
The purpose of this investigation was to determine which type of catheter would 
remain patent while in the peritoneal cavity of a rat for a two-week PMO study. From the 
study, the prolonged patency and efficient removal of infused saline with a catheter 
implanted into the rat peritoneal cavity was confirmed as difficult tasks to achieve. An 
effective peritoneal catheter required surmounting several substantial challenges that 
included tissue ingrowth, an aggressive foreign body response, and securing the catheter 
into the rat. However, two catheters were considered suitable to replace the JP catheters 
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for repeated peritoneal infusion and drainage of OMBs. The 7mm flat ¾ fluted catheters 
remained patent for the longest durations, extracted the highest average volumes of saline 
after the dwell period, and drained the highest volume of fresh saline. Further study is 
required to evaluate the effectiveness of the flat fluted catheter with OMB solutions to 
justify the use of the flat fluted catheter for continuous OMB perfusion in rats. The flat 
fluted catheter could potentially be implanted in other animal models (leporine, canine, or 
porcine) for long-term studies of validating PMO therapy. The flat fluted catheters were 
measured to be the most efficient catheter type evaluated and will be utilized in future 
studies of validating PMO therapy in rats suffering hypoxia induced by a characterized 
model of ARDS. 
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Chapter 6: Characterization of hypoxia in a rat ARDS model 
Development of viable alternative treatments to provide oxygenation in acute 
respiratory distress syndrome (ARDS) requires an injury model that mimics its 
pathophysiology in humans during the acute phase. To date, there have been few 
publications that describe in detail a long-term murine model of ARDS focused on 
oxygenation of the animal. Thus, we systematically described a long-term (up to seven 
days) model of ARDS with daily characterization to provide a framework for evaluation 
of new oxygen therapies, as well as to elucidate differing stages of development and 
resolution of ARDS pathology. Primary emphasis of characterizing the rat ARDS model 
will be in measuring the parameters that describe the animal’s level of oxygenation when 
suffering from ARDS. The clinically relevant ARDS model with depressed oxygen levels 
can then be used for validating the short and long term benefit of oxygenation with PMO 
therapy in a respiratory disease. 
6.1 Design 
ARDS was decided to be the model of respiratory disease to replicate due to its 
prevalence, limited treatment options, incidence of hypoxia, and extensive model 
development in rodents. The current standard murine ARDS model is induced by directly 
administering an aerosolized endotoxin, lipopolysaccharide (LPS), to the lung via the 
trachea [214,215]. LPS is a major component of the outer cell membrane of Gram-
negative bacteria such as Escherichia coli that performs several roles in sustaining the 
bacteria’s health. Due to the prevalence of LPS on bacteria’s surface, LPS is an 
endotoxin, which is recognized and stimulates an immune response in most animals. 
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Aerosolizing LPS through the trachea induces an inflammatory response in the lungs 
which accurately replicates many of the characteristics of moderate to severe ARDS in 
humans. Most of the studies in ARDS research focus on the protective effect of 
pharmacological agents based on the inflammatory and immune response to ARDS [216–
223]. These studies on ARDS models quantify the severity of ARDS and any potential 
benefit of the pharmacological agents by measuring the concentration of surfactant 
proteins, cytokines, or histological staining and imaging of lung samples. Few studies 
extensively investigate the oxygenation of either the animal or their recovery past 24 
hours, leading to a lack of experimental models for use in validating novel methods that 
provide supplemental oxygenation [179,192]. In phase one of ARDS trials, the current 
standard model for inducing ARDS in rats was reproduced to compare to previous studies 
and confirm that ARDS pathology was replicated. Long-term ARDS was characterized 
by several measurements to delineate the typical progression and recovery from the 
disease at 3 and 7 days post-insult. Then, a second phase of ARDS trials were performed 
to characterize the oxygen levels with arterial blood gas analysis and pulse oximetry to 
determine severity of the reduced lung function and hypoxia for 3 days post-insult.  
Baseline measurements were taken for mass, pulse oximetry, venous blood gases 
(VBG), arterial blood gases (ABG), and chest radiographs on day 0 of the study. Animals 
were then randomly assigned to one of three administration groups; negative control (Nv, 
NC), saline control (Sv, SC), or lipopolysaccharide (Lv, LPS). In phase one, the sample 
and data collection of validation trials (Nv, Sv, Lv) was performed after the intratracheal 
administration of an aerosolized solution every 12 hours over a period of 3 or 7 days, 
forming a total of six groups: Nv3, Nv7, Sv3, Sv7, Lv3, and Lv7. In phase two, the 
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oxygenation trials were observed for only 3 days post-insult forming a total of three 
groups: NC, SC, and LPS. Intra-tracheal administration of LPS typically results in a 
mortality rate between 25-52% [214,215,219,222]; thus, to increase the probability of 
having a sufficient population for characterizing ARDS, more animals were placed in the 
three LPS groups. Also, because the ARDS validation focused on the extent of 
respiratory recovery over a longer time, additional animals were distributed to the Lv7 
group. All control groups were assigned fewer animals because of the minimal risk of 
mortality within these groups. Rats that died before the end of their study period were 
allocated to another group with other rats that had died within the same day for analysis 
of lung injury scoring and cytokines. Animals were euthanized after data collection on 
the final day of observation. The lungs were harvested for histology and either collected 
bronchoalveolar lavage (BAL) fluid or measured wet and dry weights. Venous blood and 
BAL fluid were collected for analysis in phase one while arterial blood and wet/dry 
weights were sampled in phase two. 
6.2 Materials and methods 
The materials and methods section details the procedures used to establish and 
characterize the proposed ARDS model. In the experiments, ARDS was induced by 
administering an aerosolized LPS solution and performing daily sample collections. 
When the observation period of the rats was completed, lung tissue was collected for 
histology, BAL, and weights. The section ends with a summary of the statistical tests 
used to determine significant differences between intratracheal aerosol groups. 
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6.2.1 Aerosol administration 
Prior to administration of intratracheal aerosol, animals were randomly assigned 
to the negative control (Nv, NC), saline control (Sv, SC), or lipopolysaccharide (Lv, LPS) 
groups. At the start of the study (day 0), baseline measurements for mass, pulse oximetry, 
VBG, and ABG were collected. Rats were then sedated in an induction chamber with 5% 
isoflurane. When the rats’ muscles were fully relaxed, they were removed from the 
chamber for performing chest radiographs from the dorsal-ventral and left lateral views. 
If they began to wake before both images were taken, rats were returned to the chamber 
with 5% isoflurane. Upon completion of the radiographs, rats were placed in the prone 
position on a warming pad set at 38°C (T/pump Classic, Gaymar Industries, Inc., Orchard 
Park, NY) inclined at 30° with their head at the apex. To keep the rat motionless for the 
aerosol administration, they were intermittently sedated using a nosecone with 2% 
isoflurane. The rat’s head was lifted for insertion of a 3 or 3.5 cm (dependent on rat size), 
oropharyngeal intubation wedge made from a 3 mL syringe (Monoject, Covidien, 
Minneapolis, MN) into their oral cavity [224]. The wedge was positioned to view the 
vestibular folds and guide an aerosolizer (MicroSprayer®Aerosolizer IA-1B-R, 
PennCentury, Inc., Wyndmoor, PA) attached to a 1 mL syringe (Model B-SYR-PL1000, 
PennCentury, Inc., Wyndmoor, PA) into the trachea. The end of the aerosolizer was 
positioned through the trachea until it met resistance at the carina and then pulled back 2 
mm (Figure 6.1). Both the saline and LPS groups received 0.5 mL aerosolized solution 
while the negative control group was intratracheally cannulated with the aerosolizer, but 
not administered aerosolized solution. The solution aerosolized to the SC rats was sterile 
saline (0.9% NaCl solution, VetOne, Boise, ID). LPS rats were aerosolized with a 
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solution containing a 7 mg/kg dose of lipopolysaccharide (Escherichia coli 0111:B4, L 
2630, Sigma-Aldrich, St. Louis, MO). The LPS was dissolved with sterile saline to a 
concentration of 10 mg LPS per mL. When the necessary solution volume of LPS 
solution was less than 0.5 mL, sterile saline was added to increase the volume to 0.5 mL.  
For 30 minutes after the aerosol administration, rats were periodically rotated in 
the supine, prone, and side positions every 10 minutes until they awoke from anesthesia 
to aide in an even distribution of the solution delivered to the lungs. Animals were 
returned to their cages and observed while they recovered from anesthesia and endotoxin 
administration. 
 
Figure 6.1: Representation of the aerosol administration procedure used in the ARDS 
studies. 
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6.2.2 Daily sample collection 
Baseline measurements were taken for mass, pulse oximetry, chest radiographs, 
and venous or arterial blood samples before aerosol administration on day 0. After day 0, 
periodic samplings of weight, pulse oximetry, and blood were collected approximately 
every 12 hours while chest radiographs were recorded in the morning every 24 hours 
(Figure 6.2). Every collection session started with removing the animal from the cage and 
measuring its mass. The rat was restrained, but not sedated for pulse oximetry and the 
collection of blood. The rat was not sedated because inhalant sedation techniques with 
isoflurane vaporizers require the animal to be delivered ~100% O2, and injectable 
anesthetics such as ketamine-xylazine cocktails and barbiturates cause severe blood 
pressure and respiratory depression [55]. The aesthetic techniques would confound the 
parameters of oxygen saturation, so therefore were not used during collection of pulse 
oximetry and blood. 
 
Figure 6.2: Timeline of surgical procedures and daily sampling schedule conducted in 
the (a) validation and (b) oxygenation phase of ARDS characterization. 
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6.2.2a Pulse oximetry 
To observe the impact of LPS on lung function, peripheral oxygen saturation of 
the blood (SpO2) was measured by pulse oximetry (PhysioSuite MouseSTAT®, Kent 
Scientific Corporation, Torrington, CT). The pulse oximeter sensor was positioned on the 
lateral edge of the plantar surface of the rat’s hind paw with the end of the pulse oximeter 
clip over the fourth metatarsal (Figure 6.3). The position of the pulse oximeter sensor was 
obtained through trial and error to be optimal for measuring consistent pulse waveforms 
from the oximeter while the rat was awake. Measurements were monitored in 5 second 
averages and recorded every second when the pulse oximeter waveform was sinusoidal 
and consistent. The measurements over a period greater than one minute were then 
averaged to establish a single value for the session. 
 
Figure 6.3: Positioning of the sensor clip on the paw for pulse oximetry.  
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6.2.2b Blood sampling 
To completely observe the impact of ARDS induced LPS on lung function, partial 
pressure of oxygen in the blood (PO2) was measured by blood gas analysis. In phase one, 
blood was sampled from the tail vein of the rats. Blood from the tail vein was collected 
with a 23G needle (Monoject 250 #8881250289, Covidien, Minneapolis, MN) which was 
flushed with heparin (402-10, SAGENT Pharmaceuticals, Schaumburg, IL). Analysis of 
venous blood was performed with a handheld blood analyzer (VetScan iSTAT 1, Abaxis, 
Union City, CA) and single use cartridges (CG8+, Abaxis, Union City, CA) to measure 
blood chemistry and gases. Analysis of blood chemistry included measurement of sodium 
(Na), potassium (K), ionized calcium (iCa), and glucose (Glu) levels. Blood gas analysis 
with the cartridges measured hematocrit (Hct), pH, partial pressure of carbon dioxide 
(PCO2), and partial pressure of oxygen (PO2) and calculated values for hemoglobin (Hb), 
bicarbonate (HCO3
-
), base excess (BE), total carbon dioxide (tCO2), and oxygen 
saturation (SO2). Blood was observed to be difficult to sample from the tail vein 
approximately 12 hours after aerosolized LPS was administered to rats. The difficulty of 
collecting blood from the tail vein was thought to be attributed to hypotension resulting 
from anesthesia and endotoxin-mediated shock. To reduce stress on the animals and 
maintain consistency at this time point, no venous blood samples were collected for the 
afternoon session of day 0 in the validation phase. 
In phase two, arterial blood was sampled from the femoral artery through a 
catheter implanted in surgery one week before the LPS was administered (Figure 6.2b). 
In the catheter implant surgery, a small skin incision was made into the upper right hind 
leg to expose the femoral artery. The femoral artery was isolated from the femoral vein 
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and nerve, and then ligated distally. The artery was lightly pinched to limit blood flow 
while a small cut was made into the artery. The femoral catheter (504118, World 
Precision Instruments, Sarasota, FL) was then fed through the cut and secured in the 
artery with suture. The femoral catheter was subcutaneously routed dorsally where it was 
externalized through a small incision between the shoulder blades. A 21G blunt needle 
(75165A679, McMaster-Carr, Elmhurst, IL) with a luer lock injection plug (SRIP2V 
Surflo, Terumo Medical, Somerset, NJ) was then used to seal the catheter. During the 
seven day recovery period, the catheter was flushed every 12 hours with heparinized 
saline to maintain patency. Arterial blood was analyzed with the iSTAT and single use 
cartridges (CG4+, Abaxis, Union City, CA). These cartridges solely analyzed blood gases 
by measuring pH, partial pressure of carbon dioxide (PCO2), and partial pressure of 
oxygen (PO2) and calculated bicarbonate (HCO3
-
), base excess (BE), total carbon dioxide 
(tCO2), and oxygen saturation (SO2). 
The sample volume of blood required for performing the blood analysis with the 
test cartridge was 0.1 mL. Following safe blood collecting guidelines, less than 1% of the 
total circulating blood volume was collected per day. Adult male Wistar rats have an 
average of blood volume of 60 mL/kg [225,226]. The blood volume in the rat allowed for 
a maximum blood volume of 0.6 mL/kg to be collected per day which was enough for 
analysis of three samples. A third blood sample was only collected and analyzed if an 
error occurred in the analysis during one of the previous samples. 
6.2.2c Chest radiographs 
To obtain chest radiographs on days 1-3 or days 1-7, rats were anesthetized with 
5% isoflurane via nosecone until unresponsive to paw pinch after analysis of the blood 
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sample was completed. The rats were then radiographed (PRX 90, Bowie International 
LLC, Lake City, IA) in the dorsal-ventral and left lateral positions. Thoracic radiographs 
were taken to investigate the presence of pulmonary edema, alveolar consolidation, and 
bilateral infiltrates, all of which are signs suggestive of ARDS development. Once 
recovered from anesthesia, the animals were returned to their cages. 
6.2.3 Histology, BAL, and wet/dry ratio 
At the conclusion of the observation period, surviving animals were euthanized by 
CO2 inhalation and were necropsied. The chest cavity was opened and the trachea and 
lungs were harvested. The trachea was clamped while connective tissue and the heart 
were separated from the lungs. The exterior surface of the lungs was swabbed with cotton 
gauze to remove excess blood, spread flat, and then photographed. 
In phase one, a bronchoalveolar lavage (BAL) was performed by inserting a 
gavage needle (FNS-18-2, Kent Scientific Corp, Torrington, CT) into the trachea and 
filling the lungs with 7 mL sterile saline while clamped shut. Without removing the 
gavage needle, fluid was drawn back into the syringe and transferred into a sterile glass 
vacutainer tube (366441, Becton Dickinson and Company, Franklin Lakes, NJ). BAL 
fluid samples were centrifuged (Triac centrifuge, Becton Dickinson and Company, 
Franklin Lakes, NJ) at 1500 g for 5 minutes to separate the cells. The supernatant fluid 
was collected into snap-cap culture tubes (14-956-1D, Fisher Scientific, Pittsburgh, PA) 
and frozen at -20°C. BAL fluid samples were analyzed for cytokine concentrations at the 
University of Nebraska Medical Center (UNMC). Cytokines IL-6 and TNF-α were 
measured in duplicate using an enzyme-linked immunoadsorbent assay (ELISA) kits. IL-
6 was plated in dilutions of 1:5 and 1:20 (R6000B, R&D Systems, Minneapolis, MN). 
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TNF-α was plated in dilutions of 1:2 and 1:10 (88-7340, eBioscience, San Diego, CA). 
The absorbance of the ELISA plates were read with a spectrophotometer (Epoch 
Microplate Spectrophotometer, BioTek Instruments, Winooski, VT) at 450 nm and 
corrected for 570 nm. 
Excised lungs of rats were fixed by intratracheal instillation of 5 mL of 10% 
buffered formalin, then suspended in 30 mL of formalin. Lungs were submitted to an 
independent pathologist for blind sectioning, hematoxylin and eosin (H&E) staining 
(Ventana Symphony, Ventana Medical Systems, Inc., Tucson, AZ), and injury scoring. 
Lung sections were imaged with a microscope (Eclipse 55i, Nikon Instruments, Melville, 
NY) at a magnification 100X after H&E staining for visual comparison and analysis. 
Histological lung injury analysis of five lung sections from each animal included alveolar 
edema, intra-alveolar hemorrhage, and inflammation score on a 0-3 scale with 0 
indicating an absence of pathology and 3 indicating severe pathology [227]. 
Inflammation scoring was based on the amount of leukocyte infiltration, excluding 
eosinophils. Four sections of the right lung were used in histological injury analysis in 
ARDS oxygenation rats as the left lung was used for measuring wet and dry weights. 
The left lung was used for measuring the wet and dry weights in phase two trials. 
Once the lungs were excised from the rat, the left lung was separated by cutting of the left 
bronchus. The left lung was immediately weighed on a scale (CX220, Citizen Scales, 
Maharashtra, India) to measure the wet weight. The left lung was then placed in an oven 
for three days at 60°C and reweighed afterwards for the dry weight [228,229]. The 
wet/dry ratio (W/D) was calculated by dividing the wet weight by the dry weight. W/D is 
recognized as an indirect measurement of edema and vascular permeability in the lungs. 
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Thus, an increased W/D ratio is indicative of compromised lung function from reduced 
gas diffusion and exchange [228–231]. 
6.2.4 Statistics 
Log-rank (Mantel-Cox) testing was used to compare the mortality rates between 
each experimental group for any differences. Analysis of variance (ANOVA) with 
separate means followed by the Tukey multiple comparison test was performed on lung 
injury scores, cytokine concentrations, and W/D ratios to test for any differences between 
groups. Repeated measures ANOVA was used to compare the SpO2 group means of each 
collection period. All tests used the same level of significance (α = 0.05). 
6.3 Results 
The results of developing the ARDS model in rats included characterizing the 
model in two phases. In the ARDS validation phase, the experiments focused on 
confirming if the sickness induced in rats with LPS replicated the prominent features of 
ARDS. In the ARDS oxygenation phase, the experiments focused on confirming the 
severity of hypoxia inflicted to the rats with the established ARDS model. 
6.3.1 ARDS validation  
All animals were distributed to randomly assigned regimens and successfully 
administered the appropriate aerosol solution. The negative control and aerosolized saline 
(each n = 3) cohorts experienced no mortalities during the prescribed study periods. Two 
deaths occurred in Lv3 (n = 4, 50% mortality) and 3 occurred in Lv7 (n = 8, 37.5% 
mortality) for a combined mortality rate of 41.7%. From the log-rank test, the mortality 
between the LPS groups was not significant (p > 0.05). In contrast, the difference of 
mortality between the LPS and control groups was significant (p < 0.05). All deaths 
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transpired within 24 hours of aerosolized LPS administration. Lung injury scores and 
BAL data of these rats were transferred from their original LPS group to Lv1 (n = 5) for 
analysis.  
For several days, all LPS rats showed multiple physical symptoms of sickness 
including low activity with slow reaction times, piloerection, and decreased intake of 
food and water (Appendix C). LPS rats were also observed to have visible tachypnea 
with hypopnea. On day 3, LPS rats showed considerable improvement in physical health 
and appearance. Following day 3, rats in the Lv7 group continued to show signs of 
physiologic recovery until the final day of the study when they were physically 
indistinguishable from controls. 
6.3.1a Pulse oximetry 
The pulse oximetry data were occasionally imprecise because movement of the 
awake animal caused irregular pulse oximeter waveforms. The occurrence of inaccurate 
readings from rat or sensor movement were found to be unavoidable without sedating the 
animal, which was not done in order to minimize further trauma and not affect oxygen 
saturations with methods of anesthesia. The data from irregular waveforms containing 
spikes and plateaus were omitted from the averaging for each session. Through practice 
in preliminary trials, the best readings were obtained when the sensor was placed over the 
fourth metatarsal (Figure 6.3).  
The peripheral oxygen saturation for the negative and saline control groups 
displayed readings ranging from 85-95% with means consistently above 90% during the 
study. However, one day after LPS administration the LPS groups decreased by 17.3% 
from the average SpO2 baseline (Figure 6.4). The subsequent SpO2 values obtained from 
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the LPS groups remained decreased below 80% in the following days. The decrease in 
SpO2 of the LPS group was determined to be significantly different from the control 
groups for days 1-7 (p < 0.05).  
 
Figure 6.4: Average peripheral oxygen saturation of ARDS validation trials. Error bars 
indicate the standard deviation of the mean. 
6.3.1b Venous blood analysis 
Blood from the tail vein of the rat was successfully collected and analyzed every 
12 hours using the handheld blood analyzer. Overall, four instances occurred where the 
blood sampling was omitted at a sampling period because the rat reached the maximum 
collected blood volume of 0.6 mL/kg per day [225,226]. 
The cartridge type used in this study measured and calculated 13 physiological 
parameters of blood gases and chemistry. However, none of the parameters were affected 
by administering LPS and the venous partial pressures of carbon dioxide (PvCO2) and 
oxygen (PvO2) showed no indication that the respiratory function of the LPS rats was 
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inhibited (Figure 6.5). The values of the VBGs during the course of the study remained 
within similar ranges of 20-60 mmHg. All other parameters of the venous blood failed to 
exhibit any trend or correlation between the experimental groups (Appendix C). 
 
Figure 6.5: Average partial pressures of (a) carbon dioxide and (b) oxygen 
measurements of venous blood. Error bars indicate the standard deviation of the mean.  
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6.3.1c Chest radiographs 
Daily chest radiographs were taken of each rat for evaluation of pathognomonic 
signs of ARDS. The radiographs of all rats were examined for the presence of pulmonary 
edema, alveolar consolidation, and bilateral infiltrates. Radiographic anomalies 
associated with ARDS should also stabilize within several days.  
The baseline radiographs exhibited no sign of pre-existent or current respiratory 
pathology (Figure 6.6). The radiographs of negative and saline control groups did not 
present any significant change from baseline throughout the course of the study. LPS 
radiographs, however, exhibited common features seen in ARDS – specifically, 
development of diffuse bilateral infiltrates. All rats in the LPS cohort developed 
radiographic changes within 24 hours of LPS administration. Clinical evidence of 
respiratory function and radiographic changes consistent with ARDS did not significantly 
change for the Lv7 group until day 3 of the study, after which time the rats in the LPS 
cohort began to show signs of recovery.  
 
Figure 6.6: Representative chest radiographs of the healthy baseline lungs (day 0) and 
one day after aerosol administration. 
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The radiographic image processor used in the validation trials broke down when 
trials for the oxygenation phase were being performed. An older image processor was 
borrowed from a local veterinary clinic to continue performing x-rays. However, the 
quality of the x-ray film and processor was not as high as the previous machine used in 
the validation trials. Overall, radiographic features in the oxygenation phase control and 
LPS trials match those observed in the validation trials. The baseline radiographs 
exhibited no sign of pre-existent or current respiratory pathology and control groups did 
not develop any significant changes throughout the study. LPS radiographs exhibited 
strong evidence of diffuse bilateral infiltrates within 24 hours of LPS administration. The 
entire comprehensive radiographic record for the representative rats is presented in 
Appendix C. 
6.3.1.d Histology 
In validation trials, lung tissue was collected and fixed in formalin for sectioning 
as described previously. The H&E stained sections were then evaluated by an 
independent pathologist for lung injury scoring. In the trials of phase two, right lung 
tissue was collected and fixed in formalin for sectioning in all but one rat in the LPS 
group. A lobe of the right lung and the bronchus was damaged when the lungs were 
excised from the rat, which resulted in the right lung unable to be inflated and fixed with 
formalin. Additionally, three right lungs from LPS rats were submitted for sectioning and 
scoring, but never received by the pathologist. The lung samples were possibly collected 
or disposed by a different individual.  
Histological and gross images of the control rats possessed normal parenchymal 
features (Figure 6.7). The H&E sections of control lungs presented little to no sign of 
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alveolar edema, intra-alveolar hemorrhage, or leukocyte infiltration. Conversely, the LPS 
lung tissue demonstrated edema and intraparenchymal hemorrhage on gross inspection. 
LPS H&E sections featured a significant degree of congestion and edema. Additionally, 
the alveolar-capillary membranes in the control lung sections were uncompromised while 
the LPS lung sections exhibited significant thickening and collapse. 
The lung injury scores for the control groups were evaluated as zero or lower than 
0.1 in edema and hemorrhage, while LPS rats possessed significantly greater scores at 1 
and 3 days (Figure 6.8). Most lung sections of control rats exhibited a slight quantity of 
leukocytic infiltration present during the study. The leukocytic infiltration resulted in low 
inflammation scores across all control groups. The highest scores in all three areas were 
in rats that died 24 hours after aerosolized LPS was administered. Subsequent injury 
scores in the LPS rats euthanized 3 days post-insult were decreased and after 7 days LPS 
 
Figure 6.7: Characteristic images of rats’ excised lungs after euthanasia or death (top 
row). Representative H&E stained sections (bottom row) from each group were imaged 
at a 100X magnification. 
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injury scores were similar to the controls, indicating that the rats had almost completely 
recovered. The injury scores between the validation and oxygenation trials and between 
the negative and saline controls were not significant different (Appendix C).  
 
Figure 6.8: Injury scoring of lung tissue for all ARDS trials. Bars represent mean with 
standard error of the mean. 
6.3.1e BAL fluid analysis 
Analysis of BAL samples was completed at UNMC for concentrations of the 
cytokines TNF-α and IL-6. Only one sample from the Lv1 group presented a measureable 
concentration of TNF-α (21.5 pg/mL) at a 1:2 dilution. The Lv1 BAL sample was 
collected following the rat’s death that occurred approximately 5 hours after LPS was 
administered. The TNF-α concentration of all other samples was zero. BAL samples from 
the Lv1 group measured significantly higher (p < 0.05) concentrations of IL-6 compared 
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to all BAL samples analyzed from other groups (Figure 6.9). The large concentration of 
IL-6 was not measured in any other control or LPS group. 
 
Figure 6.9: Mean concentrations of IL-6 in ARDS validation trials. The error bars 
represent the standard error of the mean. ELISA for each animal was performed with 
dilutions of 1:5 (red) and 1:20 (blue). *Lv1 at both dilutions was significantly greater 
than all other groups (p < 0.05). 
6.3.2 ARDS oxygenation 
From phase one validation trials, rats were observed to begin recovering from the 
symptoms of LPS approximately 3 days after administration. As a result, the observation 
period for measuring the decreased oxygen saturations was determined to be 3 days to 
focus on when the rats were in the most critical condition. All animals were distributed to 
randomly assigned regimens and successfully administered the appropriate aerosol 
solution. The negative control (n = 6) and aerosolized saline cohorts experienced no 
mortalities during the prescribed study periods. However, two rats from the saline control 
group (n = 4) were withdrawn from the study. One developed necrosis in the leg where 
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the catheter was placed, while blood was unable to be sampled from the catheter of the 
other rat withdrawn from the study. Only one death occurred in the LPS group (n = 10) 
32 hours after LPS was administered for a mortality rate of 10%. Lung injury scores and 
W/D ratio for this rat were separated from the other LPS trials for analysis (LPS1). From 
the log-rank test, the mortality between the LPS and control groups was not significant (p 
> 0.05) in the oxygenation phase. The mortality between the LPS trials in the validation 
and oxygenation phases was also not significant (p > 0.05).  
For two days post-insult, nine of the LPS rats presented multiple physical 
symptoms of sickness including low activity with slow reaction times, piloerection, and 
decreased intake of food and water. One rat exhibited none of the physical indications of 
illness displayed by others in the LPS cohorts. All LPS rats were again observed to have 
visible tachypnea with hypopnea. On day 3, LPS rats showed considerable improvement 
in physical health and appearance.  
6.3.2a Pulse oximetry  
In phase two, pulse oximetry was performed on the hind paw where the femoral 
catheter was not implanted. However, the pulse oximeter demonstrated inconsistencies 
from one measuring period to the next, even in the controls. In the validation trials, 
measurements were reliably obtained with high reproducibility. A pulse oximeter reading 
was recorded; the sensor removed and replaced, and the same or very similar reading 
would be measured. Consistent and reproducible measurements were difficult to obtain in 
trials of phase two. 
The peripheral oxygen saturation for the saline control group ranged from 85-92% 
and remained steady during the study (Figure 6.10). However, 12 hours after the aerosol 
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procedure the NC and LPS groups decreased from baseline SpO2 by 6% and 9.4%, 
respectively. The control group returned to normal in the next 12 hours, while for the 
remainder of the observation period the SpO2 readings of LPS rats continued to indicate 
the LPS rats were slightly hypoxic. The decreased SpO2 average of the LPS group was 
not determined to be significantly different from either control group throughout the 
study (p > 0.05). The decrease in average SpO2 for the LPS oxygenation trials was 
observed to be approximately half as severe as the decrease from the baseline of phase 
one validation trials (9.4% to 17.3%).  
 
Figure 6.10: Average peripheral oxygen saturation of ARDS oxygenation trials. Error 
bars indicate the standard deviation of the mean. 
6.3.2b Arterial blood gas analysis 
Blood from the femoral artery catheter of the rat was collected and analyzed every 
12 hours using the handheld blood analyzer. One rat from the saline control group was 
withdrawn from the study due to being unable to sample blood from the femoral catheter 
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at the beginning of the experiment. The femoral catheter was found to be kinked near 
where the catheter was secured in the leg and had clotted. On the last two sample 
collections of the study, blood was not sampled from one negative control rat and three 
rats in the LPS cohort. When the rats were necropsied, the catheters were found to be 
clotted at or near where the catheter was secured in the femoral artery. The femoral 
arterial catheters were believed to clot from not being flushed completely with 
heparinized saline after the previous collection. No instances occurred where the blood 
sampling was omitted for a sampling period because the rats reached their blood 
collection limit of 0.6 mL/kg per day [225,226]. 
The cartridge type used in this study measured and calculated 7 physiological 
parameters of blood gases. For 36 hours post-insult, the average partial pressures of 
carbon dioxide (PaCO2) in arterial blood of LPS rats increased 29.7% from the average 
baseline (Figure 6.11a). Two days after LPS, PaCO2 returned to baseline values. The 
PaCO2 of control groups decreased 13-18% from baseline after 12 hours and then 
stabilized. After LPS administration, the average partial pressures of oxygen (PaO2) 
decreased from baseline by 17.6% at 36 hours and 21.9% at the end of the study (Figure 
6.11b). The PaO2 decreased in the NC group at 12 hours and then returned to baseline 
levels which corresponded to the decrease measured in the average SpO2 of the NC 
group. The PaO2 values for the saline controls remained between 80-90 mmHg during the 
entire study. The calculated parameters of bicarbonate (HCO3
-
), base excess (BE), total 
carbon dioxide (tCO2), and oxygen saturation (SO2) followed the trends of PaCO2 or PaO2 
(Appendix C). 
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Figure 6.11: Average partial pressures of (a) carbon dioxide and (b) oxygen 
measurements of arterial blood. Error bars indicate the standard deviation of the mean. 
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6.3.2c Wet/dry ratio 
Wet and dry weights of the left lung were measured from all phase two rats. 
Healthy negative and saline control animals had average W/D ratios of 4.54 ± 0.25 and 
4.47 ± 0.20, respectively (Figure 6.12). The rats aerosolized with LPS had a significantly 
increased average W/D of 4.93 ± 0.24 when euthanized 3 days post-insult compared to 
the controls (p < 0.05). The LPS rat that died 32 hours after LPS had an W/D of 7.07 and 
was significantly increased from all other rats (p < 0.05) 
 
Figure 6.12: Average W/D ratios of ARDS oxygenation trials. Error bars indicate the 
standard deviation of the mean. 
6.4 Discussion 
In this study, we characterized a murine model of ARDS that was developed and 
influenced by prior work where ARDS was induced by delivery of aerosolized LPS 
directly to the lungs [214–223]. However, prior work primarily focused on the 24-hour 
period immediately after the administration of LPS and the measured cytokine responses 
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from BAL fluid collected from the lungs. The literature is limited regarding the 
prolonged inhibition of respiratory efficiency and the rat’s oxygenation. To better 
understand the pathophysiologic timeline of ARDS in a murine model, the experimental 
objective was to characterize the development and recovery of respiratory function over a 
longer time period than those previously verified [214,215]. The histology and cytokine 
results presented herein reveal the classical ARDS model, and periodic measurements of 
several unprecedented parameters including arterial and venous blood gas analysis, pulse 
oximetry, and chest radiographs. 
From mortality and chest radiographs, the ARDS model in rats possessed 
analogous aspects observed in clinical ARDS cases. The rat model’s overall mortality 
from LPS was 27.3% (6/22) which was within the range of ARDS mortality from recent 
clinical reviews [7,9,11,232]. The risk of mortality from ARDS was highest in the 24 
hour period following the LPS administration as 5 of the 6 deaths occurred in this period. 
Chest radiographs recorded of LPS animals shared similar features such as cloudy 
bilateral white-out, alveolar consolidation, and bilateral infiltrates (Figure 6.6, Appendix 
C). No novel anomalies appeared in radiographs recorded after day 2, and in fact 
radiographs of Lv7 after day 3 or 4 presented considerable improvement overall 
(Appendix C). Substantial recovery occurring after day 3 was additionally supported by 
lung injury scores and cytokine concentrations. Lung injury scores decreased between 
one and three days post LPS, while lung injury scores seven days after LPS were not 
significantly different from controls (Figure 6.8). Only BAL fluid collected from the Lv1 
group exhibited any significant increase in quantities of IL-6 with the concentration 
substantially decreased in Lv3 with barely any trace measured in Lv7 rats (Figure 6.9). 
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Though TNF-α concentration is commonly measured, it did not have great importance in 
validating the model as only one sample showed any measurable levels. The low 
concentration of TNF-α was most likely because the production of TNF-α occurs a short 
time after LPS administration and only two BAL samples were collected during the time 
TNF-α was expressed [233–235].  
The primary goal of characterizing effects of oxygen saturation levels during 
ARDS was successful. During the study, arterial blood gases, pulse oximetry, and 
radiographs evidenced rats suffered inhibited lung function of considerable degree after 
intratracheal LPS. The PaO2 and SpO2 levels of LPS rats decreased drastically within 12 
hours post-insult (Figures 6.4, 6.10, 6.11b). LPS chest radiographs 24 hours post-insult 
revealed obvious alveolar consolidation and edema indicative of compromised lung 
function (Figure 6.6). Additionally, though health appeared to improve by the end of the 
studies, evidence that lung function continued to be compromised was observed. The 
W/D of LPS rats was significantly increased from the control rats 3 days after LPS was 
administered signifying there was residual pulmonary edema and decreased diffusion of 
oxygen and carbon dioxide (Figure 6.12). In addition, the average SpO2 and PaO2 of the 
LPS groups did not return to baseline values and indicated they were still experiencing 
hypoxia at the end of the study. In contrast, VBG sampling did not provide further 
information because there were no distinguishable differences in PvO2 or PvCO2 between 
groups (Figure 6.5). Therefore, a complete representation of oxygen levels and lung 
function in ARDS was achieved solely from pulse oximetry and arterial blood gases as 
the measured trends of SpO2 correlated to the trends of PaO2. VBG analysis did not 
support the pulse oximetry readings or ABG analysis. VBG sampling was attempted due 
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to the ease of blood collection and the lower cost compared to collecting arterial blood. 
Additional surgery and resources were required to sample arterial blood consistently 
which added more complications in performing the experiments. More complications in 
measuring arterial blood from rats were evident as several animals were withdrawn due 
to clotting of the catheter and necrosis from surgery performed in the oxygenation trials. 
Overall, similar results were obtained between the validation and oxygenation 
trials. The lung injury scores of NC, SC, and LPS were not significantly different in 
edema, hemorrhage, and inflammation (Appendix C). The LPS chest radiographs had 
homogeneous pathologies though the quality of the images was noticeably different 
between phases. The most concerning differences experienced in the oxygenation trials 
were the lower mortality rate, shorter physical recovery time, and the less severe decrease 
in SpO2 from LPS. The mortality rate decreased from 41.7% in phase one to 10% in phase 
two, though the mortality rates were not determined to be statistically significant by the 
log-rank test (p > 0.05). The LPS rats in phase two demonstrated less severe physical 
symptoms as they appeared healthier 2 days post-insult and one rat was minimally 
affected by LPS administration. However, the behavior of the rats was not analytically 
scored and was not used to quantify or delineate severity of the illness. Finally, the 
baseline decrease in SpO2 of the LPS phase two trials were approximately half of the 
decrease from baseline measured in the validation trials of phase one (Figures 6.4, 6.10). 
The different decrease of SpO2 was attributed to the lower reliability and larger variance 
of pulse oximetry readings in the oxygenation trials. However, the LPS dose used (7 
mg/kg) was determined to be adequate for evaluating improvements from supplemental 
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oxygen treatments because the SpO2 of rats was sufficiently reduced and supported by 
decreased PaO2 and increased PaCO2.  
6.5 Conclusion 
Intratracheal LPS of 7 mg/kg was successful in producing a murine model of 
moderate ARDS based upon radiographic, histological, and cytokine evidence. Analysis 
of venous blood was confirmed to be a poor indicator for evaluating ARDS and hypoxia. 
The investigations of ARDS also revealed through pulse oximetry and ABG that O2 
levels in rats with ARDS were significantly decreased from baseline during the 48 hours 
after administration of LPS. The oxygenation of the ARDS animals never fully recovered 
during the 3 and 7 day studies. Based on the outcomes from pulse oximetry and ABG 
analysis, the ARDS murine model characterized was demonstrated to be effective for 
testing novel supplementary oxygen delivery methods. The characterized ARDS model 
would subsequently be induced in rats to validate the benefits of PMO therapy in a 
respiratory disease model alongside acute hypoxia models elicited by physical lung 
injuries.  
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Chapter 7: PMO therapy for hypoxia induced by right pneumothorax 
in rats 
The approach of direct systemic oxygenation by injecting OMBs into the 
peritoneal space is a radical change from existing oxygen delivery platforms. The novelty 
of PMO therapy thus requires extensive development of procedures and validation in 
animal models of respiratory injury and disease. The procedure and apparatus for 
infusing OMBs into the peritoneal cavity was created to be simple and straightforward 
(Chapter 4). PMO therapy with the Peri3 precludes the need for an extracorporeal loop to 
circulate blood, thus potentially circumventing the complications from thrombosis and 
intracranial hemorrhage presented by ECMO. In this study, the feasibility of peritoneal 
oxygenation with OMBs was examined for treating hypoxia elicited by the physical lung 
injury of a right pneumothorax in rats. The lung injury of right pneumothorax is a model 
for pulmonary failure in rats that was utilized in prior studies to examine the efficacy of 
peritoneal oxygenation. The objective of this study was confirming the hypothesis that 
intraperitoneal infusion of oxygen microbubbles delivers oxygen in vivo and significantly 
increases the survival time of an animal experiencing acute lung injury. The first attempt 
in testing the properties of PMO therapy for treating acute hypoxia was compared to an 
intraperitoneal infusion of oxygenated saline solution.  
7.1 Design 
A controlled laboratory study was performed to test the therapeutic benefit of an 
intraperitoneal infusion of oxygen microbubbles in animals experiencing acute lung 
injury. The research subjects were male Wistar rats housed 2 per cage and acclimated for 
4 days with free access to food and water. Right pneumothorax was chosen as an 
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appropriate model for acute lung injury based on prior work reported in the literature 
[135]. The right lung of the rat is composed of four lobes, whereas the left lung consists 
of a single lobe [55]. Thus, damage to the right lung can cause a drastic reduction in 
oxygen intake and respiratory function. Previous studies in rats demonstrated that the 
volume of the right lung is approximately 60% of the total lung volume [236], and 
collapse of the right lung by pneumothorax is fatal [135]. Two treatments were applied: 
oxygen microbubbles or oxygenated saline as a control. Following induction of 
pneumothorax, the vital signs observed and measured were intraperitoneal pressure, 
infused volume, rectal temperature, heart rate, and oxygen saturation (SpO2). 
The animals were randomly assigned to cages by the caretakers and randomly 
chosen for treatments. No additional blinding was done in the study. The number of 
animals used in this study was determined from work by Matsutani et al. [135] and a 
preliminary feasibility study. In Matsutani, a synthetic oxygen carrier was injected into 
the intraperitoneal (IP) space of rats for the purpose of systemic oxygenation. The mean 
standard deviation and mean effective size were 6.9 and 19.9, respectively [135]. The 
same standard deviation was assumed, but half the effective size (μ – μ0 = 10). Using 
these values, a target Type I error of 0.05 and a sample size of 6 rats per group yielded a 
power of 0.81. In the preliminary feasibility study, a sample size of 4 rats was used in the 
oxygen microbubble group, and 3 rats were used in the control group. Using the log-rank 
test for comparison of the survival distribution (α = 0.05), a significant difference was 
found between the two groups (χ2 = 6.624, p = 0.010). Based on the results of the 
preliminary trials, a sample size of 5 rats per group was decided to be adequate for the 
lung injury study. 
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Data collection was stopped due to either cardiac arrest or achievement of the 
primary endpoint. Additional criteria were established to allow for the exclusion of 
samples where complications arose. Criteria for exclusion included the occurrence of 
unsuccessful pneumothorax or infrequent data points being collected by the veterinary 
monitor. No other data were excluded. No test for outliers was used; all data were 
included in the study. A primary endpoint of 2 hours following induction of 
pneumothorax was selected to avoid complications arising from animal recovery from 
anesthesia and the initial lung injury. Complications after recovery from anesthesia and 
lung injury were occasionally observed in animals surviving greater than 2 hours in the 
preliminary feasibility study. The 2-hour endpoint was calculated to be sufficiently long 
to demonstrate a statistically significant increase in mean survival time between animals 
receiving PMO therapy and the control group. Prior to the study, the longest mean 
survival time for an intraperitoneal oxygenation therapy following pneumothorax 
reported in the literature was 33 minutes [135]; thus, a mean survival time exceeding 2 
hours was deemed a significant improvement over the current state of the art and of high 
clinical utility. No other endpoints were specified and no trials were repeated. Each 
animal received only one pneumothorax and one treatment. 
Treatments in rats were restricted to a single bolus of approximately 1/5 of the 
body weight of the rat. This bolus volume is reported as the maximum volume to safely 
inject into the peritoneal cavity of a sedated animal [21,135,226]. The volume and 
pressure were simulated in control trials by injecting saline at the same flow rate and 
procedure as OMBs. To increase the amount of OMBs which could be delivered, 
preliminary trials investigated circulating saline into and out of the peritoneal cavity. 
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However, circulation with saline failed due to omental and intestinal tissue obstructing 
the needles and catheters attempted.  
7.2 Materials and Methods 
The materials and methods section details the procedures used to inflict the right 
pneumothorax for inducing an acute lung injury and hypoxia. Section 7.2 then overviews 
the parameters measured, treatments administered, and the protocol followed during the 
experiments. When the observation period of the rats was completed, surviving animals 
were euthanized and the experiment ended. Section 7.2 ends with a summary of the 
statistical tests used to determine significant differences between treatment groups. 
7.2.1 Right pneumothorax lung injury model 
All animals were housed and underwent procedures approved by the University of 
Nebraska-Lincoln, IACUC. Male Wistar rats (n = 10, m = 430 ± 15 g, Charles River) 
were anesthetized in an induction chamber with 5% isoflurane to effect and maintained 
on 2% isoflurane. Each rat was weighed, given an IP injection of sodium pentobarbital 
solution (50 mg/kg dose), and then placed in the supine position on a warming pad 
(T/pump Classic, Gaymar) set at 38°C to maintain body temperature (Figure 7.1). After 
the rat was fully sedated and unresponsive to pain delivered by paw pinches, a small 
incision into the skin was made to expose the fascia of the abdominal wall. A 12-gauge 
indwelling catheter was then inserted into the IP cavity and fitted by a luer lock to tubing 
(8.2 mm inner diameter, Tygon) attached to the Peri3 system (Chapter 4) for subsequent 
infusions. A 22-gauge indwelling catheter was also inserted into the IP cavity and 
connected to two pressure transducers (4426-005G, Measurement Specialties Inc.) for 
measuring intra-abdominal pressure via a data acquisition system (myDAQ, LabVIEW, 
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National Instruments). A veterinary monitor (SurgiVet Advisor, Smith’s Medical) was 
used to monitor vitals of heart rate and peripheral oxygen saturation. The monitor could 
read up to a maximum heart rate of 350 bpm and was found to be sufficient for recording 
values in an anesthetized rat. A pulse oximetry sensor (V3078, Smith’s Medical) was 
clipped to the hind leg of the rat to measure the pulse rate and peripheral oxygen 
saturation (SpO2). A temperature probe (WWV3418, Smith’s Medical) was placed 
rectally for monitoring body temperature. The treatment bolus of perfusate was pumped 
through a fluid warmer (iWarm, Midmark) set at 40.4°C and into the IP space with a 
peristaltic pump (Thermo Scientific, FH100M) at 40 mL/min for 1 min, and then at 8 
mL/min thereafter. At the time the flow rate was reduced, the rats experienced a right 
pneumothorax by perforating the pleura of the pulmonary cavity with a scalpel. Infusion 
lasted until distension of the abdomen was noticeable and while the intra-abdominal 
pressure was below 5 mmHg (0.67 kPa). When infusion into the peritoneal cavity was 
ceased, the total infused volume of perfusate was recorded. The fluids used as a perfusate 
were saline as the control and oxygen microbubbles (70 vol% O2 gas volume fraction). 
 
Figure 7.1: The experimental setup for treatment of a right pneumothorax in rats [179]. 
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During the experiment, temperature, pulse rate, and oxygen saturation (SpO2) of 
the blood was monitored in 8-second averages and recorded every 30 seconds for each 
rat. The intra-abdominal pressure was monitored and recorded at a frequency of 10 
samples per second. Survival time was measured as the elapsed time between right 
pneumothorax and cardiac arrest. If still living, the rat was intramuscularly injected with 
a second dose of sodium pentobarbital 1 hour following the administration of the 
previous dose. The endpoint of data collection occurred when the rat had suffered 
functional cardiac arrest or when the predefined endpoint of 2 hours of survival time was 
reached. At 2 hours plus 5 minutes, any surviving rats were euthanized by isoflurane 
overdose. 
7.2.2 Statistical analysis 
Kaplan-Meier survival curves were created with a sample size of 5 rats per group 
for a representation of the survival rate for the control and oxygen microbubble groups. A 
log-rank (Mandel-Cox) test was done to compare the survival distribution of the OMB 
group to the control group for a significant difference (α = 0.01).  
7.3 Results 
In this study, the right pleura in male Wistar rats (n = 10, m = 430 ± 15 g) was 
perforated by piercing a scalpel blade between two ribs of the pulmonary cavity 
(Appendix D). The injury successfully caused a pneumothorax of the right lung in all but 
one of the rats. In one rat from the saline control group, the scalpel wound was 
implemented too deep while the rat was inhaling. The scalpel lacerated the lung causing 
considerable bleeding and death from hemorrhage shock. Additionally, few data points 
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were recorded from the rat with the veterinary monitor. Therefore, the rat was excluded 
from the study because both exclusion criteria occurred in the trial. 
Infusion of the fluid treatments was completed without leaking from the 
abdominal incision and lasted until distension of the abdomen was noticeable. The total 
infused volume of OMBs was 107 ± 9 mL, which was not statistically different from the 
saline control (Figure 7.2). The intra-abdominal pressure was maintained at less than 5 
mmHg (0.67 kPa) gauge throughout the experiment for animals treated with both saline 
and OMBs (Figure 7.3). Following pneumothorax, the mean body temperature was 34.5 
± 0.8 °C for animals receiving OMBs and 33.0 ± 1.0 °C for those receiving saline (Figure 
7.4). These body temperatures were below the normal temperature range of rats (35.9-
37.5°C) [55], but were unlikely a significant factor in causing complications or death 
during the experiment [237–239]. 
 
Figure 7.2: Total infused fluid volume for rats with pneumothorax [179]. 
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Figure 7.3: The intra-abdomen pressure (mean ± SD) in rats with pneumothorax [179]. 
 
Figure 7.4: The rectal temperature (mean ± SD) in rats with pneumothorax [179]. 
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Peritoneal infusions of OMBs produced 100% survival to the predetermined  
2-hour endpoint in 5 rats experiencing a right pneumothorax, compared to a mean 
survival time of only 15.5 ± 8.1 minutes (n = 5) for oxygenated saline and 16.0 ± 4.8 
minutes (n = 6) for untreated controls (Figure 7.5). The survival from PMO treatment was 
determined to be a significant increase compared to the two other treatment groups (χ2 = 
9.701, p = 0.002). Oxygen saturations for animals treated with OMBs were observed to 
be between 80-90% throughout the 2-hour timeframe (Figure 7.6). The measured SpO2s 
for rats treated with saline dropped precipitously within minutes after pneumothorax. 
Furthermore, heart rate for animals treated with OMBs was observed to be range from 
240-350 bpm during the 2 hours, while it dropped rapidly within minutes for the controls 
treated with saline (Figure 7.7). The values of SpO2 and heart rate measured in OMB 
treated rats are considered to be within the normal range of a sedated rat [55,240–242]. 
 
Figure 7.5: The survival of treated rats with right pneumothorax [179]. 
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Figure 7.6: The peripheral oxygen saturation in rats with right pneumothorax [179]. 
 
Figure 7.7: The heart rate of rats with right pneumothorax [179]. 
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7.4 Discussion 
The OMBs used in this study were designed for high oxygen carrying capacity 
and rapid oxygen delivery to the peritoneum. A 70 vol% suspension of OMBs at 1.0 bar 
and 37°C contains an estimated 0.88 mg-O2 mL
-1
, compared to 0.31, 0.62 and 0.57 mg-
O2 mL
-1
 for blood, liposomal hemoglobin, and pure PFC, respectively (Table 3.3). 
Furthermore, OMBs provide a greater fraction of oxygen availability to the body. The 
entire mass of oxygen can be released to low-oxygen surroundings because complete 
microbubble dissolution is thermodynamically favorable. In contrast, complete oxygen 
release from PFC and HBOC formulations is restricted by the oxygen solubility of PFC 
which depends on the partial pressure of oxygen in the environment and the oxygen 
binding affinity of hemoglobin. 
However, if available oxygen carrying capacity was the only criterion for 
successful peritoneal oxygenation, then ventilation with pure oxygen (1.26 mg-O2 mL
-1
) 
should not have failed to provide clinically relevant oxygenation, as reported by Giffin et 
al. [132]. We attribute the limited uptake for pure oxygen ventilation to the problem with 
injecting a bolus of free gas into the peritoneal cavity. Surface area is minimized owing to 
the high surface free energy (~73 mJ/m
2
) of the gas/water interface. Thus, one may 
compare the transport of a centimeter-scale bubble for pure oxygen ventilation to 
hundreds of billions of micrometer-scale bubbles for OMBs. OMBs would then provide a 
greater rate of oxygen delivery to the peritoneum compared to the failed method of 
peritoneal oxygenation with oxygen ventilation.  
Achieving 100% survival to 2 hours with OMBS compared to the 15.5 minute 
mean survival time for saline controls was found to be a significant improvement. The 
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improvement with OMB treatment indicates a potential for clinical utility in patients 
suffering mild to severe hypoxemia where mechanical ventilation is inadequate or 
injurious. In neonates, for example, PMO therapy could be used to treat hypoxemia 
arising from meconium aspiration syndrome, pulmonary hypertension, congenital 
diaphragmatic hernia, sepsis, and cardiac anomalies [243]. 
There were some limitations to this study. First, there was some concern that the 
pneumothorax lung injury model would cause death, not from gas exchange failure, but 
from increased oxygen demand from work of breathing, cardiogenic failure from altered 
venous return in a depressurized thorax, or from another unanticipated complication due 
to the wound. The success of PMO in prolonging life in all five animals suggested that 
these complications were secondary to the need for rapid oxygen delivery. Another 
limitation to our study was that we only employed a one-way delivery of oxygen, but did 
not simultaneously remove carbon dioxide. The lack of carbon dioxide removal could 
ultimately result in complications such as hypercapnia and acidosis in cases where the 
lungs or ventilation are significantly inhibited. 
7.5 Conclusion 
Peritoneal oxygenation with oxygen microbubbles produced 100% survival with 
normal peripheral oxygen saturations to the 2-hour endpoint for rats suffering fatal 
hypoxia from a right pneumothorax lung injury. Whereas, untreated and saline-treated 
controls had a mean survival time of only 15.8 ± 6.2 minutes and no animals survived to 
the 2-hour endpoint. A single OMB bolus treatment achieved a significant improvement 
in oxygenation and survival of rats with pneumothorax injury. The success with a single 
OMB bolus indicated that peritoneal microbubble oxygenation therapy is capable of 
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delivering oxygen in vivo, increasing survival, and increasing systemic oxygenation. The 
improvement in fatally hypoxic rats treated with OMBs provides evidence that PMO 
therapy possesses potential clinical utility as an alternative method of supplemental 
oxygenation in patients suffering hypoxemia where mechanical ventilation and ECMO is 
inadequate or injurious. The next step of validating the clinical potential of PMO therapy 
was to evaluate PMO therapy in further experiments with larger animals experiencing 
physical injury and acute hypoxia. 
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Chapter 8: PMO therapy for asphyxia from tracheal occlusion of 
rabbits 
In the rat pneumothorax study (Chapter 7), PMO treatment with a single bolus of 
OMBs eliminated mortality and maintained normal levels of peripheral oxygen saturation 
and heart rate in rats suffering from an otherwise lethal right pneumothorax. The 
impressive results with OMBs in hypoxic rats demonstrated the feasibility and oxygen 
delivery properties of PMO therapy as a supplemental oxygen treatment. However, rats 
have a significantly lower oxygen demand and different peritoneal physiology compared 
to larger mammals and humans. Thus, success in rats alone provides insufficient evidence 
for the potential of PMO therapy in clinical applications of treating hypoxia. The current 
study addresses three critical goals for the further development of PMO technology: 1) to 
determine whether PMO can extend life following complete loss of lung function (rather 
than partial loss as in the right pneumothorax) without resuscitation; 2) to scale up the 
procedure to a larger animal; and 3) to design and test a new delivery system that 
circulates OMBs through the peritoneal cavity. 
8.1 Design 
In this study, a larger animal model was chosen in order to take the next step 
toward clinical relevance. Initial in vivo feasibility studies were performed on rats due to 
their low cost, biological relevance, and most importantly, small oxygen demand and 
correspondingly small perfusate requirements (Chapter 7). If PMO therapy had been 
ineffective on rodents, OMB treatments almost certainly would have had no benefit to 
humans and the technique would have been abandoned. Due to our success with rats and 
in order to produce studies more relevant to pre-clinical trials, larger animal models are 
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needed. Study with larger animals requires significantly improving the OMB fabrication 
technique in order to supply the OMB flow rates needed for greater oxygen demands of 
large animal. Developing the processes and equipment for generating the high flow rate 
of OMB perfusate needed for larger animals is a difficult and expensive task, and 
therefore was not initiated until feasibility of the therapy with rats was demonstrated. 
The choice of the rabbit as the next animal model for this stage of the research 
was based on procedures and knowledge from peritoneal dialysis research. Even though 
rats and rabbits are both the most commonly used models in peritoneal dialysis research, 
rabbits are seen as more clinically relevant to humans [244]. Peritoneal dialysis research 
in rabbits is considered more relevant to humans because the ratio of the rabbit’s 
intraperitoneal volume to body mass and peritoneal surface area is more similar to 
humans than that of rats [112]. Furthermore, the total oxygen demand of rabbits is much 
higher than that of rats due to their larger body mass, which allows for more relevant 
analysis of PMO therapy in humans [184,186,187,245]. The larger body mass also 
increases the total oxygen demand and, thus, requires scale up of the manufacture of 
OMBs. 
8.2 Materials and Methods 
All animal studies were performed in accordance with the University of 
Nebraska-Lincoln, IACUC. To evaluate PMO therapy, male New Zealand White rabbits 
(n = 19, m = 2.2 ± 0.2 kg) were treated with either intraperitoneal OMBs or saline as the 
control. Two infusion methods (bolus or circulation) were tested, resulting in 4 groups: 
SB- saline bolus (n = 2); SP- saline perfusion (n = 2); OB- OMB bolus (n = 9); OP- OMB 
perfusion (n = 6). The saline groups were limited to two animals each (four animals total) 
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as the use of more animals was deemed excessive considering these four trials matched 
the well-documented time of death for an untreated asphyxiation rabbit model [246–248].  
To model complete respiratory failure, the rabbit was intubated with a cuffed 
endotracheal tube (ETT), which could be hermetically sealed by occluding the end with a 
rubber membrane and plastic cap. Thus, all gas exchange in the lungs was eliminated, 
causing the animal’s oxygen intake, as well as carbon dioxide removal, to occur through 
OMBs, and any extension of life was entirely due to PMO therapy. The experimental 
endpoint was cardiac arrest determined by cessation of heartbeat and pulse. To prevent 
the disruption of hemodynamics, intra-abdominal pressure (IAP) was monitored and kept 
below 8 mmHg [125,183]. The criterion for exclusion was the rabbit breathing around the 
sealed ETT. During the experiment, body temperature, pulse rate, and SpO2 were 
monitored in 8 second averages and recorded every 30 seconds. The IAP and fluid 
infusion temperature were monitored and recorded every second. Survival time was 
calculated as the time between the ETT being sealed (time = 0) and cardiac arrest (the 
experimental endpoint). 
Each rabbit was weighed before the procedure and then sedated with 5% 
isoflurane to effect through a nosecone. The throat was then sprayed with cetacaine and 
intubated with the cuffed ETT (3 mm, JorVet). The ETT cuff was inflated and then 
secured by cotton gauze tied around the head and front incisors. The rabbit was placed in 
the supine position on a warming pad (T/pump Classic, Gaymar), and the ETT was 
attached to the anesthetic machine with the rabbit maintained on 2% isoflurane (Figure 
8.1). The abdomen was shaved and sterilized with betadine scrub and alcohol. A 
veterinary monitor (SurgiVet Advisor, Smith’s Medical) was used to monitor vitals. A  
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Figure 8.1: Schematic of the setup for the trachea occlusion experiments in rabbits [192]. 
pulse oximetry sensor (V1700, Smith’s Medical) was used to measure the pulse rate and 
peripheral oxygen saturation (SpO2). A temperature probe (WWV3418, Smith’s Medical) 
monitored body temperature. Both the pulse oximeter and temperature sensors were 
placed rectally. An intramuscular injection of ketamine-xylazine solution (35-5 mg/kg 
dose, 35 mL/kg solution) was then given to anesthetize the rabbit for the remainder of the 
procedure, while the rabbit was weaned off of the isoflurane. Once completely weaned 
off isoflurane, the ETT was disconnected from the anesthetic machine and the rabbit was 
allowed to breathe room air. Once the rabbit was confirmed unresponsive to pain by paw 
pinches, a small incision was made in the upper left quadrant of the abdomen for 
insertion of the fluid infusion tubing (3.2 mm inner diameter, Tygon) into the peritoneal 
cavity. The abdominal incision was then sutured closed around the infusion tubing. The 
infusion tubing was attached to the Peri3 (Chapter 4) for peritoneal infusion of OMB or 
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saline treatment. A 12-gauge indwelling catheter was then inserted into the peritoneal 
cavity at the upper right quadrant of the abdomen and connected to two pressure 
transducers (4426-005G, Measurement Specialties Inc.) for measuring IAP via the Peri3 
program (myDAQ, LabVIEW, National Instruments).  
8.2.1 Bolus delivery of OMBs 
A single static volume of OMBs or saline was injected into the cavity. The OMB 
or saline bolus was pumped through an inline fluid warmer (iWarm, Midmark) set at 
40.4°C and then into the peritoneal cavity with the Peri3’s peristaltic pump (Thermo 
Scientific, FH100M) at 80 mL/min for 4 min, and then at 12.6 mL min
-1
 kg
-1
 thereafter. 
The ETT was then hermetically sealed upon reduction of the infusion rate of the bolus 
treatment. Fluid infusion lasted until the IAP reached 5 mmHg or the rabbit experience 
cardiac arrest. When infusion into the peritoneal cavity was ceased, the total infused 
volume of the treatment bolus was recorded. 
8.2.2 Circulation of OMBs 
The setup of the peritoneal circulation technique, where fresh OMBs or saline 
were continually perfused through the peritoneal cavity to continuously deliver oxygen, 
was similar to that of the bolus setup. However, to remove OMBs from the peritoneal 
cavity, a medial incision was made into the peritoneal cavity, and a customized OMB 
scavenging port was implanted (Figure 8.2, Appendix E). Suture was then used to close 
the incision around the collar of the scavenging port. Tubing (7.9 mm inner diameter, 
Tygon) was then attached to the scavenging port for drainage of perfusate from the 
peritoneal cavity. The OMB or saline perfusate was then pumped through an inline fluid 
warmer (iWarm, Midmark) set at 40.4°C and into the peritoneal cavity with the Peri3’s 
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Figure 8.2: Custom scavenge port used for perfusion trials of tracheal occlusion. 
 
Figure 8.3: Control scheme implemented with LabVIEW for the perfusion experiments 
[192]. 
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peristaltic pump (Thermo Scientific, FH100M) at 80 mL/min for 4 min, and then at 12.6 
mL min
-1
 kg
-1
 thereafter. The IAP was maintained between 3 and 4 mmHg by the Peri3 
system using a 36V solenoid (ROB-10391, Sparkfun) driven valve to control the fluid 
flow. Once circulation of OMBs or saline was attained, the ETT was hermetically sealed. 
Infusion of fluid continued until the time of death, after which the total infused volume 
was recorded. The LabVIEW program of the Peri3 automatically regulated the circulation 
of fluid in the perfusion trials by simultaneously following two schemes controlled by the 
IAP and time (Figure 8.3). 
8.2.3 Statistical analysis 
Kaplan-Meier survival curves were created to analyze the survival benefit of 
OMBs versus saline control. A log-rank (Mandel-Cox) test was performed for significant 
differences between the groups’ mean survival times (α = 0.01). Levene’s test was 
performed to compare if the variances between the groups’ survival were statistically 
different (α = 0.05). Analysis of covariance (ANCOVA) with separate means was 
performed to test the overall differences among groups between the rate of change in the 
heart rate and SpO2 after the ETT was sealed. Multiple comparison tests of the means 
were performed to determine which groups were significantly different (α = 0.05).  
8.3 Results 
The results from PMO therapy experiments in rabbits comprised two types of 
peritoneal treatment administration. In the bolus delivery treatments, the peritoneal cavity 
of rabbits was infused with a single bolus of OMBs or saline. In the circulation 
treatments, the peritoneal cavity of rabbits was continually infused with fresh OMBs or 
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saline with the Peri3 system while the intra-abdominal pressure was maintained below 6 
mmHg. 
8.3.1 Bolus delivery of OMBs 
Peritoneal microbubble oxygenation resulted in a significant increase in the 
survival time of rabbits following the endotracheal tube being sealed (Table 8.1). No 
animals were observed to breathe past the ETT once sealed. Rabbits treated with a bolus 
infusion of saline (SB group) experienced cardiac arrest within 7 minutes. The rabbits 
that received a bolus injection of OMBs (OB group) had a mean survival time of  
12.2 ± 3.0 minutes, which was determined to be significantly different than the SB group 
(χ2 = 12.36, p < 0.01) (Figure 8.4). 
 
Figure 8.4: Kaplan-Meier survival curves of the treatment groups in the tracheal 
occlusion of rabbits [192].  
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Table 8.1: Mass, infused volume, and survival time data of trachea 
occlusion experimental groups [192]. 
Treatment n Mass (kg) Infused vol. (mL) Survival time (min) 
Saline Bolus (SB) 2 2.53 ± 0.02 336 ± 9 6.5 ± 0.7 
OMB Bolus (OB) 9 2.25 ± 0.16 558 ± 66 12.2 ± 3.0 
Saline Perfusion (SP) 2 2.03 ± 0.01 431 ± 37 6.8 ± 0.4 
OMB Perfusion (OP) 6 2.18 ± 0.12 646 ± 72 10.8 ± 2.4 
The temperature of the fluid infused into the peritoneal cavity ranged from 20.5°C 
to 28.0°C and the IAP was maintained below 6 mmHg. The body temperature of the SB 
and OB groups decreases slightly below the normal body temperature range for rabbits of 
38-40°C [249,250]; however, the body temperatures of all treated rabbits were in the 
range of 35-40°C during the duration of fluid infusion (Figure 8.5a, c). The slight 
decrease in body temperature of the SB and OB groups resulted from the combination of 
anesthesia, shaving of the abdomen, and peritoneal infusion of fluid that was slightly 
cooler than body temperature. The slight hypothermic condition was not enough to 
endanger the rabbit or cause hypothermia based on the duration of the procedure 
[251,252]. 
The SB group had pulse rates of 130-325 bpm, which are within the normal range 
for a sedated rabbit [249,250,253], while the OB group with a prolonged survival time 
eventually experienced pulse rates below 130 bpm (Figure 8.6a, c). Interestingly, the SB 
group experienced a rapid decline in pulse rate following sealing of the ETT, whereas the 
OB group appeared to experience a steadier and less drastic decline in pulse rate. Rabbits 
infused with OMBs exhibited a short period of stability in pulse rate 5-10 minutes after 
the ETT was sealed. 
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The SB group experienced a rapid decline in SpO2 following sealing of the ETT, 
whereas the OB group experienced a steadier and less drastic decline in SpO2 (Figure 
8.7a, c). While the oxygen saturation was below a healthy baseline of 90% in both 
groups, there appeared to be an overall improvement in SpO2 for the OB group compared 
to the SB group. From a clinical view, however, the rabbits were not systemically 
oxygenated well as the SpO2 was around 60% for most of the experiments. Note that a 
couple OB trials did have higher O2 levels (~80%). No significant difference in heart rate 
or SpO2 was indicated by ANCOVA (Table 8.2). 
 
Figure 8.5: Average body temperature of all treatment groups before and during 
experiment: (a) saline bolus, (b) saline perfusion, (c) OMB bolus, (d) OMB perfusion. 
The shaded region indicates standard deviation. Where there is no shaded region either 
there is only one sample, or the samples values are coinciding at the time (SD = 0). The 
dashed line at time zero represents when the ETT was sealed. The cardiac arrest times of 
each rabbit are indicated by circles [192]. 
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Table 8.2: Multiple comparison test results of tracheal occlusion using 
ANCOVA [192]. 
 Group 1 Group 2 C.I.
 a
 Significant difference
 b
 
H
ea
rt
 r
at
e 
SB SP [-42.01, -3.20] YES 
 
SB OB [-28.37, 0.59] NO 
SB OP [-34.20, -4.87] YES 
SP OB [-4.88, 22.31] NO 
SP OP [-10.73, 16.85] NO 
OB OP [-10.48, -0.83] YES 
S
p
O
2
 
SB SP [-7.56, 7.82] NO 
 
SB OB [-9.42, 1.77] NO 
SB OP [-11.59, -0.25] YES 
SP OB [-9.50, 1.61] NO 
SP OP [-11.68, -0.41] YES 
OB OP [-4.07, -0.12] YES 
a
 There was a significant difference if the confidence interval (C.I.) does not contain zero. 
b 
The diagram in the last column shows the overall relationships between the groups. Dashed lines 
represent a significant difference, whereas the solid lines represent lack of significant 
difference.  
8.3.2 Circulation of OMBs 
The rabbits circulated with OMBs had a baseline pulse rate of 245 ± 40 bpm and 
oxygen saturation of 87 ± 4% when intubated and freely breathing room air. Rabbits that 
received saline (SP group) experienced hypoxic cardiac arrest within 7 minutes after 
complete asphyxiation by sealing the ETT (Table 8.1). Rabbits circulated with OMBs 
(OP group) had a mean survival time of 10.8 ± 2.4 minutes, which was significantly 
longer than the SP group (χ2 = 8.33, p < 0.01) (Figure 8.4) . The survival times for the 
bolus and perfusion groups were not significantly different for either saline (χ 2 = 0.059, p 
> 0.05) or OMBs (χ 2 = 0.705, p > 0.05). 
The temperature of the fluid infused into the peritioneal cavity ranged from 
20.5°C to 28.0°C, and the IAP was maintained in the range of 2 to 4 mmHg. The body 
temperature of the OP treatment group decreased slightly below the normal body 
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temperature range for rabbits, but was in the range of 35-40°C during the period of fluid 
infusion (Figure 8.5b, d). The body temperature of the SP group, on the other hand, 
decreased from 38°C to 31°C. The combination of saline below the rabbits’ body 
temperature, the high heat capacity of the saline, and circulation contributed to lower 
body temperatures in the SP group. Decreased body temperatures were not seen in the 
rabbits in the OP treatment group because OMBs are 70% O2 gas by volume and 
therefore had a lower heat capacity than saline.  
 
Figure 8.6: Average pulse rate of all treatment groups before and during experiment: (a) 
saline bolus, (b) saline perfusion, (c) OMB bolus, (d) OMB perfusion. The shaded region 
indicates standard deviation. Where there is no shaded region either there is only one 
sample, or the samples values are coinciding at the time (SD = 0). The dashed line at time 
zero represents when the ETT was sealed. The cardiac arrest times of each rabbit are 
indicated by circles [192]. 
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Results between the OMB and saline control groups were similar to those 
presented for bolus injection (Figure 8.6b, d). The OP group had heart rates within the 
normal range, while the SP group experienced pulse rates below 130 bpm. As in the 
bolus treatments, rabbits infused with OMBs exhibited a short period of stability in pulse 
rate 5-10 minutes after the ETT was sealed. 
The OP group experienced a significant increase in SpO2 compared to all other 
treatment groups (Figure 8.7b, d). Interestingly, the decline in SpO2 and heart rate for the 
SP group began approximately 4 minutes before the ETT was sealed, when infusion was 
 
Figure 8.7: Average oxygen saturation, measured as SpO2, of all treatment groups before 
and during experiment: (a) saline bolus, (b) saline perfusion, (c) OMB bolus, (d) OMB 
perfusion.  The shaded region indicates standard deviation. Where there is no shaded 
region either there is only one sample, or the samples values are coinciding at the time 
(SD = 0). The dashed line at time zero represents when the ETT was sealed. The cardiac 
arrest times of each rabbit are indicated by circles [192]. 
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initiated. The reason for the anomaly in decreased heart rate of the SP group was 
unidentified. Overall, the measured vitals of heart rate and oxygen saturation in the OMB 
treated rabbits indicated less drastic decline than that of the saline treatment groups, but 
only the OMB perfusion method was found to significantly increase SpO2 compared to all 
other groups (Table 8.2).  
8.4 Discussion 
The first goal of this study was to determine whether PMO can extend life 
following complete loss of lung function. Based on these results, we conclude that PMO 
therapy in a complete asphyxiation model significantly increased time to cardiac arrest by 
a factor of 1.7. The increase in survival time was shorter than the 6.5-fold increase in 
survival time that was previously achieved for PMO therapy in a rat lung injury model 
(Chapter 7) [179]. In the prior injury model, however, lung function was estimated to be 
limited to about 40% [236], possibly improving over the 2-hour experimental timeframe 
as the underlying pneumothorax healed. In the study in asphyxiated rabbits, the sealed 
ETT reduced lung function to 0%. The significant improvement in survival time and 
oxygenation (SpO2) for PMO-treated animals over controls therefore demonstrated the 
potential ability of OMB treatment technology, even in the extreme scenario of complete 
lung failure or airway obstruction. 
The second goal was to scale up the procedure of OMB treatment from rats to a 
larger animal. One of the potential limitations of PMO treatment is the limited amount of 
blood flow through the splanchnic circuit. In humans, only 20-30% of the total blood 
volume passes through the peritoneal region [113], which is similar to rabbits where total 
splanchnic circulation is 22% of the total blood flow [254]. The low splanchnic blood 
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flow limits the amount of oxygen that can be transported from the peritoneum, which 
may explain the difficulty in maintaining normoxic levels in the complete asphyxiation of 
rabbits. 
The final goal was to test a new peritoneal delivery system, the Peri3, to circulate 
OMBs through the peritoneal cavity. While circulation was achieved, the method of 
infusion (bolus vs. circulation) demonstrated no measured impact on survival time in the 
complete asphyxiation model. The lack of improvement with OMB circulation was an 
unexpected outcome as more OMBs were delivered to rabbits in the perfusion group. In 
the circulation infusion method, OMBs fully loaded with oxygen were continuously 
delivered into the peritoneal cavity. However, no method was implemented to encourage 
complete mixing of OMBs in the peritoneal cavity before OMBs were removed. Fresh 
OMBs possibly exited the cavity through the scavenge tubing before completely 
releasing their oxygen load. Thus, transfer efficiency may have been negatively impacted 
for the continuous infusion method such that circulation of OMBs was analogous to a 
single bolus injection. In the future, OMB perfusion will be evaluated more thoroughly 
by determination of OMB quality and gas concentrations (O2, CO2, N2) directly before 
and after the administration of OMB treatment. Additional refinements of the circulation 
technique may be needed to increase mass transfer between the OMB perfusate and 
peritoneum.  
The variance in survival time of the OMB treated groups merits future 
investigation as it was significantly different from the controls (p < 0.05). Several factors 
could have caused variability in survival time. For example, rabbit weight, individual 
metabolism, and depth of anesthesia all affect O2 consumption. The splanchnic blood 
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flow and vascularization of the peritoneum varied between animals and impacted the 
diffusion rate of O2 into the body. Some of these variables could possibly be controlled. 
For example, enhancing splanchnic blood flow could be achieved by administration of 
drugs such as cisapride [131]. Also, varying IAP levels could be investigated in order to 
determine the pressure threshold for vasculature collapse and its effect on OMB diffusion 
dynamics. 
8.5 Conclusion 
From the study of total asphyxiation in rabbits, the current PMO system was 
inadequate to provide 100% of a sedated rabbit’s oxygen demand because animals 
exhibited a gradual decrease in SpO2 before death. Though total systemic oxygenation 
with OMBs was not possible in asphyxiated rabbits, local tissue oxygenation of the 
abdomen may have been substantially increased (Appendix E). Additionally, the 
pneumothorax experiments demonstrated that PMO could supplement 60% of a rat’s 
oxygen demand (Chapter 7). If OMB treatment demonstrates similar efficacy in humans 
as in rats and rabbits, PMO therapy may be able to provide supplemental oxygen for 
systemic oxygenation in a wide variety of respiratory injuries which result in hypoxia. 
PMO therapy was subsequently investigated in an ARDS hypoxia model of rats (Chapter 
6) to validate PMO therapy for cases of hypoxia attributed to respiratory diseases 
including asthma, sepsis, pneumonia, and ARDS.  
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Chapter 9: Oxygenation in a sedated rat with ARDS via a single OMB 
bolus  
PMO therapy was validated to provide beneficial oxygenation in hypoxic models 
of physical lung injury. The last form of hypoxic model investigated in this work was 
validating PMO therapy in an animal model of respiratory disease. The respiratory 
disease selected for evaluating PMO therapy was ARDS in rats because of the extensive 
literature that exists detailing the ARDS rat model and because the current medical 
methods are ill-suited for treating hypoxia attributed to ARDS. However, the volume of 
blood that can be sampled from a rat is limited to approximately 2-3 samples per day 
without altering the hematocrit and oxygen capacity of the circulating blood 
[55,225,226]. The low number of blood samples restricts how comprehensive of an 
oxygen profile that is measured from an individual rat induced with ARDS. Therefore, 
when comparing PMO therapy to other treatments, the blood samples must be taken at 
times when the improvement in systemic oxygenation from OMB treatment is greatest. 
To determine when the oxygen saturation in the blood peaks from injection of an OMB 
bolus, an experiment was conducted in rats suffering from ARDS. Discovering when the 
oxygen increase from an OMB bolus treatment was greatest would determine the optimal 
time to sample blood and pulse oximetry for the best representation of clinical benefit of 
PMO in a long term ARDS study. Also, the time after OMB infusion when improvement 
in oxygenation has peaked would be relevant for approximating the minimum number of 
OMB boluses that would be optimal for maintaining elevated oxygen levels for the 
longest duration. 
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9.1 Design 
In previous work investigating the oxygen diffusion through the peritoneum, 
healthy rats were sedated with an IP injection of ketamine-xylazine and injected with a 60 
mL bolus of OMBs for determining diffusion of gases in vivo [191]. Over 20 minutes, 10 
mL samples of OMBs were removed from the peritoneal cavity every 5 minutes. The 
OMBs removed after 20 minutes of dwelling in the peritoneal cavity contained ~76% O2 
and the SpO2 of the rats was still increasing. Because the oxygen was not completely 
diffused from the OMBs and most of the OMBs were removed from the peritoneal 
cavity, the maximum increase in systemic oxygenation from an OMB bolus could 
possibly occur after 20 minutes in healthy rats. Also, the only decrease in systemic 
oxygenation was the respiratory depression from anesthesia because the rats in the 
experiment were healthy. In hypoxic rats with ARDS, the oxygen saturation of the blood 
will be decreased causing the concentration gradient of oxygen between the OMBs and 
blood to be increased. An increased oxygen gradient would theoretically result in a faster 
diffusion rate of oxygen from the OMBs and entering the blood. If the diffusion rate of 
oxygen from the OMBs is greater in hypoxic rats, the estimated time the systemic 
oxygenation peaks from an OMB bolus would be within 30 minutes of the OMB 
injection into the peritoneal cavity. The duration of the experiment was set at 60 minutes 
to ensure that the peak of increased oxygenation would be measured. A duration of 60 
minutes for the experiment was also the approximate interval that a single IP injection of 
ketamine-xylazine would sedate a rat [255]. Seven blood samples were collected during 
the experiment because the blood volume required for analyzing seven samples 
represents less than 10% of the circulating blood volume of a 500 g rat, which is the 
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maximum volume that can be removed within a 24 hour period without negatively 
effecting the hemodynamics of the rat or oxygen capacity of the blood [225,226]. The 
volume collected for seven blood samples also allowed for extra samples to be collected. 
A 10 minute interval time between each collection point was required for sufficient time 
to analyze each sample immediately after the blood was collected.  
The experiment for investigating the increase of oxygen from an OMB bolus was 
performed 16 hours after LPS administration. The experiment was chosen to be 
performed when the rats were most critically ill and hypoxic to ensure the greatest 
oxygen gradient and rate of oxygen diffusion from OMBs. Thus, PMO therapy would 
theoretically be more effective and the oxygenation increase from OMB treatment easier 
to discern. Additionally, enough time was allowed to implant the femoral arterial 
catheter, wean off isoflurane and oxygen anesthesia, and conduct the experiment before 
the rat was at the greatest risk of dying from ARDS. The mortality from ARDS in the 
model characterized was 27.3% with three rats dying 21-24 hours and four rats dying 21-
32 hours post-insult (Chapter 6). Thus, rats were most critically ill from aerosolized LPS 
~20 hours after administration. Thus, sixteen hours post LPS insult was selected as the 
rats were suffering the highest degree of hypoxia and there was sufficient time for the 
experiment to be completed while the rats had minimal risk of dying during the 
experiment.  
9.1.1 Treatments to be administered 
The maximum bolus volumes that will be administered for future long-term 
peritoneal OMB treatments in a ~500 gram conscious rat were determined to be 50 mL 
(Chapter 5.1). Thus, to determine when oxygenation from PMO therapy in a rat with 
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ARDS would be optimum, a 50 mL bolus of OMBs was infused into the peritoneal 
cavity. OMBs used in evaluation of PMO therapy are composed of 30% saline, thus each 
OMB dose of 50 mL contains 15 mL saline [179,191,192,197]. Therefore, 15 mL saline 
was infused to represent a control treatment with an equivalent fluid volume to OMBs. 
To replicate a treatment that possessed the same gas and fluid volumes, inert gas 
microbubbles (IMBs) were used. IMBs are equivalent to OMBs in their manufacturing 
process, PEG surface structure, and lipid monolayer composition. Instead of O2, the 
phospholipid membrane of IMBs encapsulates a biologically inert gas, sulfur 
hexafluoride (SF6). A 50 mL bolus of IMBs was infused as a control for the physical 
properties of OMBs and to further confirm that the therapeutic benefits of OMBs for 
hypoxia are attributes of the OMBs’ oxygen carrying and delivery properties.  
9.2 Materials and Methods 
All animal studies were performed in accordance with the University of 
Nebraska-Lincoln, IACUC. Male Wistar rats (n = 14, m = 530.4 ± 27.7 g) were housed 
individually with free access to food and water. The animals were randomly assigned 
housing by the animal facility staff and allowed to acclimate 4 days before the study. Rats 
were sedated and induced with ARDS as described previously (Section 6.2.1). LPS 
(Escherichia coli 0111:B4, L 2630, Sigma-Aldrich, St. Louis, MO) at a dose of 7 mg/kg 
was administered into the lungs through the trachea with a rodent aerosolizer 
(MicroSprayer®Aerosolizer IA-1B-R, PennCentury, Inc., Wyndmoor, PA). Rats were 
returned to their home cage and allowed to recover from anesthesia and endotoxin shock. 
Approximately 16 hours after LPS administration, rats were sedated in an induction 
chamber with 5% isoflurane. When they were fully sedated and unresponsive to a paw 
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pinch, the rats were removed from the chamber and placed in the prone position on a 
warming pad set at 38°C (T/pump Classic, Gaymar Industries, Inc., Orchard Park, NY). 
The pulse oximeter sensor (PhysioSuite MouseSTAT®, Kent Scientific Corporation, 
Torrington, CT) was positioned on the rat’s hind paw to monitor and record the vitals of 
SpO2 and heart rate for the duration of the experiment (Figure 9.1). 
The right hind leg was then shaved and sterilized with povidone-iodine and 
isopropyl alcohol scrubs. A small skin incision was made into the leg to expose and 
isolate the femoral artery. The artery was ligated distally and lightly pinched to limit 
blood loss when a small cut was made into the artery for inserting a femoral catheter 
(504118, World Precision Instruments, Sarasota, FL). The catheter was secured into the 
artery with suture and sealed with a 21G needle (Monoject 250 #8881250172, Covidien, 
Minneapolis, MN) and injection plug (SRIP2V Surflo, Terumo Medical, Somerset, NJ).  
 
Figure 9.1: Setup of the study to determine the peak oxygenation from OMB bolus in a 
rat with ARDS. 
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The leg incision was loosely sutured closed and covered with sterile gauze wetted with 
sterile saline. The rat was then given an IP injection of ketamine-xylazine (18-2 mg/kg) 
and weaned off of isoflurane and 100% O2. Once the oxygen levels of the rat stabilized 
while breathing room air, the baseline blood sample was collected and analyzed (ABL80 
FLEX CO-OX, Radiometer, Brea, CA). The rat was randomly treated with an 
intraperitoneal bolus of OMBs, IMBs, or saline (t = 0 min). The volume injected was 50 
mL of OMBs, IMBs, or the fluid volume equivalent 15 mL of saline. Blood samples were 
then collected every 10 minutes for 60 minutes for a total of 7 blood samples including 
the baseline.  
At the end of 60 minutes or when the rat began to awaken from the anesthetic 
ketamine-xylazine, the rat was euthanized by carbon dioxide inhalation following 
approved IACUC guidelines. The lungs were excised with the right lung fixed for 
histology and injury scoring, while the left lung was weighed to measure wet/dry ratios 
both as described previously (Chapter 6.2.3). The histological scores and W/D ratios 
were used to confirm degree of lung injury to previous LPS insulted rats.  
9.2.1 Statistics 
The PaO2 and FO2Hb were fitted with a repeated measures model where the 
within-subjects variable was time. Statistical difference was then determined with the 
Tukey-Kramer multiple comparison test. Analysis of variance (ANOVA) with separate 
means followed by the Tukey multiple comparison test was performed on lung injury 
scores and wet/dry ratios to test for any differences between groups. All tests used the 
same level of significance (α = 0.05). 
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9.3 Results 
Male Wistar rats (n = 14, m = 530.4 ± 27.7 g) were aerosolized with LPS and 
developed physical symptoms of ARDS similar to previously characterized trials 
(Chapter 6.3). Rats were sedated and successfully implanted with a femoral artery 
catheter for short term blood sampling approximately 16 hours after LPS administration. 
However, five rats died after IP injection of ketamine-xylazine while being weaned off of 
100% O2. The remaining nine rats (n = 9, m = 525.6 ± 25.5 g) had a baseline blood 
sample collected and randomly injected with 15 mL saline or 50 mL of OMBs or IMBs. 
In one rat treated with OMBs, samples collected 40, 50, and 52 minutes after the bolus 
was injected were excluded as air contaminated the sample during analysis. This OMB 
treated rat also began to awaken 52 minutes after the OMB bolus was infused so, was 
euthanized before a sample was collected at 60 minutes after the bolus. Two other blood 
samples were excluded from the study due to air contamination in a saline treated rat at 0 
minutes and in an IMB treated rat 10 minutes after bolus injection. 
Pulse oximetry was used for monitoring the vitals of the rats during the procedure. 
Average SpO2 readings indicated rats were moderately to severely hypoxic at the start of 
the experiment when the bolus was injected (Figure 9.2a). As the depth of anesthesia 
decreased over the experiment, oxygenation of the rats recovered to be mildly hypoxic. 
Stepwise shifts in SpO2 and heart rate values indicated times when the sensor on the paw 
was disturbed by injecting the peritoneal bolus or collecting blood samples. The average 
SpO2 values of the rats injected with OMBs increased immediately after infusion and 5-
10 minutes earlier than the rats treated with saline that experienced a continued decrease 
in SpO2s shortly after peritoneal infusion. Average SpO2 readings from the rats infused 
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with IMBs increased after injection, but were noticeably erratic during the experiments. 
The heart rates measured were depressed from anesthesia, but remained within the 
accepted range (Figure 9.2b) [55,240–242]. The average heart rate of OMB rats increased 
45 minutes after bolus injection, which corresponded to the effective time limit for 
anesthesia with an IP of ketamine-xylazine. In contrast, the average heart rates of IMB 
and saline treated rats decreased approximately 45 minutes after intraperitoneal bolus 
infusion.  
 
Figure 9.2: Average (a) SpO2 and (b) heart rate recorded by pulse oximeter after 
peritoneal bolus injection. 
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The PaCO2 of rats were slightly elevated from normal levels at the start and 
marginally decreased toward the end of the experiment (Figure 9.3a). The PaO2 and 
FO2Hb values matched those from the pulse oximeter and indicated that rats experienced 
moderate to severe hypoxia at the start of the experiment (Figure 9.3b, 9.4). The PaO2s 
and FO2Hbs of OMB rats increased after the bolus injection (t=0 min) and the 10 minute 
samples. In contrast, the PaO2 and FO2Hb of rats infused with IMBs and saline decreased 
at 10 minutes and increased at 20 minutes. 
 
Figure 9.3: Average (a) PaCO2 and (b) PaO2 analyzed from blood samples after bolus 
injection. Error bars indicate the standard deviation of the mean. 
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Figure 9.4: Average oxygen saturation of hemoglobin in blood samples analyzed by 
hemoximetry after bolus injection. Error bars indicate the standard deviation of the mean. 
9.3.1 Slopes of blood oxygenation  
To determine when the increased oxygenation from intraperitoneal OMBs was 
greatest, the rate the oxygen levels changed was evaluated and compared to rats treated 
with intraperitoneal IMBs and saline. The average slopes of blood oxygenation were 
evaluated from the baseline when bolus was injected (t=0 min) to subsequent sample 
times and between two consecutively collected sample times. From the baseline to each 
sample point, the average PaO2 and FO2Hb slopes were positive for the OMB treated rats 
(Figure 9.5). The greatest magnitude of the average PaO2 slopes was 0.55±0.17 
mmHg/min at 20 minutes after OMB injection, while the average FO2Hb slopes had a 
peak magnitude of 0.94±0.37 %/min after 10 minutes. The average slopes of blood 
oxygenation from the bolus injection of saline were negative at 10 minutes and were 
positive at the 20 minute sample, while the average slopes of blood oxygenation for rats 
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injected with IMB boluses were negative during the entire experiment. For the OMB and 
saline trials, the average slopes of blood oxygenation in the interval between each blood 
sample corresponded to the average slopes measured between the baseline and each 
sample point (Figure 9.6). The greatest average magnitude in the PaO2 interval slopes was 
0.65±0.21 mmHg/min at 10-20 minutes after OMB injection while the average FO2Hb 
slopes had a peak magnitude of 0.94±0.37 %/min from 0-10 minutes. The average  
 
Figure 9.5: The mean rate (a) PaO2 and (b) FO2Hb changed from the baseline after the 
bolus was injected (t=0). A time offset of ±1 minute was added to prevent overlap. Error 
bars indicate the standard deviation of the mean. 
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interval slopes of blood oxygenation in IMB rats corresponded to the trend of the saline 
infused group and had a positive rate of change in blood oxygen values between the 10 
and 20 minute samples.  
 
Figure 9.6: The mean rate (a) PaO2 and (b) FO2Hb changed between each sample period. 
Error bars indicate the standard deviation of the mean. 
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9.3.2 Histology, lung injury scoring, and W/D 
Lung tissue was collected and fixed in formalin for sectioning as described 
previously in Chapter 6.2.3. The H&E stained images were then evaluated by an 
independent pathologist for lung injury scoring. The lung injury scores were not 
significantly different between the IP bolus treatments of OMBs, IMBs, and saline 
(Figure 9.7). Overall, edema scores averaged below 0.5 and were not statistically 
different than edema scores from rats euthanized 3 days after being aerosolized with LPS 
(LPS3). Edema scores were significantly less severe compared to the scores of rats that 
died one day after LPS administration (LPS1). Only slight indications of hemorrhage  
 
Figure 9.7: The lung injury scores from the bolus diffusion study (OMB1, IMB1, Sal1) 
compared to the ARDS characterization study (LPS1, LPS3). Error bars indicate the 
standard error of the mean. 
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were observed from two sections of OMB and IMB lungs and were scored with an injury 
score of one. Inflammation scores from the rats treated with an OMB bolus were not 
significantly different than LPS3 rats (p < 0.05), but significantly less severe overall 
compared to LPS1 rats (p > 0.05). In contrast, rats injected with peritoneal IMBs and 
saline were not significantly different to rats that had died one day after LPS 
administration (p > 0.05). 
The left lungs of all rats infused with an intraperitoneal bolus were collected and 
weighed for wet and dry weights. A corrupted data file resulted in the loss of the dry 
weights for the OMB treated rats. The wet/dry ratios of IMB and saline treated rats were 
4.92 ± 0.20 and 4.70 ± 0.25, respectively, and were not significantly different from each 
other. The combined W/D of IP treated rats with ARDS (LPS+IP) was 4.81 ± 0.23 and 
significantly less than LPS1 rats (p < 0.05), but not statistically different than the LPS3 
rats (Figure 9.8). 
 
Figure 9.8: The W/D ratios from the bolus diffusion study (LPS+IP) compared to the 
ARDS characterization study (LPS1, LPS3). Error bars indicate the standard deviation of 
the mean. 
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9.4 Discussion 
To discover when the oxygen increase from an OMB bolus treatment occurred, an 
experiment administering intraperitoneal boluses was conducted in rats suffering from 
ARDS. Rats inflicted with ARDS were confirmed as moderately to severely hypoxic 
from pulse oximetry, arterial blood gases, and hemoximetry approximately 16 hours post-
LPS. At the beginning of the experiments, baseline values of SpO2, PaO2, and FO2Hb 
were ~70%, 50 mmHg, and 60%, respectively, for OMB and saline trials (Figure 9.2a, 
9.3b, 9.4). In contrast, SpO2, PaO2, and FO2Hb values in IMB rats indicated only mild 
hypoxia of ~85%, 70 mmHg, and 85%. The degree of hypoxia was attributed to a 
combination of ARDS induced with LPS and respiratory depression from ketamine-
xylazine anesthesia. Ketamine-xylazine cocktails used for sedating rats were reported to 
decrease the PaO2 to 63-73 mmHg or by approximately 24% for 60 minutes after 
injection [56,255,256]. The enduring hypoxia at the end of the experiment was attributed 
to respiratory injury of ARDS as the oxygen levels remained indicative of hypoxia when 
the effects of ketamine-xylazine were ceasing. 
A high mortality occurred in the study after injection of ketamine-xylazine 
(35.7%, 5/14). The high mortality was considered a result of the combined stress from 
ARDS and anesthetic, however, a defective batch of ketamine was suspected as an 
additional factor. The mortality rates from ketamine-xylazine anesthesia from our earlier 
studies in healthy rats corresponded the reported mortality of 16.7% (1/6) [257]. 
However, a mortality rate of ~33% from ketamine-xylazine cocktails administered to 
male rats was reported by other facilities and UNL’s clinical veterinarian when the study 
was conducted (unpublished data). Though a defective batch of ketamine was never 
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officially confirmed, when the UNL facility switched to a different batch of ketamine, the 
mortality rate in male rats was decreased to the reported mortality rate of anesthetic 
ketamine cocktails.  
Immediately after the injection of the OMB boluses, rats experienced an increase 
in SpO2, PaO2, and FO2Hb while the measurements of systemic oxygen in the saline and 
IMB infused rats did not increase until 20 minutes after (Figure 9.2a, 9.3b, 9.4). To 
determine when the increased oxygenation from peritoneal infusion of OMBs was 
maximal, the rate the blood oxygen levels changed was evaluated and compared. Average 
slopes for blood oxygenation were evaluated from the baseline when the bolus was 
injected (t=0 min) to subsequent sample periods and from the interval between each 
collected sample. When the peritoneal bolus was injected to each subsequent sample 
point, the average PaO2 and FO2Hb slopes were positive for the OMB treated rats (Figure 
9.5). For the OMB trials, the greatest magnitude of the PaO2 slopes was at 20 minutes 
after OMB injection and in the 10-20 minute interval, while the average slopes of FO2Hb 
peaked 10 minutes after OMBs were infused. The average magnitude of the slopes for 
blood oxygenation stabilized 30 minutes after the OMB treatment. Thus, the time when 
blood oxygenation reflected the greatest increase from OMB bolus treatment was 20 
minutes after injected into the peritoneal cavity. However, no statistical differences were 
determined in the PaO2 and FO2Hb values or their average slopes between the treatment 
groups of saline, IMBs, and OMBs (p < 0.05). 
The slopes from the bolus injection of IMBs remained negative the entire duration 
of the experiments. The negative slopes for blood oxygenation were considered a result 
from multiple contributing factors. High oxygenation values were measured in rats 
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infused with IMBs at the start of the experiments and was attributed to IMB rats possibly 
suffering less lung injury, being healthier, or not being sedated as deeply. Additionally, 
IMBs infused into the peritoneal cavity was considered to be a diffusion “sink” for 
oxygen as the IMB perfusate contained an oxygen concentration of approximately zero 
percent. The oxygen in the blood then diffused into the IMBs within the cavity due to the 
concentration gradient and contributed to the greater negative slopes for blood 
oxygenation measured in the interval immediately after IMB infusion. 
This study was limited by several issues. The first was that the sample sizes of the 
treatment groups were considerably decreased by the high mortality from the 
combination of anesthetic drugs and LPS. The data obtained from the study were 
sufficient to achieve the objective, but the differences observed between treatment groups 
and oxygenation at sample times were not statistically significant. Another limitation was 
how the rats were affected by ketamine-xylazine. All individuals reacted slightly 
differently to the injectable drugs either in the time to become sedated, depth of 
anesthesia reached, and recovery time. Thus, all experiments began the same time after IP 
injection with ketamine-xylazine. Overall, rats started to recover from anesthesia 65 
minutes after IP infusion of the treatment bolus. The final limitation was that the rats in 
the IP bolus groups were not evidenced to be as affected by LPS as previous trials 
performed in the ARDS characterization study. From the lung injury scores and W/D 
ratios, the degree of injury in LPS+IP rats corresponded more to rats with ARDS 
euthanized 3 days after LPS than ARDS rats 24 hours post-insult (Figure 9.7, 9.8). 
However, samples collected from rats 24 hours after LPS (LPS1) were the most severely 
injured as they died from ARDS. The LPS1 rats were possibly not a true indication for 
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the typical severity of lung injury 24 hours after aerosolized LPS. The IMB rats from this 
study were further evidence that the severity of lung injury from LPS was decreased. The 
three IMB rats were only mildly hypoxic from the combination of LPS and anesthetsia 
throughout the duration of the experiments. 
9.5 Conclusion 
This experiment in rats suffering from ARDS investigated when the oxygen 
saturation in the blood peaks from a peritoneal injection of the OMB bolus. The greatest 
increase in blood oxygenation from an OMB bolus treatment was determined to be the 
optimal time for sampling blood and pulse oximetry. Intratracheal LPS of 7 mg/kg 
produced mild hypoxia 16 hours after administration and when combined with an IP 
injection of ketamine-xylazine, the respiratory depression was increased to moderate to 
severe hypoxia. Analysis of pulse oximetry, arterial blood gases, and hemoximetry 
completely characterized the oxygen saturation of the rats in the experiments. Lung 
injury scores, W/D ratios, and pulse oximetry indicated the severity in ARDS induced by 
aerosolized LPS was possibly decreased from the ARDS characterization study (Chapter 
6). The slope comparison of blood oxygen levels confirmed that the diffusion of oxygen 
from OMBs within the peritoneal cavity was maximal 20 minutes after infusion of the 
OMB bolus. Thus, blood and pulse oximeter samples should be collected 20 minutes 
after infusion of the OMB bolus in rats with ARDS to measure the optimal improvement 
in systemic oxygenation due to peritoneal OMB treatment. The best representation of 
clinical benefit of PMO therapy was consequently capable of being validated in a long 
term study with hypoxic rats inflicted our characterized model of ARDS. 
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Chapter 10: PMO therapy for improving the oxygenation of rats 
inflicted with ARDS 
PMO treatment with OMBs was demonstrated to provide a significant 
improvement in studies of acute hypoxia attributed to physical trauma. When PMO 
therapy was administered to rats with a lethal right pneumothorax, the rats maintained 
normal levels of peripheral oxygen saturation and 0% mortality. In treating asphyxiated 
rabbits, the survival time until cardiac arrest occurred was increased by approximately 1.7 
compared to saline treated controls. The current study addresses the goal for the further 
validation of PMO therapy in treating rats with hypoxia induced by a respiratory disease 
model. A characterized ARDS model in rats was previously confirmed to elicit 
significant and prolonged hypoxia from pulse oximetry and arterial blood gas analysis 
(Chapter 6). Additionally, the optimal improvement in systemic oxygenation due to PMO 
therapy was determined to occur 20 minutes after peritoneal infusion of the OMB bolus 
by blood and pulse oximeter samples collected in sedated rats with ARDS (Chapter 9). 
Thus, PMO therapy was administered to rats experiencing ARDS to validate that 
prolonged periods of hypoxia from a respiratory disease can be alleviated by providing 
supplemental oxygenation with repeated boluses of OMBs.  
10.1 Design 
The treatments investigated were OMBs for PMO therapy, saline as a fluid 
volume control, and IMBs as a microbubble control. The reasoning for administering 
these peritoneal infusates and volumes was described previously (Chapters 5.1 and 9.1.1).  
An intraperitoneal catheter, the Jackson-Pratt catheter, was selected to be 
implanted for delivering treatment boluses due to the JP catheters high effectiveness at 
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removing OMBs from the peritoneal cavity in previous studies [191]. However, in 
preliminary trials completed, the JP catheters failed to drain saline and OMBs from the 
abdominal cavity after seven days designated as a recovery period from the catheter 
implant surgery. The failure of the catheters forced a premature end to the preliminary 
trials because the drainage of previous saline and OMB bolus infusions was not 
accomplished. The infusion of additional treatments through the JP catheter was still 
possible, so the treatment regimen was altered to avoid causing high abdominal pressures 
that pose a risk to the animal [21,123–126]. While a new peritoneal catheter was 
investigated, a reduced bolus regimen was implemented to evaluate the effectiveness of 
PMO therapy in treating rats with ARDS. The reduced bolus regimen decreased the 
volume of the fresh treatment bolus by 20% from the previous bolus volume 
administered. Thus, the current bolus to be delivered, Vi, depended upon the volume of 
the previous bolus treatment infused, Vi-1 by the equation:  
 𝑉𝑖 = 0.8 ∗ 𝑉𝑖−1 [Eq. 10.1] 
The maximum treatment dose was administered 3 hours after LPS insult with 50 mL for 
the OMB and IMB treatments and 15 mL for the saline treatments. The reduced bolus 
regimen decreased the bolus volume of the treatment as the rat recovered from ARDS 
and permitted time for the fluid volume of an infused bolus to be adequately absorbed 
[201–203].  
10.2 Materials and Methods 
All animal studies were performed in accordance with the University of 
Nebraska-Lincoln, IACUC. Male Wistar rats (n = 10, m = 490.0 ± 26.2 g) were housed 
individually with free access to food and water. The animals were randomly assigned 
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housing by the animal facility staff and acclimated for 4 days after arrival at the facility. 
Rats were sedated and implanted with a femoral artery catheter as described in Chapter 
6.2.2b and a JP peritoneal catheter as described in Chapter 5.2.1. Both catheters were 
implanted using the same incision in the upper right leg and subcutaneously routed to the 
same back incision for external access. Rats were allowed to recover from the catheter 
surgery for seven days with the femoral arterial catheter being flushed with heparinized 
saline every 12 hours (Figure 10.1). ARDS was induced in all rats with 7 mg/kg LPS 
(Escherichia coli 0111:B4, L 2630, Sigma-Aldrich, St. Louis, MO) as described 
previously (Section 6.2.1). While rats were sedated, LPS was administered into the lungs 
through the trachea with a rodent aerosolizer (MicroSprayer®Aerosolizer IA-1B-R, 
PennCentury, Inc., Wyndmoor, PA). Rats were randomly to a treatment group receiving 
IP boluses of OMBs, IMBs, or saline and returned to their home cage to recover from the 
aerosol administration procedure. Three hours after LPS aerosol insult, all rats were 
infused with an initial bolus of 15 mL of saline, 50 mL of OMBs, or 50 mL of IMBs.  
 
Figure 10.1: Timeline of surgical procedures and daily sampling schedule conducted in 
the PMO treatment of ARDS trials.  
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Arterial blood and pulse oximetry was collected 20 minutes after the treatment bolus as 
this time after infusion was determined to be when the increase in oxygen saturation due 
to a bolus of OMBs was maximal (Chapter 9). 
10.2.1 Daily sample collection 
Daily sample collection for mass, pulse oximetry, chest radiographs, and arterial 
blood followed the same procedure as the ARDS characterization trials detailed in 
Chapter 6. Baseline measurements were collected for samples 12 hours before aerosol 
administration of LPS on day 0. After LPS administration, weight, pulse oximetry, and 
blood were sampled approximately every 12 hours while chest radiographs were recorded 
in the morning every 24 hours (Figure 10.1). Every collection session started with 
measuring the respiratory rate three times in 20 second intervals while the rat was resting 
in its cage. The rat was then removed from the cage to measure its mass and infuse the 
intraperitoneal treatment bolus through the JP catheter. The rat was returned to its cage 
for 20 minutes when pulse oximetry and arterial blood was collected. 
The rat was restrained, but not sedated for pulse oximetry (PhysioSuite 
MouseSTAT®, Kent Scientific Corporation, Torrington, CT) and the collection of 
arterial blood. The pulse oximeter sensor was positioned on the rat’s hind paw with the 
end of the pulse oximeter clip over the fourth metatarsal (Figure 6.3). Measurements 
were monitored in 5 second averages and recorded every second when the pulse oximeter 
waveform was sinusoidal and consistent. The measurements recorded in a period greater 
than one minute were averaged to establish a single value for the session.  
Blood samples were collected from the femoral artery catheter and analyzed for 
blood gases and hemoximetry (ABL80 FLEX CO-OX, Radiometer, Brea, CA). The 
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sample volume required for performing the blood analysis was 0.1 mL. Safe blood 
collecting guidelines were followed with less than 1% of the total circulating blood 
volume and a maximum of three samples collected per day [225,226]. A third blood 
sample was collected if an error occurred in the analysis during one of collection points.  
Rats were anesthetized with 5% isoflurane in an induction chamber to perform 
chest radiographs on days 1-3 after pulse oximetry and arterial blood was collected. The 
rats were radiographed (PRX 90, Bowie International LLC, Lake City, IA) in the dorsal-
ventral and left lateral positions. Thoracic radiographs were recorded to investigate the 
effect of IP treatments on the presence of pulmonary edema, alveolar consolidation, and 
bilateral infiltrates. Once the radiographs were imaged, the rat as returned to its cages to 
recover from anesthesia. 
10.2.2 Histology and wet/dry ratio 
The lungs were fixed by intratracheal instillation of 5 mL of 10% buffered 
formalin, and then suspended in 30 mL of formalin. Lungs were submitted to an 
independent pathologist for blind sectioning, hematoxylin and eosin (H&E) staining 
(Ventana Symphony, Ventana Medical Systems, Inc., Tucson, AZ), and injury scoring. 
Lung sections were imaged with a microscope (Eclipse 55i, Nikon Instruments, Melville, 
NY) at a magnification 100X after H&E staining for visual comparison and analysis. 
Histological lung injury analysis of four right lung sections from each animal included 
alveolar edema, intra-alveolar hemorrhage, and inflammation score on a 0-3 scale with 0 
indicating an absence of pathology and 3 indicating severe pathology [227]. 
Inflammation scoring was based on the amount of leukocyte infiltration, excluding 
eosinophils. 
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The left lung was used for measuring the wet and dry weights. Once the lungs 
were excised from the rat, the left lung was separated by cutting of the left bronchus. The 
left lung was immediately weighed on a scale (CX220, Citizen Scales, Maharashtra, 
India) to measure the wet weight. The left lung was then placed in an oven for three days 
at 60°C and reweighed afterwards for the dry weight [228,229]. 
10.2.3 Statistics 
Log-rank (Mantel-Cox) test was used to compare the mortality rates between each 
experimental group for any differences. Analysis of variance (ANOVA) with separate 
means followed by the Tukey multiple comparison test was performed on lung injury 
scores and wet/dry ratios to test for any differences between groups. Repeated measures 
ANOVA was used to compare the SpO2 group means of each collection period. All tests 
used the same level of significance (α = 0.05). 
10.3 Results 
Male Wistar rats (n = 10, m = 490.0 ± 26.2 g) were successfully implanted with a 
femoral artery and peritoneal catheter with no dropouts from failure of the femoral 
catheter occurring. Rats were aerosolized with LPS and developed physical symptoms of 
ARDS similar to previously characterized trials (Chapters 6 and 9). No rats died from the 
respiratory illness that resulted due to aerosolized LPS. However, during the study five of 
the rats were not infused with the entire bolus volume predetermined by the reduced 
bolus regimen (Eq. 10.1) as the JP peritoneal catheters began to leak from the back 
incision. Partial treatment boluses were infused through the failed catheters until fluid 
leaked (Table 10.1). The partial bolus volumes infused with the failed JP catheter were 
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recorded; however, the amount of the treatment actually delivered into the peritoneal 
cavity successfully was unknown. 
The average respiratory rate in breaths per minute (bpm) was measured in all rats 
prior to being removed from their cage for sample collection. The respiratory rates of rats 
inflicted with ARDS increased in all groups 12 hours after LPS (Figure 10.2). At 24 
hours after LPS, the average respiratory rate of the IMB and saline groups increased 
39.1% and 48.8% from the baseline, respectively. The respiratory rate for OMB treated 
rats experienced the greatest increase of 71.6% from the baseline 36 hours post-insult. 
The average respiratory rate of all groups plateaued at 36 hours and decreased until the 
end of the observation period.  
Table 10.1: Volumes infused into the peritoneal cavity in the PMO -ARDS 
trials.  
Treatment 
# 
Time 
after LPS 
(hours) 
Volume infused in 
functional catheters 
(mL)  
Volume infused in failed peritoneal 
catheters (mL) 
OMB/IMB Saline 
OMB 
#1 
OMB 
#2 
IMB 
#1 
IMB 
#2 
Saline 
#1 
1 3 50 15 27 50 20 50 7 
2 12 40 12 21.6 35 16 40 5.6 
3 24 32 9.6 17.3 24 12.8 14 4.5 
4 36 25.6 7.7 13.8 19.2 10.3 0 3.6 
5 48 20.5 6.1 11.1 15.4 8.2 0 2.9 
6 60 16.4 4.9 8.8 12.3 6.6 0 2.3 
7 72 13.1 3.9 7.1 9.8 5.3 0 1.8 
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Figure 10.2: The average respiratory rate counted for the PMO-ARDS rats. Error bars 
indicate the standard deviation of the mean. 
10.3.1 Pulse oximetry and blood oxygenation  
Pulse oximetry measurements indicated the rats developed mild hypoxia 3 hours 
after the administration of LPS (Figure 10.3). The OMB treated group experienced a 
maximum decrease of 6.3% in the average SpO2 at 3 hours post-insult and subsequently 
returned to the baseline 36 hours after LPS. The average SpO2 of the IMB group 
decreased 12.4% from baseline at 12 hours post-insult and frequently fluctuated with the 
lowest average SpO2 observed 36 hours post-LPS. The average SpO2 for the saline infused 
rats exhibited the greatest decrease from the baseline at 14.0% after 12 hours, but then the 
average SpO2 with saline treatment increased for the remainder of the experiment.  
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Figure 10.3: Average peripheral oxygen saturation of PMO-ARDS trials. Error bars 
indicate the standard deviation of the mean. 
At 3 hours post-insult, the average partial pressures of carbon dioxide in arterial 
blood (PaCO2) increased 42.1% and 37.2% from the average baseline for the OMB and 
saline groups, respectively (Figure 10.4a). The average PaCO2 in the two treatment 
groups returned to baseline values 12 hours after LPS administration. The PaCO2 of the 
IMB treated rats decreased 13.5% from baseline after 12 hours then remained consistent 
for the duration of the observation period. Three hours post-insult, the average partial 
pressures of oxygen (PaO2) increased 26.5%, 11.3%, and 13.3% for the OMB, IMB, and 
saline groups, respectively (Figure 10.4b). The PaO2 for all groups subsequently 
decreased at 12 hours and returned to baseline values. The average PaO2 of saline and 
OMB treated groups indicated that rats experienced mild hypoxia 48 hours after 
administration of LPS, while the IMB treated group exhibited similar fluctuations in the 
measured average of PaO2 and SpO2.  
 181 
 
 
Figure 10.4: Average partial pressures of (a) carbon dioxide and (b) oxygen 
measurements of arterial blood. Error bars indicate the standard deviation of the mean. 
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Figure 10.5: Average oxygen saturation of hemoglobin in blood samples analyzed by 
hemoximetry 20 minutes after bolus treatments. Error bars indicate the standard deviation 
of the mean. 
The hemoximetry results from collected blood samples exhibited little differences 
between the three peritoneal treatments for ARDS (Figure 10.5). The averages for 
fraction of oxyhemoglobin (FO2Hb) were ~95% in the IMB and saline groups during the 
entire study except for a decreased in the average FO2Hb of the IMB group at 12 hours 
after LPS administration. The OMB treated group was ~95% until 36 hours post-insult 
when the average FO2Hb decreased a total 3.2% from baseline by the end of the 72 hour 
observation period. 
10.3.2 Chest radiographs 
The baseline radiographs exhibit no sign of pre-existent or current respiratory 
pathology (Figure 10.6). The radiographs of the PMO-ARDS groups exhibited some 
features of diffuse bilateral infiltrates. However, the development of the diffuse bilateral 
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infiltrates was not as pronounced as those seen in the radiographs of the LPS trials of the 
ARDS characterization study.  
 
Figure 10.6: Representative chest radiographs of the healthy baseline (day 0) and one 
day after aerosol administration. 
10.3.3 Histology, lung injury scoring, and W/D 
The excised lungs of PMO-ARDS rats appeared to possess limited visual features 
of congestion and edema (Figure 10.7). The H&E sections of the lungs exhibited minimal 
signs of alveolar edema or intra-alveolar hemorrhage with moderate degrees of leukocyte 
infiltration. The sections in all treatment groups showed slight thickening of the alveolar-
capillary membranes. 
Lung tissue was successfully collected and fixed in formalin for sectioning when 
the rats were euthanized 3 days after aerosolized LPS. The H&E stained images were 
then evaluated by an independent pathologist for lung injury scoring. The lung injury 
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scores were not significantly different between the bolus treatments of OMBs, IMBs, and 
saline (Figure 10.8). Overall, edema scores of the PMO-ARDS rat lungs averaged mostly 
below 0.25 and were significantly less (p < 0.05) than the edema scores from the lungs of 
rats in the ARDS characterization study collected at the same time after LPS (LPS3). 
Three sections of OMB lungs and one section of IMB and saline lungs were scored with 
an injury score of one due to slight indications of hemorrhage. The inflammation scores 
from the saline bolus treated rats were less severe overall compared to OMB and IMB 
rats though it was not significant. Inflammation of IP saline treated rats was significantly 
less than rats from the ARDS characterization study (p < 0.05). 
The left lungs of all rats in the PMO-ARDS study were collected and weighed for 
wet and dry weights. The W/D ratios of OMB, IMB, and saline treated rats were 
5.15±0.31, 5.50±0.20, and 5.19±0.21 respectively, and were not significantly different 
from each other (Figure 10.9). The W/D of IMB treated rats was significantly greater 
than the previous ARDS study of LPS3 rats (p < 0.05). 
 
Figure 10.7: Characteristic images of rats’ excised lungs (top row). Representative H&E 
stained sections (bottom row) from each group were imaged at a 100X magnification. 
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Figure 10.8: Injury scoring of lung sections for all IP treatments of ARDS compared to 
scores of previous ARDS trials collected 3 days after LPS. Bars represent mean with 
standard error of the mean. 
 
Figure 10.9: Average W/D ratios of PMO-ARDS trials. Error bars indicate the standard 
deviation of the mean. 
 186 
10.4 Discussion 
In this study, rats with ARDS were treated with intraperitoneal bolus injections of 
OMBs, IMBs, or saline every 12 hours for 3 days after aerosolized with LPS. Due to the 
failure of the Jackson-Pratt catheters in preliminary trials, a reduced bolus regimen was 
implemented to infuse peritoneal treatment without causing harmful intra-abdominal 
pressures. The reduced bolus regimen involved each bolus treatment to be decreased by 
20% from the previous treatment where the initial bolus volume was 50 mL for the OMB 
and IMB groups and 15 mL for the saline group. The oxygen levels were measured by 
pulse oximetry, ABG analysis, and hemoximetry to determine if there was an increase in 
oxygenation due to PMO therapy with OMBs.  
Immediately after aerosolized with the LPS, rats experienced a decreased SpO2 
and an increased PaO2, and PaCO2 (Figure 10.3, 10.4). Pulse oximetry suggested that the 
rats developed mild hypoxia 3 hours after the administration of LPS. However, PaO2 
averages were above normal levels and FO2Hb averages were on the margin between 
normal levels and mild hypoxia for the entire duration of the study. The average SpO2 of 
saline and IMB treated groups decreased 14.0% and 12.4% from the baseline after 12 
hours of ARDS, where the saline group started to return to the baseline while the IMB 
group fluctuated around 85% (Figure 10.3). The average SpO2 of the OMB treated group 
decreased 6.3% from the baseline at 3 hours post-insult which was half the decrease in 
SpO2 experienced by the other two groups. Additionally, the average PaO2 for the OMB 
group increased approximately twice as much as the IMB and saline groups (26.5% vs. 
11.3% and 13.3%). Therefore, PMO therapy slightly increased the oxygen saturation of 
rats inflicted with ARDS because the rats infused with OMBs exhibited a smaller 
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decrease SpO2 and a greater increase in PaO2 compared to rats administered the saline and 
IMB treatments. However, the difference in the two parameters of oxygenation was not 
significant (p > 0.05). The increased levels of SpO2 and PaO2 of the OMB group may 
have resulted from the greater increase in the respiratory rate of OMB rats compared to 
the saline and IMB treatment groups (Figure 10.2).  
A significant complication that occurred in the study was half of the peritoneal 
catheters implanted into the rats leaked on the first or second bolus treatment (Table 
10.1). When the bolus was infused into a failed catheter, the fluid leaked from the back 
incision where the access port of the peritoneal catheter was secured. The failure of the 
catheters also occurred in the parallel study performed to discover a replacement for the 
Jackson-Pratt catheter currently used (Section 9.4). The failure of the JP catheters 
prevented the complete treatment volume to be infused in one saline, two IMB, and two 
OMB trials. The measured SpO2 values were not distinguishable between the individual 
PMO therapy trials with a partial or complete bolus volume of OMBs. However, rats 
inflicted with ARDS and infused with a complete OMB bolus through a working catheter 
exhibited increased in blood oxygen levels throughout the study. When only a partial 
OMB bolus was infused, the PaO2 and FO2Hb of rats steadily decreased 24 hours post-
LPS (Appendix E). The difference revealed between the blood oxygen trends of complete 
OMB bolus treatments and partial boluses with a leaking catheter merits further 
consideration. The importance of using a more effective peritoneal catheter was further 
evidenced by the bolus treatments of IMBs. The SF6 gas contained in IMBs was unable to 
be removed with the peritoneal catheter resulting in the SF6 gas remained in the cavity for 
extended periods (Appendix E). The residual SF6 gas caused an increase in abdominal 
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pressure that may have altered hemodynamics and respiratory function by compromising 
the function of the diaphragm [123,258]. In future implants of the peritoneal catheters, 
the access port of the catheters will be secured more thoroughly by fixing the access port 
to the subcutaneous tissue below the back incision. The peritoneal catheter will also be 
routed from the abdomen to the back incision less tightly to decrease tension on the 
suture, skin, and fascia. Also, the flat fluted drain catheter was selected for use in future 
trials in rats to drain bolus treatments that were infused (Chapter 9).  
The final limitation of the study was several factors indicated that the severity of 
ARDS inflicted to the rats was substantially reduced. Though the same dose of LPS (7 
mg/kg) and procedure was used to induce ARDS in the rats, the severity of hypoxia was 
decreased from moderate to mild and the infiltrates in the chest radiographs were not as 
prominent (Figure 10.6). Additionally, the edema scores of the lungs in the PMO-ARDS 
trials were significantly less than those from the ARDS characterization trials even 
though both sets of trials were collected 3 days after the LPS was administered (Figure 
10.8). The decreased severity of the ARDS model thus requires further investigation to 
determine the cause.  
10.5 Conclusion 
The purpose of this study was to verify PMO therapy as a potential treatment for 
delivering oxygen to rats experiencing prolonged hypoxia due to respiratory disease. 
Previously, an ARDS model in rats was developed with intratracheally aerosolized LPS 
which was characterized by prolonged moderate hypoxia. However, in this study only 
mild hypoxia was induced in the rats experiencing ARDS that caused the possible impact 
of OMB boluses on oxygenation more difficult to evaluate. When ARDS was treated in 
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rats with a reduced bolus regimen of OMBs, rats experienced greater averages in PaO2 
and SpO2 compared to control treatments of saline and IMBs. Another hindrance of 
evaluating the benefit of PMO therapy for ARDS was the failure of half the peritoneal 
catheters implanted. The peritoneal catheters leaked from the back incision which 
decreased the treatment volume infused and created suspicion that the bolus treatments 
were successfully delivered to the peritoneal cavity. The ARDS rats treated with a 
complete OMB bolus regimen through a functional peritoneal catheter experienced an 
increase in blood oxygenation sustained for the entire study, while rats treated through a 
leaking peritoneal catheter experienced decreased blood oxygenation 24 hours after LPS 
insult. Despite the mild severity of ARDS and leaking peritoneal catheters, rats with 
ARDS administered PMO therapy exhibited evidence of increased oxygenation in a 
hypoxic model of respiratory disease. 
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Chapter 11: Conclusions 
Peritoneal microbubble oxygenation (PMO) therapy is a novel method of 
extrapulmonary oxygenation that involves infusing oxygen microbubbles (OMBs) into 
the abdominal cavity where the peritoneum functions as a membrane for gas exchange 
and diffusion. The ultimate goal of PMO therapy is to provide supplemental oxygen in 
cases of respiratory failure and disease where the use of mechanical ventilation and 
ECMO is inadequate or injurious for the patient. In this work, multiple aspects of 
progressing PMO therapy towards future clinical trials were explored. Techniques for 
infusing OMBs into the peritoneal cavity were developed for administrating PMO 
therapy in animal trials. Then, acute respiratory distress syndrome (ARDS) in rats was 
characterized for evaluating PMO therapy in a clinically relevant disease model of 
hypoxia. Finally, PMO therapy was implemented as a means of delivering supplemental 
oxygen to hypoxic animals with critical lung injury.  
The first major goal of the research was to develop methods for infusing OMBs 
into the peritoneal cavity. Peritoneal infusion was achieved in animal studies by 
developing an automated device to infuse fluid treatments and evaluating catheters for 
prolonged function in rats. The Peri3 was the automated system created that safely and 
accurately administered a bolus treatment or circulated perfusate to the peritoneal cavity. 
The Peri3 system was composed of a peristaltic pump, pressure sensors, solenoid, and a 
LabVIEW interface. The Peri3 design was light weight and durable to facilitate transport 
between the lab and animal facilities. The Peri3 was also designed with the flexibility to 
be used in different injury models and animals. The Peri3 device successfully maintained 
intra-abdominal pressures below 6 mmHg and administered PMO therapy to sedated rats 
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and rabbits. Future iterations of the Peri3 system were developed for OMB treatment of 
conscious rats and underwent successful preliminary testing [191]. Another aspect of 
infusing OMBs into the peritoneal cavity that was investigated was determining the most 
effective catheter for performing prolonged PMO therapy in rats with multiple injections 
of OMBs. Through testing of four catheters implanted in the peritoneal cavity of rats for 
12 days, the flat fluted drain catheter (072210, Bard Medical, Covington, GA) was 
determined to be effective for administering long-term PMO therapy. The flat fluted 
catheter was selected to be implanted for future PMO studies in animals.  
To evaluate the benefit of PMO therapy in treating hypoxia resulting from 
respiratory disease, a model of ARDS was replicated and characterized in rats. The 
pathology of ARDS was reproduced in rats by aerosolizing LPS (7 mg/kg) into the lungs. 
The characterized ARDS model elicited a mortality rate of 27.3%, significant 
inflammation of the alveolocapillary membrane, pulmonary edema, and mild to moderate 
hypoxemia. The ARDS model in rats was determined to induce hypoxia with a severity 
sufficient for evaluating PMO therapy and other methods of supplemental oxygen 
delivery. 
Finally, PMO therapy was investigated in hypoxic animal models to validate that 
OMB infusion into the peritoneal cavity delivered oxygen in vivo, increased survival, and 
increased systemic oxygenation. To validate these properties of PMO therapy, OMBs 
were administered as peritoneal treatment for hypoxia in three animal models. The first 
animal study was a lung injury model of hypoxia in rats induced by a right 
pneumothorax. The pneumothorax of the right lung proved to be a fatal injury as rats 
experienced decreased peripheral oxygen saturation and death after 15.8 ± 6.2 minutes 
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(n = 11) without OMB treatment [179]. The rats injected with a 107 ± 9 mL bolus of 
OMBs (n = 5) survived for 2 hours after pneumothorax to the designed endpoint of the 
experiment. PMO therapy of rats with a right pneumothorax demonstrated a 100% 
survival and increased SpO2s levels that were normal for healthy sedated rats. Thus, the 
infusion of OMBs was confirmed to deliver O2 in vivo and that PMO therapy was 
feasible for treating hypoxia by supplying oxygen to the bloodstream. The drastic 
improvement of surviving to 2 hours with OMBS compared to the 15.8 minute mean 
survival time for controls indicated a significant clinical benefit for mild to severe 
hypoxia.  
The second hypoxic animal model replicated asphyxia by occluding the trachea of 
rabbits. The goal of this study was to test the limits of PMO therapy in a model of 
complete respiratory failure more relevant to future clinical trials. Rabbits administered 
intraperitoneal treatment of saline suffered cardiac arrest 6.6 ± 0.6 minutes (n = 4) after 
the trachea was occluded, while asphyxiated rabbits infused with OMBs survived for a 
significantly greater time of 11.7 ± 2.8 minutes. Several observed outcomes of PMO 
therapy in asphyxiated rabbits were acknowledged to merit further investigation. The 
variance in survival time of OMB treatment and the SpO2 values of OMB perfusion was 
significantly increased compared to saline treated controls. Though total systemic 
oxygenation with OMBs was not possible in asphyxiated rabbits, local tissue oxygenation 
of the abdomen may have substantially increased despite being unable to breathe 
(Appendix E). Increasing the diffusion of O2 from the OMBs into the blood of the 
splanchnic circuit was hypothesized to possibly improve oxygenation and survival. The 
OMB circulation system could be more rigorously optimized by testing how much 
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oxygen and CO2 was in the OMBs drained from the peritoneal cavity. The OMB 
circulation system could possibly be improved by mixing the OMBs while dwelling in 
the cavity to promote the unloading and diffusing of O2. The study in asphyxiation of 
rabbits revealed the current system for PMO therapy was able to increase survival, but 
inadequate to provide 100% of a sedated rabbit’s oxygen demand because asphyxiated 
rabbits exhibited a gradual decrease in SpO2 before death.  
The third model evaluated PMO therapy in the ARDS model of hypoxia 
characterized in rats. OMBs were confirmed to rapidly deliver O2 to the bloodstream 
when infused into the peritoneal cavity of hypoxic rats as the SpO2, PaO2, and FO2Hb 
increased within 10 minutes of OMB injection. In contrast, ARDS rats with hypoxia 
treated with intraperitoneal saline and IMB did not experience an increase in oxygenation 
until they began to recover from anesthesia ~20 minutes after peritoneal injection of the 
bolus. The optimal time to sample blood for analysis and pulse oximetry was determined 
to be 20 minutes after OMBs were injected from comparison of the slopes of blood 
oxygenation. Finally, PMO therapy of rats inflicted with ARDS was administered by 
repeated infusions of OMBs boluses. As fluid was not able to be drained from the 
peritoneal cavity, the volume of each bolus treatment was reduced by 20% to prevent a 
hazardous elevation of intra-abdominal pressures. Despite the hypoxia from ARDS not as 
severe as previous trials and peritoneal catheters that leaked infusate from the back 
incision, ARDS rats administered PMO therapy exhibited evidence of increased 
oxygenation. ARDS rats treated with repeated infusion of OMB boluses experienced a 
decrease in average SpO2 of 6.3% from the baseline, while the saline and IMBs treated 
rats decreased an average of 14.0% and 12.4% from the baseline. The ARDS rats treated 
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with OMBs also experienced an increase in average PaO2 that was twice as much as the 
IMB and saline groups (26.5% vs. 11.3% and 13.3%). In addition, ARDS rats treated 
with a complete OMB bolus regimen through a functional peritoneal catheter experienced 
an increased blood oxygenation that was sustained for the entire study. In contrast, the 
rats treated with OMBs through a leaking peritoneal catheter experienced decreased 
blood oxygenation 24 hours after LPS insult. 
The ultimate objective of this dissertation was to demonstrate that PMO therapy is 
a viable treatment option for delivering supplemental oxygen during incidents of hypoxia. 
The ultimate objective of the research was accomplished by validating PMO therapy in 
three animal models of hypoxia where survival time and systemic oxygenation was 
significantly increased with peritoneal infusion of OMBs. Thus, PMO therapy was 
concluded to be a potential as a treatment for supplemental extrapulmonary oxygenation 
that merits further investigation. 
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11.1 Future work 
Further work must be done to extend the technology for circulation, removal, and 
replenishment of the OMBs in the peritoneal cavity. These engineering challenges are not 
major obstacles for ultimate clinical translation given the precedent set by methods of 
peritoneal dialysis. Instead from the result of this work, the challenge of OMB circulation 
and drainage applies specifically to small animal models and in long term studies where 
the animal will be required to be conscious during the treatment. Prior to translation, 
however, peritoneal microbubble oxygenation must be examined in additional lung injury 
and large animal models.  
Additional research must be done to investigate peritoneal microbubble 
oxygenation in larger animals, such as swine, where the ratio of the peritoneal area to 
total body mass is closer to that of humans. The investigation of PMO therapy in large 
animals will contribute towards validating the limits of oxygen diffusion from peritoneal 
oxygenation and determining the clinical relevance of PMO therapy as a hypoxic 
treatment. To mitigate the limitations of lower surface area ratio and low blood flow in 
the splanchnic circuit, the pleural cavity can be perfused to increase the surface area and 
blood available for O2 transfer. Pleural microbubble oxygenation is possible by 
collapsing one lung with a chest tube and circulating OMBs through the intrapleural 
space. As shown in this work, supportive oxygenation through a serous membrane is 
feasible due to the high O2 carrying capacity and rapid diffusion capability provided by 
OMBs. 
The manufacturing of OMBs is another aspect of future research for improving 
PMO therapy. Clinical utilization of PMO therapy requires the mass production of OMBs 
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to be cost effective and efficient for large scale manufacture. The storage of OMBs also 
requires improvement as glass serum bottles and the current shelf life of 2 weeks is not 
practical for clinical applications. Research is being conducted in increasing the storage 
duration of OMBs and transporting OMBs in gas impermeable plastic containers similar 
to IV bags. The safety of OMBs must be evaluated with extensive toxicology studies to 
guarantee the prolonged biocompatibility of OMBs as health risks are a significant 
limitation of other artificial oxygen carriers. An important aspect of OMBs that requires 
investigation is determining if the phospholipids of the OMB membranes are 
decomposed, removed, or incorporated into the body without generating harmful 
products or if the phospholipids are retained. The OMBs should also be confirmed to not 
cause oxygen toxicity or generate large concentrations of reactive oxygen species.  
OMBs have demonstrated significant effectiveness at in vivo oxygen delivery. 
Thus, OMBs can be investigated for use in other biomedical applications where a demand 
for oxygen delivery exists. OMBs can be used to supplement and improve the organ 
preservation techniques of static cold storage and machine perfusion. The OMBs would 
be added to current organ preservations solutions for delivering oxygen to the tissue and 
reducing the incidence of ischemic damage organs experience during transport. In an 
unpublished preliminary study we performed, the lobes of rat livers were preserved in 
OMBs for 16 hours without developing any histological indications of ischemic injury. 
An additional biomedical application of OMBs is cancer treatment. Cancer cells exhibit 
increased vulnerability to radiation treatment and cytotoxic drugs when hypoxic 
conditions surrounding the tumor are reduced. Thus, an administration of a small volume 
of OMBs to the site of the tumor would significantly decrease local tissue hypoxia and 
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allow cancer cells to be killed more effectively. OMBs also possess potential for 
biomedical research in the field of tissue engineering. OMBs would be utilized for 
oxygen delivery to tissue engineered constructs and organs by circulating solutions with 
OMBs through the scaffolds or microchannels. 
With further research and investigation, PMO therapy possesses substantial 
potential as a treatment for supplemental extrapulmonary oxygenation and OMBs can be 
utilized for multiple biomedical applications. 
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Appendices  
Appendix A 
Table A.1: Bill of materials for the Peri3 device. 
Component Manufacturer Supplier Part No. Quantity 
Price per 
unit ($) 
FH100M 
Thermo 
Scientific 
Thermo 
Scientific 
72-320-084 1 2899.00 
myDAQ 
National 
Instruments 
National 
Instruments 
--- 2 179.00 
DB-25 M/F 
cable 
Cables 2 Go Amazon B000051183 1 4.47 
DB-25 Male 
connector 
Winford 
Engineering 
Winford 
Engineering 
BRKSD25M-C 1 23.50 
MS4426-
005G 
Measurement 
Specialties 
Digikey 223-1095-ND 2 36.33 
iWarm Midmark --- 396.42350.2 1 299.00 
K 
thermocouple 
UXcell Amazon B005CG2W3U 1 3.58 
AD595AQ Burr-Brown Digikey AD595AQ-ND 1 15.42 
PCB UNL EE Shop 
UNL EE 
Shop 
--- 1 0.00 
Solenoid 
ZonHen 
Electric 
Appliances 
Sparkfun ROB-10391 1 14.95 
Solid state 
relay 
Continental 
Industries 
UNL EE 
Shop 
RSDC-DC-
108-000 
1 2.00 
24 V power 
adapter 
Electro-
Harmonix 
Amazon B0042RHT4M 1 11.09 
Acrylic case BallQube Amazon B000LBB63S 1 15.99 
1/8” Tygon 
tubing 
Tygon McMaster 5155T16 25 ft 0.42 
TOTAL  $3730.16 
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A.1 Pinout diagrams 
 
 
Figure A.1: Pinout diagram of FH100M peristaltic pump. 
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Figure A.2: Pinout diagram of myDAQ. 
 
Figure A.3: Pinout diagram of pressure transducer (MS4426-005G). 
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Figure A.4: Pinout diagram of thermocouple amplifier and cold junction compensator 
chip (AD595AQ-ND). 
A.2 Equations for design of Peri3 
A.2.1 Pressure conversion for pressure transducer MS4426-005G (volts to mmHg) 
Vs – supply voltage to pressure transducer (typically = 14.95 V) 
𝐶 = |
1 psi
 mV
|
51.7419 mmHg
 1 psi
|
1000 mV
𝑉𝑠 
| 
C – conversion factor (3461 mmHg/V) 
Vo – voltage output from the pressure transducer [V] 
P – intra-abdominal pressure [mmHg] 
 𝑃 = 𝑉𝑜 ∙ 𝐶 [Eq. A.1] 
 
 
 
 
A.2.2 Temperature conversion for thermocouple amplifier and compensator chip (Volts 
to °C) 
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C – conversion factor 
Vo – voltage output from the thermocouple amplifier [V] 
T – inflow temperature [°C] 
𝑉𝑜 =
1 °C
10 mV
|
1000  mV
1 V
| =  100 
°C
V
 
 𝑇 = 𝑉𝑜 ∙ 𝐶 [Eq. A.2] 
A.2.3 Patient inputs to needed flow rate (input voltage for pump) 
VO2 – resting oxygen consumption rate of patient [mLO2/(kg x min)] 
 Rat: 12 Rabbit: 8.5 Pig: 7 
ρO2 – density of oxygen at STP = 1.3 mg/mL 
BO2
OMB
 – O2 carrying capacity of OMBs = 0.88 mgO2/mL 
DOMB – OMB demand of patient [mL/(kg x min)] 
 Rat: 17.73 Rabbit: 12.557 Pig: 10.34 
m – mass of patient [kg] 
Q – flow rate of OMBs patient requires [mL/min] 
n – number of lines needed 
C – conversion factor [(V x min)/mL] 
 n = 1:  0.0625 n = 2:  0.0313 n = 3:  0.0208 n = 4:  0.0156 
Vi – voltage input to pump 
 𝐷𝑂𝑀𝐵 =  
𝑉𝑂2∙𝜌𝑂2
𝐵𝑂2
𝑂𝑀𝐵  [Eq. A.3] 
 𝑄 = 𝐷𝑂𝑀𝐵 ∙ 𝑚   [Eq. A.4] 
𝐶 =  |
10 rpm
8 mL/min
|
10 V
200  rpm
|
1
𝑛
| 
 𝑉𝑖 =  𝑄 ∙ 𝐶 [Eq. A.5] 
 223 
A.3 SolidWorks 
 
Figure A.5: Part drawings of electronics case. 
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Figure A.6: Part drawings of 3D printed tubing mount of the solenoid assembly. 
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A.4 LabVIEW code 
 
Figure A.7: Entire LabVIEW program for controlling the Peri3. 
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A.4.1 Temperature measurement 
Functions of code 
1) Separate voltage supply to thermocouple amplifier 
2) Filter for both graphical feedback and stored date 
3) Write data and time stamp to Excel file 
 
Figure A.8: Subroutine of Peri3 LabVIEW program for temperature measurement. 
A.4.2 Pressure measurement 
Functions of code 
1) Applying the different calibration equations for each transducer to the 
measured pressures 
2) Convert back and forth between data arrays and matrices 
3) Array and matrix manipulations 
4) Filter for both graphical feedback and stored date 
5) Write voltage output and converted pressure data to Excel file with time stamp 
 
Figure A.9: Subroutine of Peri3 LabVIEW program for pressure measurement. 
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A.4.3 Solenoid Control 
Functions of code 
1) Manual override switches  
2) Shift register to “remember” the current position of the solenoid  
3) Digital output for the solid state relay 
 
Figure A.10: Subroutine controlling the solenoid for regulating intraperitoneal volume in 
the Peri3 LabVIEW program.  
A.4.4 Pump control 
Functions of code 
1) Infusion at accelerated rate for a set time to fill IPC quickly 
2) Ring input for drop down of different possible patient species 
3) Case structure (similar to ifelse statements) for different conversions for pump 
input voltages based on required flow rate and the corresponding number of 
infusion lines 
4) Stop pump when program stopped 
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Figure A.11: Subroutine controlling the pump in the Peri3 LabVIEW program. 
Appendix B 
B.1 Design of a custom catheter for prolonged peritoneal infusion and drainage 
The goal of a newly designed catheter was to mimic T-fluted catheters, which 
exhibited high efficiencies at fluid removal from studies of peritoneal dialysis in dogs and 
humans [207,208]. The flutes provide an external path for capillary movement along the 
outside of the catheter rather than an internal path [209]. The goal of fluted catheter 
designs is to provide a large surface area for fluid to flow limiting the potential to have 
fluid flow obstructed by tissue. The original design comprised 4 lengths of 2 mm outer 
diameter tubing (EW-06449-10, Cole Parmer, Vernon Hills, IL) twisted around each 
other and secured at 3.2 cm (1.25 inch) intervals with narrow segments of heat shrink 
tubing (Figure 6.1). The twisting of the segments tightened the segments together and 
increased the rigidity of the catheter much like a braided rope. The custom design 
replicated the function and structure of flutes the grooves created between the segments 
 229 
of tubing. The custom design was also created to allow for an inexpensive alternative that 
could be easily manufactured on site. The custom design was then compared against 
fluted catheters similar to those found successful in peritoneal dialysis of dogs and that 
were currently available for purchase.  
 
Figure B.1: Build and design of the custom catheter. 
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Appendix C 
C.1 Phase 1: ARDS validation  
 
Figure C.1: Mass loss from baseline. 
C.1.1 Blood chemistry 
 
Figure C.2: Concentration of potassium (K). 
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Figure C.3: Concentration of glucose. 
 
Figure C.4: Concentration of ionized calcium (Ca). 
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Figure C.5: Concentration of sodium (Na). 
 
Figure C.6: Concentration of hemoglobin. 
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5  
Figure C.7: Hematocrit of the blood. 
C.1.2 Blood acid/base 
 
Figure C.8: Concentration of base excess (BE). 
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Figure C.9: Concentration of bicarbonate (HCO3
-
). 
 
Figure C.10: Blood pH. 
 235 
 
Figure C.11: Calculated concentration of total carbon dioxide (tCO2). 
C.1.3 Pulse oximetry 
 
Figure C.12: Heart rate. 
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Figure C.13: Perfusion of blood in the rat’s paw. 
C.2 Phase 2: ARDS oxygenation 
C.2.1 Blood gases 
 
Figure C.14: Calculated oxygen saturation.  
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C.2.2 Blood acid/base 
 
Figure C.15: Concentration of base excess (BE).  
 
Figure C.16: Concentration of bicarbonate (HCO3
-
). 
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Figure C.17: Blood pH. 
 
Figure C.18: Calculated concentration of total carbon dioxide (tCO2). 
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C.2.3 Pulse oximetry 
 
Figure C.19: Heart rate. 
 
Figure C.20: Perfusion of blood in the paw. 
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C.3 Chest radiographs 
 
Figure C.21: Complete chest radiograph record for representatives of negative (Nv3) and 
saline controls (Sv3). 
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Figure C.22: Chest radiograph record for seven days of a representative given LPS. 
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Figure C.23: Complete chest radiograph record for representatives of ARDS validation 
(Lv3) and oxygenation (LPS) trials. 
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C.4 Lung injury scores 
 
Figure C.24: Lung injury scores of all ARDS characterization groups.  
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Appendix D 
 
Figure D.1: Actual experimental setup of OMB treatment in a rat with a right 
pneumothorax. 
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Appendix E 
E.1 SolidWorks 
 
Figure E.1: Part drawings of scavenge port used in perfusion trials of asphyxia in rabbits. 
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E.2 Tissue oxygenation 
 
Figure E.2: Local tissue oxygenation of rabbits’ abdomen (a) before asphyxia and OMB 
infusion and (b) after asphyxiated and treated with PMO. 
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Appendix F 
F.1 Oxygenation of PMO-ARDS rats given OMBs 
 
Figure F1: The peripheral oxygen saturation of rats with ARDS given PMO therapy with 
catheters that worked (PMO #1, #2) and catheters that failed (Failed #1, #2).  
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Figure F2: The partial pressure of oxygen in rats with ARDS given PMO therapy with 
catheters which worked (PMO #1, #2) and catheters that failed (Failed #1, #2). 
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Figure F3: The oxyhemoglobin fraction in rats with ARDS given PMO therapy with 
catheters which worked (PMO #1, #2) and catheters that failed (Failed #1, #2). 
F.2 Chest radiographs of IMB treated rats 
 
Figure F4: Retention of gas in PMO-ARDS rats treated with IMB boluses. 
